~~0000200406 us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-01-01 2018-07-01~~

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q




☑	☑	Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

for the quarterly period ended ~~June 30, 2019~~March 29, 2020




☐	☐	Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to

Commission file number 1-3215

Johnson && Johnson

(Exact name of registrant as specified in its charter)



New Jersey		22-1024240
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

One Johnson && Johnson Plaza

New Brunswick, New Jersey08933

(Address of principal executive offices)

~~Registrant’s~~Registrant’s telephone number, including area code ~~(732)~~ (732) 524-0400

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☑☑ ~~Yes~~ ☐Yes☐ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☑☑ ~~Yes~~ ☐Yes☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of ~~“large~~“large accelerated filer,~~” “accelerated~~” “accelerated filer,~~” “smaller~~” “smaller reporting company,”” and "emerging growth company" in Rule 12b-2 of the Exchange Act.



Large accelerated filer	☑ ☑	Accelerated filer	☐ ☐
Non-accelerated filer	☐ ☐	Smaller reporting company	☐ ☐
Emerging growth company	☐ ☐

If an emerging growth company, indicated by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐☐ Yes ☑☑ No

SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT



Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock, Par Value $1.00	JNJ	New York Stock Exchange
~~4.75% Notes Due November 2019~~	~~JNJ~~	~~New York Stock Exchange~~
0.250% Notes Due January 2022	JNJ	New York Stock Exchange
0.650% Notes Due May 2024	JNJ	New York Stock Exchange
5.50% Notes Due November 2024	JNJ	New York Stock Exchange
1.150% Notes Due November 2028	JNJ	New York Stock Exchange
1.650% Notes Due May 2035	JNJ	New York Stock Exchange

Indicate the number of shares outstanding of each of the ~~issuer’s~~issuer’s classes of common stock, as of the latest practicable date.

On ~~July 24, 2019, 2,639,165,527~~April 22, 2020, 2,634,594,535 shares of Common Stock, $1.00 par value, were outstanding.

JOHNSON && JOHNSON AND SUBSIDIARIES

TABLE OF CONTENTS



		Page
		No.
Part I —— Financial Information		1

Item 1. Financial Statements (unaudited)		1

Consolidated Balance Sheets ~~— June 30, 2019~~— March 29, 2020 and December ~~30, 2018~~29, 2019		1

Consolidated Statements of Earnings for the Fiscal ~~Second~~First Quarter Ended ~~June 30,~~March 29, 2020 and March 31, 2019 ~~and July 1, 2018~~		2

~~Consolidated Statements of Earnings for the Fiscal Six Months Ended June 30, 2019 and July 1, 2018~~		3

Consolidated Statements of Comprehensive Income for the Fiscal ~~Second~~First Quarter Ended March 29, 2020 and ~~Fiscal Six Months Ended June 30,~~March 31, 2019 ~~and July 1, 2018~~		43

Consolidated Statements of Equity for the Fiscal ~~Second~~First Quarter Ended March 29, 2020 and ~~Fiscal Six Months Ended June 30,~~March 31, 2019 ~~and July 1, 2018~~		54

Consolidated Statements of Cash Flows for the Fiscal ~~Six~~Three Months Ended ~~June 30,~~March 29, 2020 and March 31, 2019 ~~and July 1, 2018~~		75

Notes to Consolidated Financial Statements		86

Item 1A. Risk Factors		42

Item 2. ~~Management’s~~Management’s Discussion and Analysis of Financial Condition and Results of Operations		4643

Item 3. Quantitative and Qualitative Disclosures About Market Risk		5954

Item 4. Controls and Procedures		5954

Part II —— Other Information		6055

Item 1 - Legal Proceedings		6055

Item 2 - Unregistered Sales of Equity Securities and Use of Proceeds		6055

Item 6 - Exhibits		6156

Signatures		6257

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q and Johnson && Johnson's other publicly available documents contain ““forward-looking statements”” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Management and representatives of Johnson && Johnson and its subsidiaries (the Company) also may from time to time make forward-looking statements. Forward-looking statements do not relate strictly to historical or current facts and reflect ~~management’s~~management’s assumptions, views, plans, objectives and projections about the future. Forward-looking statements may be identified by the use of words such as ~~“plans,” “expects,” “will,” “anticipates,” “estimates,”~~“plans,” “expects,” “will,” “anticipates,” “estimates,” and other words of similar meaning in conjunction with, among other things: discussions of future operations, expected operating results, financial performance; impact of planned acquisitions and dispositions; impact and timing of restructuring initiatives including associated cost savings and other benefits; the Company's strategy for growth; product development activities; regulatory approvals; market position and expenditures.

Because forward-looking statements are based on current beliefs, expectations and assumptions regarding future events, they are subject to uncertainties, risks and changes that are difficult to predict and many of which are outside of the Company's control. Investors should realize that if underlying assumptions prove inaccurate, or known or unknown risks or uncertainties materialize, the ~~Company’s~~Company’s actual results and financial condition could vary materially from expectations and projections expressed or implied in its forward-looking statements. Investors are therefore cautioned not to rely on these forward-looking statements. Risks and uncertainties include, but are not limited to:

Risks Related to Product Development, Market Success and Competition


•	Challenges and uncertainties inherent in innovation and development of new and improved products and technologies on which the Company’s continued growth and success depend, including uncertainty of clinical outcomes, additional analysis of existing clinical data, obtaining regulatory approvals, health plan coverage and customer access, and initial and continued commercial success;


•	Challenges to the Company’s ability to obtain and protect adequate patent and other intellectual property rights for new and existing products and technologies in the United States and other important markets;


•	The impact of patent expirations, typically followed by the introduction of competing biosimilars and generics and resulting revenue and market share losses;

•

Increasingly aggressive and frequent challenges to the Company’s patents by competitors and others seeking to launch competing generic, biosimilar or other products and increased receptivity of courts, the United States Patent and Trademark Office and other decision makers to such challenges, potentially resulting in loss of market exclusivity and rapid decline in sales for the relevant product sooner than expected;


•	Competition in research and development of new and improved products, processes and technologies, which can result in product and process obsolescence;


•	Competition to reach agreement with third parties for collaboration, licensing, development and marketing agreements for products and technologies;


•	Competition based on cost-effectiveness, product performance, technological advances and patents attained by competitors; and


•	Allegations that the Company’s products infringe the patents and other intellectual property rights of third parties, which could adversely affect the Company’s ability to sell the products in question and require the payment of money damages and future royalties.

Challenges and uncertainties inherent in innovation and development of new and improved products and technologies on which the Company’s continued growth and success depend, including uncertainty of clinical outcomes, additional analysis of existing clinical data, obtaining regulatory approvals, health plan coverage and customer access, and initial and continued commercial success;

Challenges to the Company’s ability to obtain and protect adequate patent and other intellectual property rights for new and existing products and technologies in the United States and other important markets;

~~The impact of patent expirations, typically followed by the introduction of competing biosimilars and generics and resulting revenue and market share losses;~~

~~Competition in research and development of new and improved products, processes and technologies, which can result in product and process obsolescence;~~

~~Competition to reach agreement with third parties for collaboration, licensing, development and marketing agreements for products and technologies;~~

~~Competition based on cost-effectiveness, product performance, technological advances and patents attained by competitors; and~~

Allegations that the Company’s products infringe the patents and other intellectual property rights of third parties, which could adversely affect the Company’s ability to sell the products in question and require the payment of money damages and future royalties.

Risks Related to Product Liability, Litigation and Regulatory Activity

Product efficacy or safety concerns, whether or not based on scientific evidence, potentially resulting in product withdrawals, recalls, regulatory action on the part of the United States Food and Drug Administration (or international counterparts), declining sales, reputational damage, increased litigation expense and share price impact;

Impact, including declining sales and reputational damage, of significant litigation or government action adverse to the Company, including product liability claims and allegations related to pharmaceutical marketing practices and contracting strategies;

Impact of an adverse judgment or settlement and the adequacy of reserves related to legal proceedings, including patent litigation, product liability, personal injury claims, securities class actions, government investigations, employment and other legal proceedings;


•	Product efficacy or safety concerns, whether or not based on scientific evidence, potentially resulting in product withdrawals, recalls, regulatory action on the part of the United States Food and Drug Administration (or international counterparts), declining sales, reputational damage, increased litigation expense and share price impact;


•	Impact, including declining sales and reputational damage, of significant litigation or government action adverse to the Company, including product liability claims and allegations related to pharmaceutical marketing practices and contracting strategies;


•	Impact of an adverse judgment or settlement and the adequacy of reserves related to legal proceedings, including patent litigation, product liability, personal injury claims, securities class actions, government investigations, employment and other legal proceedings;


•	Increased scrutiny of the health care industry by government agencies and state attorneys general resulting in investigations and prosecutions, which carry the risk of significant civil and criminal penalties, including, but not limited to, debarment from government business;


•	Failure to meet compliance obligations in the McNEIL-PPC, Inc. Consent Decree or any other compliance agreements with governments or government agencies, which could result in significant sanctions;


•	Potential changes to applicable laws and regulations affecting United States and international operations, including relating to: approval of new products; licensing and patent rights; sales and promotion of health care products; access to, and reimbursement and pricing for, health care products and services; environmental protection and sourcing of raw materials;


•	Compliance with local regulations and laws that may restrict the Company’s ability to manufacture or sell its products in relevant markets including, requirements to comply with medical device reporting regulations and other requirements such as the European Union's Medical Devices Regulation;


•	Changes in domestic and international tax laws and regulations, including changes related to The Tax Cuts and Jobs Act in the United States, the Federal Act on Tax Reform and AHV Financing in Switzerland, increasing audit scrutiny by tax authorities around the world and exposures to additional tax liabilities potentially in excess of existing reserves; and


•	Issuance of new or revised accounting standards by the Financial Accounting Standards Board and regulations by the Securities and Exchange Commission.

Increased scrutiny of the health care industry by government agencies and state attorneys general resulting in investigations and prosecutions, which carry the risk of significant civil and criminal penalties, including, but not limited to, debarment from government business;

~~Failure to meet compliance obligations in the McNEIL-PPC, Inc. Consent Decree or any other compliance agreements with governments or government agencies, which could result in significant sanctions;~~

Potential changes to applicable laws and regulations affecting United States and international operations, including relating to: approval of new products; licensing and patent rights; sales and promotion of health care products; access to, and reimbursement and pricing for, health care products and services; environmental protection and sourcing of raw materials;

Compliance with local regulations and laws that may restrict the Company’s ability to manufacture or sell its products in relevant markets including, requirements to comply with medical device reporting regulations and other requirements such as the European Union's Medical Devices Regulation;

Changes in domestic and international tax laws and regulations, including changes related to The Tax Cuts and Jobs Act in the United States, the Federal Act on Tax Reform and AHV Financing in Switzerland, increasing audit scrutiny by tax authorities around the world and exposures to additional tax liabilities potentially in excess of existing reserves; and

~~Issuance of new or revised accounting standards by the Financial Accounting Standards Board and regulations by the Securities and Exchange Commission.~~

Risks Related to the ~~Company’s~~Company’s Strategic Initiatives and ~~Health Care~~Healthcare Market Trends

•

Pricing pressures resulting from trends toward health care cost containment, including the continued consolidation among health care providers and other market participants, trends toward managed care, the shift toward governments increasingly becoming the primary payers of health care expenses, significant new entrants to the health care markets seeking to reduce costs and government pressure on companies to voluntarily reduce costs and price increases;


•	Restricted spending patterns of individual, institutional and governmental purchasers of health care products and services due to economic hardship and budgetary constraints;


•	Challenges to the Company’s ability to realize its strategy for growth including through externally sourced innovations, such as development collaborations, strategic acquisitions, licensing and marketing agreements, and the potential heightened costs of any such external arrangements due to competitive pressures;


•	The potential that the expected strategic benefits and opportunities from any planned or completed acquisition or divestiture by the Company may not be realized or may take longer to realize than expected; and


•	The potential that the expected benefits and opportunities related to past and ongoing restructuring actions may not be realized or may take longer to realize than expected.

~~Restricted spending patterns of individual, institutional and governmental purchasers of health care products and services due to economic hardship and budgetary constraints;~~

Challenges to the Company’s ability to realize its strategy for growth including through externally sourced innovations, such as development collaborations, strategic acquisitions, licensing and marketing agreements, and the potential heightened costs of any such external arrangements due to competitive pressures;

The potential that the expected strategic benefits and opportunities from any planned or completed acquisition or divestiture by the Company may not be realized or may take longer to realize than expected; and

~~The potential that the expected benefits and opportunities related to past and ongoing restructuring actions may not be realized or may take longer to realize than expected.~~

Risks Related to Economic Conditions, Financial Markets and Operating Internationally


•	The risks associated with global operations, including the impact of global public health crises and pandemics, such as the outbreak of the novel coronavirus (COVID-19), on the Company and its customers and suppliers, including foreign governments in countries in which the Company operates.


•	Impact of inflation and fluctuations in interest rates and currency exchange rates and the potential effect of such fluctuations on revenues, expenses and resulting margins;


•	Potential changes in export/import and trade laws, regulations and policies of the United States and other countries, including any increased trade restrictions or tariffs and potential drug reimportation legislation;


•	The impact on international operations from financial instability in international economies, sovereign risk, possible imposition of governmental controls and restrictive economic policies, and unstable international governments and legal systems;


•	Changes to global climate, extreme weather and natural disasters that could affect demand for the Company's products and services, cause disruptions in manufacturing and distribution networks, alter the availability of goods and services within the supply chain, and affect the overall design and integrity of the Company's products and operations;


•	The impact of armed conflicts and terrorist attacks in the United States and other parts of the world including social and economic disruptions and instability of financial and other markets; and

~~Market conditions and the possibility that the Company’s share repurchase program may be delayed, suspended or discontinued;~~

~~Impact of inflation and fluctuations in interest rates and currency exchange rates and the potential effect of such fluctuations on revenues, expenses and resulting margins;~~

Potential changes in export/import and trade laws, regulations and policies of the United States and other countries, including any increased trade restrictions or tariffs and potential drug reimportation legislation;

The impact on international operations from financial instability in international economies, sovereign risk, possible imposition of governmental controls and restrictive economic policies, and unstable international governments and legal systems;

Changes to global climate, extreme weather and natural disasters that could affect demand for the Company's products and services, cause disruptions in manufacturing and distribution networks, alter the availability of goods and services within the supply chain, and affect the overall design and integrity of the Company's products and operations; and

~~The impact of armed conflicts and terrorist attacks in the United States and other parts of the world including social and economic disruptions and instability of financial and other markets.~~

Risks Related to Supply Chain and Operations


•	Difficulties and delays in manufacturing, internally through third party providers or otherwise within the supply chain, that may lead to voluntary or involuntary business interruptions or shutdowns, product shortages, withdrawals or suspensions of products from the market, and potential regulatory action;


•	Interruptions and breaches of the Company's information technology systems or those of the Company's vendors which, could result in reputational, competitive, operational or other business harm as well as financial costs and regulatory action;


•	Reliance on global supply chains and production and distribution processes that are complex and subject to increasing regulatory requirements that may adversely affect supply, sourcing and pricing of materials used in the Company’s products; and

•

The potential that the expected benefits and opportunities related to restructuring actions contemplated for the global supply chain, including the Company's transaction with Jabil Inc., may not be realized or may take longer to realize than expected, including due to any required approvals from applicable regulatory authorities. Disruptions associated with the announced global supply chain actions may adversely affect supply and sourcing of materials used in the Company's products.

Difficulties and delays in manufacturing, internally through third party providers or otherwise within the supply chain, that may lead to voluntary or involuntary business interruptions or shutdowns, product shortages, withdrawals or suspensions of products from the market, and potential regulatory action;

Interruptions and breaches of the Company's information technology systems or those of the Company's vendors which, could result in reputational, competitive, operational or other business harm as well as financial costs and regulatory action;

Reliance on global supply chains and production and distribution processes that are complex and subject to increasing regulatory requirements that may adversely affect supply, sourcing and pricing of materials used in the Company’s products; and

The potential that the expected benefits and opportunities related to restructuring actions contemplated for the global supply chain may not be realized or may take longer to realize than expected, including due to any required approvals from applicable regulatory authorities. Disruptions associated with the announced global supply chain actions may adversely affect supply and sourcing of materials used in the Company's products.

Investors also should carefully read the Risk Factors described in Item 1A of the Company's Annual Report on Form 10-K for the fiscal year ended December ~~30, 2018,~~29, 2019, for a description of certain risks that could, among other things, cause the ~~Company’s~~Company’s actual results to differ materially from those expressed in its forward-looking statements. Investors should understand that it is not possible to predict or identify all such factors and should not consider the risks described above to be a complete statement of all potential risks and uncertainties. The Company does not undertake to publicly update any forward-looking statement that may be made from time to time, whether as a result of new information or future events or developments.

Table of Contents

Part I —— FINANCIAL INFORMATION

Item 1 —— FINANCIAL STATEMENTS

JOHNSON && JOHNSON AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(Unaudited; Dollars in Millions Except Share and Per Share Data)


		June 30, 2019			December 30, 2018			March 29, 2020			December 29, 2019
ASSETS	ASSETS						ASSETS
Current assets:
Cash and cash equivalents		$	14,376		18,107			$	15,530		17,305
Marketable securities		902			1,580			2,494			1,982
Accounts receivable, trade, less allowances for doubtful accounts $251 (2018, $248)		14,653			14,098
Accounts receivable, trade, less allowances for doubtful accounts and credit losses $234 (2019, $226)								14,874			14,481
Inventories (Note 2)		9,263			8,599			8,868			9,020
Prepaid expenses and other		2,411			2,699			2,358			2,392
Assets held for sale (Note 10)		194			950			102			94
Total current assets		41,799			46,033			44,226			45,274
Property, plant and equipment at cost		42,905			41,851			43,247			43,332
Less: accumulated depreciation		(25,657		)	(24,816	)		(25,846		)	(25,674	)
Property, plant and equipment, net		17,248			17,035			17,401			17,658
Intangible assets, net (Note 3)		49,332			47,611			47,338			47,643
Goodwill (Note 3)		33,661			30,453			33,471			33,639
Deferred taxes on income		7,647			7,640
Deferred taxes on income (Note 5)								7,539			7,819
Other assets		5,430			4,182			5,042			5,695
Total assets		$	155,117		152,954			$	155,017		157,728
LIABILITIES AND SHAREHOLDERS’ EQUITY
LIABILITIES AND SHAREHOLDERS’ EQUITY							LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Loans and notes payable		$	1,719		2,796			$	2,190		1,202
Accounts payable		6,912			7,537			7,411			8,544
Accrued liabilities		8,297			7,601			8,384			9,715
Accrued rebates, returns and promotions		10,433			9,380			11,608			10,883
Accrued compensation and employee related obligations		2,291			3,098			2,166			3,354
Accrued taxes on income		1,701			818
Accrued taxes on income (Note 5)								1,930			2,266
Total current liabilities		31,353			31,230			33,689			35,964
Long-term debt (Note 4)		27,699			27,684			25,393			26,494
Deferred taxes on income		7,725			7,506
Employee related obligations		9,910			9,951
Long-term taxes payable		7,543			8,242
Deferred taxes on income (Note 5)								5,766			5,958
Employee related obligations (Note 6)								10,529			10,663
Long-term taxes payable (Note 5)								7,402			7,444
Other liabilities		10,102			8,589			10,944			11,734
Total liabilities		94,332			93,202			93,723			98,257
Commitments and Contingencies (Note 11)
Shareholders’ equity:
Common stock — par value $1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares)		$	3,120		3,120
Shareholders’ equity:
Common stock — par value $1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares)								$	3,120		3,120
Accumulated other comprehensive income (loss) (Note 7)		(14,969		)	(15,222	)		(16,243		)	(15,891	)
Retained earnings		109,809			106,216			112,901			110,659
Less: common stock held in treasury, at cost (477,778,000 and 457,519,000 shares)		37,175			34,362
Total shareholders’ equity		60,785			59,752
Less: common stock held in treasury, at cost (487,451,000 and 487,336,000 shares)								38,484			38,417
Total shareholders’ equity								61,294			59,471
Total liabilities and shareholders' equity		$	155,117		152,954			$	155,017		157,728

See Notes to Consolidated Financial Statements

Table of Contents

JOHNSON && JOHNSON AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF EARNINGS

(Unaudited; Dollars && Shares in Millions Except Per Share Amounts)


	Fiscal Second Quarter Ended										Fiscal First Quarter Ended
	June 30, 2019			Percent to Sales		July 1, 2018			Percent to Sales		March 29, 2020			Percent to Sales		March 31, 2019			Percent to Sales
Sales to customers (Note 9)	$	20,562		100.0	%	$	20,830		100.0	%	$	20,691		100.0	%	$	20,021		100.0	%
Cost of products sold	6,940			33.8		6,927			33.3		7,062			34.1		6,615			33.0
Gross profit	13,622			66.2		13,903			66.7		13,629			65.9		13,406			67.0
Selling, marketing and administrative expenses	5,546			27.0		5,743			27.5		5,203			25.1		5,219			26.1
Research and development expense	2,666			13.0		2,639			12.7		2,580			12.5		2,858			14.3
In-process research and development											—			—		890			4.4
Interest income	(88		)	(0.4	)	(126		)	(0.6	)	(67		)	(0.3	)	(99		)	(0.5	)
Interest expense, net of portion capitalized	83			0.4		253			1.2		25			0.1		102			0.5
Other (income) expense, net	(1,683		)	(8.2	)	364			1.7		(679		)	(3.3	)	(22		)	(0.1	)
Restructuring (Note 12)	57			0.2		57			0.3		58			0.3		36			0.2
Earnings before provision for taxes on income	7,041			34.2		4,973			23.9		6,509			31.5		4,422			22.1
Provision for taxes on income (Note 5)	1,434			6.9		1,019			4.9		713			3.5		673			3.4
NET EARNINGS	$	5,607		27.3	%	$	3,954		19.0	%	$	5,796		28.0	%	$	3,749		18.7	%

NET EARNINGS PER SHARE (Note 8)
Basic	$	2.11				$	1.47				$	2.20				$	1.41
Diluted	$	2.08				$	1.45				$	2.17				$	1.39

AVG. SHARES OUTSTANDING
Basic	2,652.5					2,682.3					2,633.7					2,660.8
Diluted	2,691.7					2,721.3					2,671.0					2,698.8

See Notes to Consolidated Financial Statements

~~JOHNSON & JOHNSON AND SUBSIDIARIES~~

~~CONSOLIDATED STATEMENTS OF EARNINGS~~

~~(Unaudited; Dollars & Shares in Millions Except Per Share Amounts)~~

Fiscal Six Months Ended
June 30,
2019
Percent
to Sales
July 1,
2018
Percent
to Sales
Sales to customers (Note 9) $ 40,583
100.0 % $ 40,839
100.0 %
Cost of products sold 13,555
33.4
13,541
33.2
Gross profit 27,028
66.6
27,298
66.8
Selling, marketing and administrative expenses 10,765
26.5
11,006
27.0
Research and development expense 5,524
13.6
5,043
12.3
In-process research and development 890
2.2
—
—
Interest income (187 ) (0.5 ) (240 ) (0.6 )
Interest expense, net of portion capitalized 185
0.5
512
1.3
Other (income) expense, net (1,705 ) (4.2 ) 424
1.0
Restructuring (Note 12) 93
0.3
99
0.2
Earnings before provision for taxes on income 11,463
28.2
10,454
25.6
Provision for taxes on income (Note 5) 2,107
5.1
2,133
5.2
NET EARNINGS $ 9,356
23.1 % $ 8,321
20.4 %

NET EARNINGS PER SHARE (Note 8)
Basic $ 3.52
$ 3.10

Diluted $ 3.47
$ 3.05

AVG. SHARES OUTSTANDING
Basic 2,656.7
2,682.2

Diluted 2,697.0
2,728.5

See Notes to Consolidated Financial Statements

Table of Contents

JOHNSON && JOHNSON AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(Unaudited; Dollars in Millions)


	Fiscal Second Quarter Ended					Fiscal Six Months Ended					Fiscal First Quarter Ended
	June 30, 2019			July 1, 2018		June 30, 2019			July 1, 2018		March 29, 2020			March 31, 2019
Net earnings	$	5,607		3,954		$	9,356		8,321		$	5,796		3,749

Other comprehensive income (loss), net of tax
Foreign currency translation	350			(2,190	)	92			(1,567	)	(1,519		)	(258	)

Securities:
Unrealized holding gain (loss) arising during period	1			—		1			—		2			—
Reclassifications to earnings	—			—		—			—		—			—
Net change	1			—		1			—		2			—

Employee benefit plans:
Prior service cost amortization during period	(5		)	(5	)	(12		)	(11	)	(6		)	(7	)
Gain (loss) amortization during period	142			190		318			382		201			176
Net change	137			185		306			371		195			169

Derivatives & hedges:
Derivatives & hedges:
Unrealized gain (loss) arising during period	86			(61	)	(216		)	(225	)	832			(302	)
Reclassifications to earnings	(26		)	(103	)	70			75		138			96
Net change	60			(164	)	(146		)	(150	)	970			(206	)

Other comprehensive income (loss)	548			(2,169	)	253			(1,346	)	(352		)	(295	)

Comprehensive income	$	6,155		1,785		$	9,609		6,975		$	5,444		3,454

See Notes to Consolidated Financial Statements

The tax effects in other comprehensive income for the fiscal ~~second~~first quarter were as follows for ~~2019~~2020 and ~~2018,~~2019, respectively: Foreign Currency Translation: ~~$106~~$46 million and ~~$346~~$61 million; Securities: $1 million in 2020, Employee Benefit Plans: ~~$34~~$56 million and ~~$51~~$1 million; Derivatives && Hedges: ~~$16~~$256 million and ~~$44~~$55 million.

The tax effects in other comprehensive income for the fiscal six months were as follows for 2019 and 2018, respectively: Foreign Currency Translation: $44 million and $183 million; Employee Benefit Plans: $35 million and $103 million; Derivatives & Hedges:$39 million and $40 million.

Table of Contents

JOHNSON && JOHNSON AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF EQUITY

(Unaudited; Dollars in Millions)

Fiscal ~~Second~~First Quarter Ended ~~June 30, 2019~~March 29, 2020

Total
Retained
Earnings

Accumulated
Other
Comprehensive
Income

Common Stock
Issued Amount

Treasury
Stock
Amount
Balance, March 31, 2019 $ 58,955
106,650
(15,517 ) 3,120
(35,298 )
Net earnings 5,607
5,607
—
—
—
Cash dividends paid ($0.95 per share) (2,522 ) (2,522 ) —
—
—
Employee compensation and stock option plans 683
74
—
—
609
Repurchase of common stock (2,486 ) —
—
—
(2,486 )
Other —
—
—
—
—
Other comprehensive income (loss), net of tax 548
—
548
—
—
Balance, June 30, 2019 $ 60,785
109,809
(14,969 ) 3,120
(37,175 )



	Total			Retained Earnings		Accumulated Other Comprehensive Income		Common Stock Issued Amount	Treasury Stock Amount
Balance, December 29, 2019	$	59,471		110,659		(15,891	)	3,120	(38,417	)
Net earnings	5,796			5,796		—		—	—
Cash dividends paid ($0.95 per share)	(2,505		)	(2,505	)	—		—	—
Employee compensation and stock option plans	595			(1,049	)	—		—	1,644
Repurchase of common stock	(1,711		)	—		—		—	(1,711	)
Other comprehensive income (loss), net of tax	(352		)	—		(352	)	—	—
Balance, March 29, 2020	$	61,294		112,901		(16,243	)	3,120	(38,484	)

~~Fiscal Six Months Ended June 30, 2019~~

Total
Retained
Earnings

Accumulated
Other
Comprehensive
Income

Common Stock
Issued Amount

Treasury
Stock
Amount
Balance, December 30, 2018 $ 59,752
106,216
(15,222 ) 3,120
(34,362 )
Net earnings 9,356
9,356
—
—
—
Cash dividends paid ($1.85 per share) (4,918 ) (4,918 ) —
—
—
Employee compensation and stock option plans 1,034
(845 ) —
—
1,879
Repurchase of common stock (4,692 ) —
—
—
(4,692 )
Other —
—
—
—
—
Other comprehensive income (loss), net of tax 253
—
253
—
—
Balance, June 30, 2019 $ 60,785
109,809
(14,969 ) 3,120
(37,175 )

Fiscal First Quarter EndedMarch 31, 2019



	Total			Retained Earnings		Accumulated Other Comprehensive Income		Common Stock Issued Amount	Treasury Stock Amount
Balance, December 30, 2018	$	59,752		106,216		(15,222	)	3,120	(34,362	)
Net earnings	3,749			3,749		—		—	—
Cash dividends paid ($0.90 per share)	(2,396		)	(2,396	)	—		—	—
Employee compensation and stock option plans	351			(919	)	—		—	1,270
Repurchase of common stock	(2,206		)	—		—		—	(2,206	)
Other	—			—		—		—	—
Other comprehensive income (loss), net of tax	(295		)	—		(295	)	—	—
Balance, March 31, 2019	$	58,955		106,650		(15,517	)	3,120	(35,298	)

See Notes to Consolidated Financial Statements

Table of Contents

~~JOHNSON & JOHNSON AND SUBSIDIARIES~~

~~CONSOLIDATED STATEMENTS OF EQUITY (cont.)~~

~~(Unaudited; Dollars in Millions)~~

~~Fiscal Second Quarter Ended July 1, 2018~~

Total
Retained
Earnings

Accumulated
Other
Comprehensive
Income

Common Stock
Issued Amount

Treasury
Stock
Amount
Balance, April 1, 2018 $ 63,255
104,339
(12,608 ) 3,120
(31,596 )
Cumulative Adjustment to retained earnings —
—
—
—
—
Net earnings 3,954
3,954
—
—
—
Cash dividends paid ($0.90 per share) (2,415 ) (2,415 ) —
—
—
Employee compensation and stock option plans 409
245
—
—
164
Repurchase of common stock (145 ) —
—
—
(145 )
Other —
—
—
—
—
Other comprehensive income (loss), net of tax (2,169 ) —
(2,169 ) —
—
Balance, July 1, 2018 $ 62,889
106,123
(14,777 ) 3,120
(31,577 )

JOHNSON & JOHNSON AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited; Dollars in Millions)

	Fiscal Three Months Ended
	March 29, 2020			March 31, 2019
CASH FLOWS FROM OPERATING ACTIVITIES
Net earnings	$	5,796		3,749
Adjustments to reconcile net earnings to cash flows from operating activities:
Depreciation and amortization of property and intangibles	1,747			1,761
Stock based compensation	263			258
Asset write-downs	11			913
Contingent consideration reversal	(983		)	—
Net gain on sale of assets/businesses	—			(72	)
Deferred tax provision	54			(362	)
Accounts receivable allowances and credit losses	22			(3	)
Changes in assets and liabilities, net of effects from acquisitions and divestitures:
(Increase) / Decrease in accounts receivable	(812		)	157
Increase in inventories	(159		)	(369	)
Decrease in accounts payable and accrued liabilities	(2,523		)	(1,833	)
Decrease / (Increase) in other current and non-current assets	271			(488	)
Decrease in other current and non-current liabilities	(329		)	(168	)

NET CASH FLOWS FROM OPERATING ACTIVITIES	3,358			3,543

CASH FLOWS FROM INVESTING ACTIVITIES
Additions to property, plant and equipment	(625		)	(656	)
Proceeds from the disposal of assets/businesses, net	17			253
Acquisitions, net of cash acquired	(939		)	(1,683	)
Purchases of investments	(2,064		)	(730	)
Sales of investments	1,544			1,495
Proceeds from credit support agreements, net	1,743			—
Other	(257		)	(96	)

NET CASH USED BY INVESTING ACTIVITIES	(581		)	(1,417	)

CASH FLOWS FROM FINANCING ACTIVITIES
Dividends to shareholders	(2,505		)	(2,396	)
Repurchase of common stock	(1,711		)	(2,206	)
Proceeds from short-term debt	10			13
Repayment of short-term debt	(18		)	(16	)
Repayment of long-term debt	(11		)	(1,002	)
Proceeds from the exercise of stock options/employee withholding tax on stock awards, net	332			94
Other	(412		)	(3	)

NET CASH USED BY FINANCING ACTIVITIES	(4,315		)	(5,516	)

Effect of exchange rate changes on cash and cash equivalents	(237		)	17
Decrease in cash and cash equivalents	(1,775		)	(3,373	)
Cash and Cash equivalents, beginning of period	17,305			18,107
CASH AND CASH EQUIVALENTS, END OF PERIOD	$	15,530		14,734

Acquisitions
Fair value of assets acquired	$	1,136		2,154
Fair value of liabilities assumed and noncontrolling interests	(197		)	(471	)
Net cash paid for acquisitions	$	939		1,683

~~Fiscal Six Months Ended July 1, 2018~~

Total
Retained
Earnings

Accumulated
Other
Comprehensive
Income

Common Stock
Issued Amount

Treasury
Stock
Amount
Balance, December 31, 2017 $ 60,160
101,793
(13,199 ) 3,120
(31,554 )
Cumulative Adjustment to retained earnings 1,264
1,496
(232 ) —
—
Net earnings 8,321
8,321
—
—
—
Cash dividends paid ($1.74 per share) (4,668 ) (4,668 ) —
—
—
Employee compensation and stock option plans 760
(806 ) —
—
1,566
Repurchase of common stock (1,589 ) —
—
—
(1,589 )
Other (13 ) (13 ) —
—
—
Other comprehensive income (loss), net of tax (1,346 ) —
(1,346 ) —
—
Balance, July 1, 2018 $ 62,889
106,123
(14,777 ) 3,120
(31,577 )

See Notes to Consolidated Financial Statements

Table of Contents

JOHNSON & JOHNSON AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited; Dollars in Millions)
Fiscal Six Months Ended
June 30,
2019 July 1,
2018
CASH FLOWS FROM OPERATING ACTIVITIES
Net earnings $ 9,356
8,321
Adjustments to reconcile net earnings to cash flows from operating activities:
Depreciation and amortization of property and intangibles 3,466
3,463
Stock based compensation 572
580
Asset write-downs 989
27
Net gain on sale of assets/businesses (2,079 ) (443 )
Deferred tax provision (694 ) (285 )
Accounts receivable allowances 1
(16 )
Changes in assets and liabilities, net of effects from acquisitions and divestitures:
Increase in accounts receivable (336 ) (989 )
Increase in inventories (423 ) (491 )
Decrease in accounts payable and accrued liabilities (444 ) (49 )
Increase in other current and non-current assets (862 ) (267 )
Decrease in other current and non-current liabilities (55 ) (166 )

NET CASH FLOWS FROM OPERATING ACTIVITIES 9,491
9,685

CASH FLOWS FROM INVESTING ACTIVITIES
Additions to property, plant and equipment (1,493 ) (1,533 )
Proceeds from the disposal of assets/businesses, net 3,018
870
Acquisitions, net of cash acquired (5,346 ) (222 )
Purchases of investments (1,517 ) (951 )
Sales of investments 2,132
743
Other 1
(33 )

NET CASH USED BY INVESTING ACTIVITIES (3,205 ) (1,126 )

CASH FLOWS FROM FINANCING ACTIVITIES
Dividends to shareholders (4,918 ) (4,668 )
Repurchase of common stock (4,692 ) (1,589 )
Proceeds from short-term debt 15
27
Retirement of short-term debt (12 ) (2,433 )
Proceeds from long-term debt, net of issuance costs 1
3
Retirement of long-term debt (1,005 ) (9 )
Proceeds from the exercise of stock options/employee withholding tax on stock awards, net 463
162
Other 98
(137 )

NET CASH USED BY FINANCING ACTIVITIES (10,050 ) (8,644 )

Effect of exchange rate changes on cash and cash equivalents 33
(170 )
Decrease in cash and cash equivalents (3,731 ) (255 )
Cash and Cash equivalents, beginning of period 18,107
17,824
CASH AND CASH EQUIVALENTS, END OF PERIOD $ 14,376
17,569

Acquisitions
Fair value of assets acquired $ 6,744
334
Fair value of liabilities assumed and noncontrolling interests (1,398 ) (112 )
Net cash paid for acquisitions $ 5,346
222

~~See Notes to Consolidated Financial Statements~~

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 —— The accompanying unaudited interim consolidated financial statements and related notes should be read in conjunction with the audited Consolidated Financial Statements of Johnson && Johnson and its subsidiaries (the Company) and related notes as contained in the ~~Company’s~~Company’s Annual Report on Form 10-K for the fiscal year ended December ~~30, 2018~~29, 2019. The unaudited interim financial statements include all adjustments (consisting only of normal recurring adjustments) and accruals necessary in the judgment of management for a fair statement of the results for the periods presented.

Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures.

Use of Estimates

The extent to which COVID-19 impacts the Company’s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of COVID-19, the extent to which it will impact worldwide macroeconomic conditions including interest rates, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts COVID-19 as of March 29, 2020 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company’s allowance for doubtful accounts and credit losses, inventory and related reserves and the carrying value of the goodwill and other long-lived assets. While there was not a material impact to the Company’s consolidated financial statements as of and for the quarter ended March 29, 2020, the Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company’s consolidated financial statements in future reporting periods.

New Accounting Standards

The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on the Company's financial statements and below describes the impacts from newly adopted standards, as well as material updates to previous assessments, if any, from the Company’s Annual Report on Form 10-K for the fiscal year ended December 29, 2019.

Recently Adopted Accounting Standards

ASU ~~2016-02: Leases~~2018-18: Collaborative Arrangements

The Company adopted this standard as of the beginning of the fiscal year 2019, on a prospective basis. This update requires the recognition of lease assets and lease liabilities on the balance sheet for all lease obligations and disclosing key information about leasing arrangements. This update requires the recognition of lease assets and lease liabilities by lessees for arrangements that are classified as operating leases. The Company’s operating leases resulted in the recognition of additional assets and the corresponding liabilities on its Consolidated Balance Sheet, however it did not have a material impact on the consolidated financial statements.

The Company determines whether an arrangement is a lease at contract inception by establishing if the contract conveys the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration.

Right of Use (ROU) Assets and Lease Liabilities for operating leases are included in Other assets, Accrued liabilities, and Other liabilities on the consolidated balance sheet. The ROU Assets represent the right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. Commitments under finance leases are not significant, and are included in Property, plant and equipment, Loans and notes payable, and Long-term debt on the consolidated balance sheet.

ROU Assets and Lease Liabilities are recognized at the lease commencement date based on the present value of all minimum lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments, when the implicit rate is not readily determinable. Lease terms may include options to extend or terminate the lease. These options are included in the lease term when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term.

The Company has elected the following policy elections on adoption: use of portfolio approach on leases of assets under master service agreements, exclusion of short term leases on the balance sheet, and not separating lease and non-lease components.

The Company primarily has operating leases for space, vehicles, manufacturing equipment, and data processing equipment. Leases have remaining lease terms ranging from 1 year to 37 years, some of which could include options to extend the leases when they are reasonably certain.

As noted in the Company’s 2018 10-K, the approximate minimum rental payments required under operating leases that had initial or remaining non-cancelable lease terms in excess of one year at December 30, 2018 were:

~~(Dollars in Millions)~~

2019 2020 2021 2022 2023 After 2023 Total
$223 188 154 116 76 139 896

~~Commitments under finance leases are not significant.~~

~~Maturity of Lease Liabilities related to Operating Lease~~

~~The minimum rental payments required under operating leases that have initial or remaining non-cancellable lease terms in excess of one year as of June 30, 2019 are:~~

(Dollars in Millions) Operating Leases
2019 (for the remainder of fiscal 2019) $ 185
2020 245
2021 201
2022 156
2023 98
After 2023 214
Total lease payments 1,099
Less: Interest 88
Present Value of lease liabilities $ 1,011

~~The Weighted Average Remaining Lease Term and discount rate:~~

~~Operating leases 6.2 years~~

~~Weighted Average Discount Rate 3%~~

For the fiscal second quarter and first fiscal six months ended June 30, 2019, the operating lease costs were $50 million and $124 million, respectively. Cash paid for amounts included in the measurement of lease liabilities were $76 million and $147 million for the fiscal second quarter and fiscal six months of 2019, respectively. Other supplemental information related to these leases are as follows:

~~Supplemental balance sheet information (for the fiscal first quarter ended June 30, 2019)~~:

(Dollars in Millions)
Non-current operating lease right-of-use assets $ 980
Current operating lease liabilities 262
Non-current Operating lease liabilities 749
Total operating lease liabilities $ 1,011

~~ASU 2018-02: Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income~~

This update allows a Company to elect to reclassify stranded tax effects resulting from the Tax Cuts and Job Act enacted in December 2017 from accumulated other comprehensive income to retained earnings. The Company has elected not to reclassify the income tax effects of this standard and therefore this standard will not impact the Company's consolidated financial statements.

~~ASU 2018-16: Derivatives and Hedging (Topic ASC 815)~~

This update adds the Overnight Index Swap (OIS) rate based on the Secured Overnight Financing Rate (SOFR) as an eligible benchmark interest rate permitted in the application of hedge accounting. The guidance was effective for the Company as of the fiscal fourth quarter of 2018, due to the previous adoption of ASU 2017-12. The impact of the adoption of this guidance did not have a material impact on the Company’s consolidated financial statements and related disclosures. The standard may have an impact in the future as the market for SOFR derivatives develops over time and if SOFR is used to hedge the Company’s financial instruments.

~~Recently Issued Accounting Standards~~

~~Not Adopted as of June 30, 2019~~

~~ASU 2018-18: Collaborative Arrangements~~

2020. This update clarifies the interaction between ASC 808, Collaborative Arrangements and ASC 606, Revenue from Contracts with Customers. The update clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606 when the counterparty is a customer. In addition, the update precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue if the counterparty is not a customer for that transaction. This update will be effective for the Company for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. ASU 2018-18 should be applied retrospectively to the date of initial application of ASC 606 and earlyThe adoption ~~is permitted. The Company is currently assessing the impact~~ of this ~~update~~standard did not have a material impact on the ~~Company’s~~Company's consolidated financial ~~statements and related disclosures.~~statements.

ASU ~~2016-13~~:2016-13: Financial Instruments - Credit Losses

The Company adopted this standard as of the beginning of the fiscal year 2020. This update introduces the current expected credit loss (CECL) model, which ~~will require~~requires an entity to measure credit losses for certain financial instruments and financial assets, including trade receivables. Under this update, on initial recognition and at each reporting period, an entity ~~will be~~is required to recognize an allowance that reflects the ~~entity’s~~entity’s current estimate of credit losses expected to be incurred over the life of the financial instrument. ~~This update will be effective for the Company for fiscal years beginning after December 15, 2019 and interim periods within those fiscal years. Early~~The adoption ~~is permitted. The Company is currently assessing the impact~~ of this ~~update~~standard did not have a material impact on the ~~Company’s~~Company's consolidated financial ~~statements and related disclosures.~~statements.

Reclassification

Certain prior period amounts have been reclassified to conform to current year presentation.

Table of Contents

NOTE 2 —— INVENTORIES


(Dollars in Millions)	June 30, 2019		December 30, 2018	March 29, 2020		December 29, 2019
Raw materials and supplies	$	1,198	1,114	$	1,213	1,117
Goods in process	2,024		2,109	2,252		1,832
Finished goods	6,041		5,376	5,403		6,071
Total inventories⁽¹⁾	$	9,263	8,599	$	8,868	9,020

⁽¹⁾~~The balance as of June 30, 2019, does not include~~See Note 10 to the Consolidated Financial Statements for details on assets held for sale and the related to the strategic collaboration with Jabil Inc. of approximately $0.2 billion. The balance as of December 30, 2018, does not include the assets held for sale related to the divestiture of the Advanced Sterilization Products (ASP) business of approximately $0.2 billion and $0.3 billion related to the strategic collaboration with Jabil Inc.divestitures.

NOTE 3 —— INTANGIBLE ASSETS AND GOODWILL

Intangible assets that have finite useful lives are amortized over their estimated useful lives. The latest annual impairment assessment of goodwill and indefinite lived intangible assets was completed in the fiscal fourth quarter of ~~2018~~2019. Future impairment tests for goodwill and indefinite lived intangible assets will be performed annually in the fiscal fourth quarter, or sooner, if warranted.


(Dollars in Millions)	June 30, 2019		December 30, 2018	March 29, 2020		December 29, 2019
Intangible assets with definite lives:
Patents and trademarks — gross	$	36,582	35,194
Patents and trademarks — gross				$	36,214	36,634
Less accumulated amortization	11,500		9,784	13,857		13,154
Patents and trademarks — net	25,082		25,410
Customer relationships and other intangibles — gross	21,862		21,334
Patents and trademarks — net				22,357		23,480
Customer relationships and other intangibles — gross				22,084		22,056
Less accumulated amortization	8,874		8,323	9,728		9,462
Customer relationships and other intangibles — net	12,988		13,011
Customer relationships and other intangibles — net*				12,356		12,594
Intangible assets with indefinite lives:
Trademarks	6,939		6,937	6,829		6,922
Purchased in-process research and development ⁽¹⁾	4,323		2,253	5,796		4,647
Total intangible assets with indefinite lives	11,262		9,190	12,625		11,569
Total intangible assets — net	$	49,332	47,611
Total intangible assets — net				$	47,338	47,643

*The majority is comprised of customer relationships

⁽¹⁾In the fiscal first quarter of 2019, the Company recorded an IPR&D impairment charge of $0.9 billion for the remaining intangible asset value related to the development program of AL-8176, an investigational drug for the treatment of Respiratory Syncytial Virus (RSV) and human metapneumovirus (hMPV) acquired with the 2014 acquisition of Alios Biopharma Inc. The impairment charge was based on

additional information, including clinical data, which became available and led to the Company's decision to abandon the development of AL-8176. A partial impairment charge of $0.8 billion was previously recorded in the fiscal third quarter of 2018 related to the development program of AL-8176. In the fiscal second quarter of 2019,2020, the Company completed the acquisition of ~~Auris Health,~~bermekimab and certain related assets from XBiotech Inc. as well as the acquisition of all outstanding shares in Verb Surgical Inc. and recorded an in-process research and development intangible ~~asset~~assets of ~~$2.9 billion.~~$0.8 billion and $0.4 billion, respectively.

Goodwill as of ~~June 30, 2019~~March 29, 2020 was allocated by segment of business as follows:


(Dollars in Millions)	Consumer			Pharm	Med Devices	Total		Consumer Health			Pharmaceutical		Medical Devices		Total
Goodwill, net at December 30, 2018	$	8,670		9,063	12,720	30,453
Goodwill at December 29, 2019								$	9,736		9,169		14,734		33,639
Goodwill, related to acquisitions	1,196			—	2,019	3,215		—			1		156		157
Currency translation/Other	(49		)	41	1	(7	)	(223		)	(96	)	(6	)	(325	)
Goodwill, net at June 30, 2019	$	9,817		9,104	14,740	33,661
Goodwill at March 29, 2020								$	9,513		9,074		14,884		33,471

The weighted average amortization period for patents and trademarks is 12 years. The weighted average amortization period for customer relationships and other intangible assets is 21 years. The amortization expense of amortizable intangible assets included in cost of products sold was ~~$1.1~~$1.1 billion for each of the fiscal ~~second~~first quarters ended ~~June 30,~~March 29, 2020 and March 31, 2019 and July 1, 2018. The amortization expense of amortizable intangible assets included in cost of products sold was $2.2 billion for each of the fiscal six months ended June 30, 2019 and July 1, 2018. The estimated amortization expense for the five succeeding years approximates $4.4 billion, before tax, per year.. Intangible asset write-downs are included in Other (income) expense, net.

The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately:

Table of Contents



(Dollars in Millions)
2020	2021	2022	2023	2024
$4,500	4,300	4,100	4,100	4,000

See Note 10 to the Consolidated Financial Statements for additional details related to acquisitions and divestitures.

NOTE 4 —— FAIR VALUE MEASUREMENTS

The Company uses forward foreign exchange contracts to manage its exposure to the variability of cash flows, primarily related to the foreign exchange rate changes of future intercompany product and third-party purchases of materials denominated in a foreign currency. The Company uses cross currency interest rate swaps to manage currency risk primarily related to borrowings.

Both types of derivatives are designated as cash flow hedges.

Additionally, the Company uses interest rate swaps as an instrument to manage interest rate risk related to fixed rate borrowings. These derivatives are designated as fair value hedges. The Company uses cross currency interest rate swaps and forward foreign exchange contracts designated as net investment hedges. Additionally, the Company uses forward foreign exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward foreign exchange contracts are not designated as hedges, and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities.

~~The Company early adopted ASU 2017-12: Targeted Improvements to Accounting for Hedge Activities effective as of the beginning of fiscal second quarter of 2018.~~

The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features. The Company maintains credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements. As of ~~June 30, 2019,~~March 29, 2020, the total amount of cash collateral ~~paid~~held by the Company under the credit support agreements (CSA) amounted to ~~$384 million,~~$2.0 billion, net. On an ongoing basis, the Company monitors counter-party credit ratings. The Company considers credit non-performance risk to be low, because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating. Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions. As of ~~June 30, 2019,~~March 29, 2020, the Company had notional amounts outstanding for forward foreign exchange contracts, and cross currency interest rate swaps of $44.0 billion, and ~~interest rate swaps of $49.7~~$20.1 billion ~~$15.3 billion and $0.5 billion,~~ respectively. As of December ~~30, 2018,~~29, 2019, the Company had notional amounts outstanding for forward foreign exchange contracts, and cross currency interest rate swaps of $45.3 billionand ~~interest rate swaps of $41.1~~$20.1 billion ~~$7.3 billion and $0.5 billion,~~ respectively.

All derivative instruments are recorded on the balance sheet at fair value. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction.

The designation as a cash flow hedge is made at the entrance date of the derivative contract. At inception, all derivatives are expected to be highly effective. Foreign exchange contracts designated as cash flow hedges are accounted for under the forward method and all gains/losses associated with these contracts will be recognized in the income statement when the hedged item impacts earnings. Changes in the fair value of these derivatives are recorded in accumulated other comprehensive income until the underlying transaction affects earnings and are then reclassified to earnings in the same account as the hedged transaction.

Gains and losses associated with interest rate swaps and changes in fair value of hedged debt attributable to changes in interest rates are recorded to interest expense in the period in which they occur. Gains and losses on net investment hedges are accounted for through the currency translation account within accumulated other comprehensive income. The portion excluded from effectiveness testing is recorded through interest (income) expense using the spot method. On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items. If and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued.

The Company designated its Euro denominated notes issued in May 2016 with due dates ranging from 2022 to 2035 as a net investment hedge of the Company's investments in certain of its international subsidiaries that use the Euro as their functional currency in order to reduce the volatility caused by changes in exchange rates.

As of ~~June 30, 2019,~~March 29, 2020, the balance of deferred net ~~loss~~gain on derivatives included in accumulated other comprehensive income was ~~$341~~$675 million after-tax. For additional information, see the Consolidated Statements of Comprehensive Income and Note 7. The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the next 12 months as a result of transactions that are expected to occur over that period. The maximum length of

Table of Contents

time over which the Company is hedging transaction exposure is 18 months, excluding interest rate contracts, net investment hedges and equity collar contracts. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative.

The following table is a summary of the activity related to derivatives and hedges for the fiscal ~~second~~first quarters ended in ~~2019~~2020 and ~~2018~~2019:, net of tax:


	June 30, 2019										July 1, 2018										March 29, 2020									March 31, 2019
(Dollars in Millions)	Sales			Cost of Products Sold		R&D Expense	Interest (Income) Expense		Other (Income) Expense		Sales		Cost of Products Sold		R&D Expense		Interest (Income) Expense		Other (Income) Expense		Sales		Cost of Products Sold		R&D Expense		Interest (Income) Expense	Other (Income) Expense		Sales		Cost of Products Sold		R&D Expense		Interest (Income) Expense	Other (Income) Expense
The effects of fair value, net investment and cash flow hedging:
Gain (Loss) on fair value hedging relationship:
Interest rate swaps contracts:
Hedged items	$	—		—		—	1		—		—		—		—		5		—
Derivatives designated as hedging instruments	—			—		—	(1	)	—		—		—		—		(5	)	—

Gain (Loss) on net investment hedging relationship:
Cross currency interest rate swaps contracts:
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing	—			—		—	39		—		—		—		—		2		—		—		—		—		40	—		—		—		—		38	—
Amount of gain or (loss) recognized in AOCI	—			—		—	39		—		—		—		—		2		—		—		—		—		40	—		—		—		—		38	—

Gain (Loss) on cash flow hedging relationship:
Forward foreign exchange contracts:
Amount of gain or (loss) reclassified from AOCI into income	(14		)	(101	)	36	—		2		17		76		(14	)	—		(10	)	9		(173	)	(110	)	—	(2	)	(21	)	(35	)	(139	)	—	6

Amount of gain or (loss) recognized in AOCI	—			(50	)	18	—		(3	)	(49	)	(57	)	21		—		3		11		302		(110	)	—	(36	)	(6	)	(296	)	(110	)	—	(13	)

Cross currency interest rate swaps contracts:
Amount of gain or (loss) reclassified from AOCI into income	—			—		—	64		—		—				—		32		—		—		—		—		98	—		—				—		55	—
Amount of gain or (loss) recognized in AOCI	$	—		—		—	82		—		—		—		—		19		—		$	—	—		—		625	—		—		—		—		59	—

The following table is ~~a summary~~the effect of ~~the activity related to~~ derivatives ~~and hedges~~not designated as hedging instruments for the fiscal ~~six months ended in~~first quarters 2020 and 2019:

~~2019~~ ~~and~~ ~~2018~~:



		Gain/(Loss) Recognized In Income on Derivative
(Dollars in Millions)	Location of Gain /(Loss) Recognized in Income on Derivative	Fiscal First Quarter Ended
Derivatives Not Designated as Hedging Instruments		March 29, 2020		March 31, 2019
Foreign Exchange Contracts	Other (income) expense	$	89	(38	)

June 30, 2019 July 1, 2018
(Dollars in Millions) Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense
The effects of fair value, net investment and cash flow hedging:
Gain (Loss) on fair value hedging relationship:
Interest rate swaps contracts:
Hedged items $ —
—
—
1
—
—
—
—
10
—
Derivatives designated as hedging instruments —
—
—
(1 ) —
—
—
—
(10 ) —

Gain (Loss) on net investment hedging relationship:
Cross currency interest rate swaps contracts:
   Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing —
—
—
78
—
—
—
—
2
—
   Amount of gain or (loss) recognized in AOCI —
—
—
78
—
—
—
—
2
—

Gain (Loss) on cash flow hedging relationship:
Forward foreign exchange contracts:
   Amount of gain or (loss) reclassified from AOCI into income (35 ) (136 ) (103 ) —
8
46
78
(252 ) —
(21 )

   Amount of gain or (loss) recognized in AOCI (6 ) (346 ) (92 ) —
10
(18 ) (54 ) (216 ) —
(15 )

Cross currency interest rate swaps contracts:
   Amount of gain or (loss) reclassified from AOCI into income —
—
—
118
—
—
—
—
72
—
   Amount of gain or (loss) recognized in AOCI $ —
—
—
140
—
—
—
—
76
—

~~As of June 30, 2019, and December 30, 2018, the following amounts were recorded on the Consolidated Balance Sheet related to cumulative basis adjustment for fair value hedges:~~

Line item in the Consolidated Balance Sheet in which the hedged item is included
Carrying Amount of the Hedged Liability

Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of the Hedged Liability
(Dollars in Millions) June 30, 2019 December 30, 2018 June 30, 2019 December 30, 2018
Current Portion of Long-term Debt $ 498
494
1
5
Long-term Debt —
—
—
—

The following table is the effect of derivatives not designated as hedging instrument for the fiscal second quarter and fiscal six months ended in 2019 and 2018:

Gain/(Loss)
Recognized In
Income on Derivative
Gain/(Loss)
Recognized In
Income on Derivative
(Dollars in Millions) Location of Gain /(Loss) Recognized in Income on Derivative Fiscal Second Quarter Ended Fiscal Six Months Ended
Derivatives Not Designated as Hedging Instruments June 30, 2019 July 1, 2018 June 30, 2019 July 1, 2018
Foreign Exchange Contracts Other (income) expense $ (50 ) (53 ) (88 ) (72 )

Table of Contents

The following table is the effect of net investment hedges for the fiscal ~~second~~first quarters ended in ~~2019~~2020 and ~~2018~~2019


	Gain/(Loss) Recognized In Accumulated OCI				Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income	Gain/(Loss) Reclassified From Accumulated OCI Into Income		Gain/(Loss) Recognized In Accumulated OCI			Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income	Gain/(Loss) Reclassified From Accumulated OCI Into Income
(Dollars in Millions)	June 30, 2019			July 1, 2018		June 30, 2019	July 1, 2018	March 29, 2020		March 31, 2019		March 29, 2020	March 31, 2019
Debt	$	(57	)	306	Other (income) expense	—	—	$	46	71	Interest (income) expense	—	—
Cross Currency interest rate swaps	$	(57	)	37	Other (income) expense	—	—	$	827	370	Interest (income) expense	—	—

~~The following table is the effect of net investment hedges for the fiscal six months ended in~~ ~~2019~~ ~~and~~ ~~2018~~:

Gain/(Loss)
Recognized In
Accumulated OCI
Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income
Gain/(Loss) Reclassified From
Accumulated OCI
Into Income
(Dollars in Millions) June 30, 2019 July 1, 2018 June 30, 2019 July 1, 2018
Debt $ 14
156

Other (income) expense

—
—
Cross Currency interest rate swaps $ 313
37
Other (income) expense —
—

The Company holds equity investments with readily determinable fair values and equity investments without readily determinable fair values. The Company has elected to measure equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.

The following table is a summary of the activity related to equity investments:


(Dollars in Millions)	December 30, 2018					June 30, 2019		December 29, 2019					March 29, 2020
	Carrying Value		Changes in Fair Value Reflected in Net Income ⁽¹⁾		Sales/ Purchases/Other ⁽²⁾	Carrying Value	Non Current Other Assets	Carrying Value		Changes in Fair Value Reflected in Net Income ⁽¹⁾		Sales/ Purchases/Other ⁽²⁾	Carrying Value	Non Current Other Assets
Equity Investments with readily determinable value	$	511	292		160	963	963	$	1,148	(327	)	5	826	826

Equity Investments without readily determinable value	$	681	(23	)	19	677	677	$	712	(33	)	15	694	694

⁽¹⁾ Recorded in Other Income/Expense

⁽²⁾ Other includes impact of currency

For equity investments without readily determinable market values, ~~$22~~$33 million of the decrease in the fair value reflected in net income were the result of impairments. ~~There was a $1 million decrease in the fair value reflected in net income due to changes in observable prices.~~

Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. In accordance with ASC 820, a three-level hierarchy was established to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described below with Level 1 inputs having the highest priority and Level 3 inputs having the lowest.

The fair value of a derivative financial instrument (i.e., forward foreign exchange contracts, interest rate contracts) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S. Dollar at the current spot foreign exchange rate. The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on the ~~Company’s~~Company’s results of operations, cash flows or financial position. The Company also holds equity investments which are classified as Level 1 and debt securities which are classified as Level 2. The Company holds acquisition related contingent liabilities based upon certain regulatory and commercial events, which are classified as Level 3, whose values are determined using discounted cash flow methodologies or similar techniques for which the determination of fair value requires significant judgment or estimations.

The following three levels of inputs are used to measure fair value:

Level 1 —— Quoted prices in active markets for identical assets and liabilities.

Level 2 —— Significant other observable inputs.

Level 3 —— Significant unobservable inputs.

Table of Contents

The ~~Company’s~~Company’s significant financial assets and liabilities measured at fair value as of ~~June 30, 2019~~March 29, 2020 and December ~~30, 2018~~29, 2019 were as follows:


	June 30, 2019					December 30, 2018	March 29, 2020					December 29, 2019
(Dollars in Millions)	Level 1		Level 2	Level 3	Total	Total⁽¹⁾	Level 1		Level 2	Level 3	Total	Total⁽¹⁾
Derivatives designated as hedging instruments:
Assets:
Forward foreign exchange contracts	$	—	251	—	251	501	$	—	941	—	941	209
Interest rate contracts ⁽⁴⁾⁽³⁾	—		325	—	325	161	—		1,569	—	1,569	693
Total	—		576	—	576	662	—		2,510	—	2,510	902
Liabilities:
Forward foreign exchange contracts	—		481	—	481	548	—		530	—	530	426
Interest rate contracts ⁽³⁾⁽⁴⁾	—		394	—	394	292
Interest rate contracts ⁽³⁾							—		247	—	247	193
Total	—		875	—	875	840	—		777	—	777	619
Derivatives not designated as hedging instruments:
Assets:
Forward foreign exchange contracts	—		23	—	23	32	—		120	—	120	23
Liabilities:
Forward foreign exchange contracts	—		55	—	55	32	—		106	—	106	33
Other Investments:
Equity investments ⁽⁵⁾⁽⁴⁾	963		—	—	963	511	826		—	—	826	1,148
Debt securities⁽⁶⁾⁽⁵⁾	$	—	2,767	—	2,767	9,734	$	—	5,673	—	5,673	4,368
Other Liabilities
Contingent consideration ⁽⁷⁾⁽⁶⁾				1,479	1,479	335				784	784	1,715



Gross to Net Derivative Reconciliation	March 29, 2020			December 29, 2019
(Dollars in Millions)
Total Gross Assets	$	2,630		925
Credit Support Agreement (CSA)	(2,530		)	(841	)
Total Net Asset	100			84

Total Gross Liabilities	883			652
Credit Support Agreement (CSA)	(531		)	(586	)
Total Net Liabilities	$	352		66

Table of Contents

Gross to Net Derivative Reconciliation June 30, 2019 December 30, 2018
(Dollars in Millions)
Total Gross Assets $ 599
694
Credit Support Agreement (CSA) (437 ) (423 )
Total Net Asset 162
271

Total Gross Liabilities 930
872
Credit Support Agreement (CSA) (821 ) (605 )
Total Net Liabilities $ 109
267

Summarized information about changes in liabilities for contingent consideration is as follows:



	Fiscal first quarter ended
	March 29, 2020			March 31, 2019
(Dollars in Millions)
Beginning Balance	$	1,715		$	397
Changes in estimated fair value ⁽⁷⁾	(977		)	32
Additions	106			23
Payments	(60		)	—
Ending Balance	$	784		$	452


⁽¹⁾	December 30, ~~2018~~2019 assets and liabilities are all classified as Level 2 with the exception of equity investments of ~~$511~~$1,148 million, which are classified as Level 1 and ~~$335~~contingent consideration of $1,715 million, classified as Level 3.


⁽²⁾	Includes $6$1 million of non-current other assets as of March 29, 2020 and December ~~30, 2018.~~29, 2019.


⁽³⁾	Includes ~~$1 million~~cross currency interest rate swaps and ~~$3 million of non-current other liabilities as of June 30, 2019 and December 30, 2018, respectively.~~interest rate swaps.


⁽⁴⁾	~~Includes cross currency interest rate swaps and interest rate swaps.~~ Classified as non-current other assets.


⁽⁵⁾	Classified ~~as non-current other assets. The carrying amount of the equity investments were $963 million~~within cash equivalents and ~~$511 million as of June 30, 2019 and December 30, 2018, respectively.~~current marketable securities.


⁽⁶⁾	~~Classified within cash equivalents~~ Includes $759 million and $1,631 million (primarily related to Auris Health), classified as non-current other liabilities as of March 29, 2020 and December 29, 2019, respectively. Includes $25 million and $84 million classified as current ~~marketable securities.~~liabilities as of March 29, 2020 and December 29, 2019, respectively.


⁽⁷⁾	~~Includes $1,370 million (primarily related to Auris Health)~~ Ongoing fair value adjustment amounts are primarily recorded in Research and ~~$335 million, classified as non-current other liabilities as of June 30, 2019 and December 30, 2018, respectively. Includes $109 million classified as current liabilities as of June 30, 2019~~Development expense.

During the fiscal first quarter of 2020, the Company recorded a contingent consideration reversal of $983 million related to the timing of certain developmental milestones associated with the Auris Health acquisition. The one-time reversal of the contingent consideration was recorded in Other income and expense. As of March 29, 2020 the estimated fair value of the remaining contingent consideration is $165 million. For additional details see Note 10 to the Consolidated Financial Statements.

Table of Contents

The Company's cash, cash equivalents and current marketable securities as of ~~June 30, 2019~~March 29, 2020 comprised:


(Dollars in Millions)	Carrying Amount		Unrecognized Gain	Estimated Fair Value	Cash & Cash Equivalents	Current Marketable Securities	Carrying Amount		Unrecognized Gain	Unrecognized Loss		Estimated Fair Value	Cash & Cash Equivalents	Current Marketable Securities
Cash	$	2,615	—	2,615	2,615		$	2,499	—	—		2,499	2,499
Other sovereign securities⁽¹⁾	380		—	380	380
Non-U.S. sovereign securities⁽¹⁾							90		—	—		90	90	—
U.S. reverse repurchase agreements	7,014		—	7,014	7,014		3,965		—	—		3,965	3,965	—
Other reverse repurchase agreements	219		—	219	219		473		—	—		473	473
Corporate debt securities⁽¹⁾	264		—	264	264		2,135		1	(1	)	2,135	1,039	1,096
Money market funds	1,368		—	1,368	1,368		2,424		—	—		2,424	2,424
Time deposits⁽¹⁾	651		—	651	651		765		—	—		765	765
Subtotal	12,511		—	12,511	12,511	—	12,351		1	(1	)	12,351	11,255	1,096

			Unrealized Gain						Unrealized Gain	Unrealized Loss
Government securities	2,501		1	2,502	1,845	657
Other sovereign securities	—		—	—	—	—
U.S. Gov't securities							5,418		4	—		5,422	4,260	1,162
Corporate debt securities	265		—	265	20	245	253		—	(2	)	251	15	236
Subtotal available for sale debt⁽²⁾	$	2,766	1	2,767	1,865	902	$	5,671	4	(2	)	5,673	4,275	1,398
Total cash, cash equivalents and current marketable securities	$	15,277	1	15,278	14,376	902	$	18,022	5	(3	)	18,024	15,530	2,494

⁽¹⁾Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings.

⁽²⁾Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.

In the fiscal year ended December ~~30, 2018~~29, 2019 the carrying amount was the same as the estimated fair value.

Fair value of government securities and obligations and corporate debt securities was estimated using quoted broker prices and significant other observable inputs.

The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. Available for sale securities with stated maturities of greater than one year from the date of purchase are available ~~for~~to fund current operations and are classified as cash equivalents and current marketable securities.

The contractual maturities of the available for sale securities as of ~~June 30, 2019~~March 29, 2020 are as follows:


(Dollars in Millions)	Cost Basis		Fair Value	Cost Basis		Fair Value
Due within one year	$	2,711	2,712	$	5,632	5,635
Due after one year through five years	55		55	39		38
Due after five years through ten years	—		—	—		—
Total debt securities	$	2,766	2,767	$	5,671	5,673

Table of Contents

Financial Instruments not measured at Fair Value:

The following financial liabilities are held at carrying amount on the consolidated balance sheet as of ~~June 30, 2019~~March 29, 2020:


(Dollars in Millions)	Carrying Amount		Estimated Fair Value	Carrying Amount		Estimated Fair Value

Financial Liabilities

Current Debt	$	1,719	1,739	$	2,190	2,234

Non-Current Debt
3% Zero Coupon Convertible Subordinated Debentures due in 2020	52		99
1.950% Notes due 2020	499		498
2.95% Debentures due 2020	548		554
3.55% Notes due 2021	449		462	449		463
2.45% Notes due 2021	349		353	350		356
1.65% Notes due 2021	999		993
0.250% Notes due 2022 (1B Euro 1.1364)	1,134		1,150
0.250% Notes due 2022 (1B Euro 1.0980)				1,097		1,096
2.25% Notes due 2022	997		1,004	998		1,019
6.73% Debentures due 2023	250		298	250		301
3.375% Notes due 2023	805		852	804		875
2.05% Notes due 2023	498		498	499		512
0.650% Notes due 2024 (750MM Euro 1.1364)	849		882
5.50% Notes due 2024 (500 MM GBP 1.2709)	631		770
0.650% Notes due 2024 (750MM Euro 1.0980)				821		826
5.50% Notes due 2024 (500 MM GBP 1.2023)				597		697
2.625% Notes due 2025	748		762	748		796
2.45% Notes due 2026	1,992		2,024	1,993		2,112
2.95% Notes due 2027	996		1,032	997		1,074
2.90% Notes due 2028	1,493		1,541	1,494		1,640
1.150% Notes due 2028 (750MM Euro 1.1364)	845		916
1.150% Notes due 2028 (750MM Euro 1.0980)				817		833
6.95% Notes due 2029	297		414	297		419
4.95% Debentures due 2033	498		618	498		661
4.375% Notes due 2033	856		1,008	856		1,099
1.650% Notes due 2035 (1.5B Euro 1.1364)	1,688		1,910
1.650% Notes due 2035 (1.5B Euro 1.0980)				1,631		1,699
3.55% Notes due 2036	988		1,049	989		1,172
5.95% Notes due 2037	992		1,377	992		1,477
3.625% Notes due 2037	1,487		1,592	1,487		1,719
3.40% Notes due 2038	990		1,032	991		1,144
5.85% Debentures due 2038	696		946	696		1,072
4.50% Debentures due 2040	538		635	539		689
4.85% Notes due 2041	297		364	297		432
4.50% Notes due 2043	495		594	495		696
3.70% Notes due 2046	1,973		2,144	1,973		2,406
3.75% Notes due 2047	991		1,089	991		1,230
3.50% Notes due 2048	742		778	742		890
Other	37		37	5		5
Total Non-Current Debt	$	27,699	30,275	$	25,393	29,410

The weighted average effective interest rate on non-current debt is ~~3.19%~~3.26%.

The excess of the estimated fair value over the carrying value of debt was $~~0.3~~3.0 billion at December ~~30, 2018.~~29, 2019.

Fair value of the non-current debt was estimated using market prices, which were corroborated by quoted broker prices and significant other observable inputs.

~~NOTE 5 — INCOME TAXES~~

Table of Contents

NOTE 5 — INCOME TAXES

The worldwide effective income tax rates for the fiscal first quarters of 2020 and 2019were11.0%and 15.2%, respectively. In the third fiscal ~~six months~~quarter of 2019, Switzerland enacted the Federal Act on Tax Reform and ~~2018 were 18.4% and 20.4%~~AHV Financing (TRAF), ~~respectively. The U.S. Tax Cuts and Jobs Act (TCJA) was enacted into law~~which became effective on January 1, ~~2018. This law reduced~~2020. More information on the ~~U.S. statutory corporate tax rate from 35% to 21%, eliminated or reduced certain corporate income tax deductions and introduced a tax~~provisions of TRAF can be found in the Company’s Annual Report on ~~Global Intangible Low-Taxed Income (GILTI) and a Base Erosion and Anti Abuse Tax (BEAT)~~Form 10-K for the fiscal year ended December 29, 2019. During the first fiscal ~~six months~~quarter of ~~2018,~~2020, the final canton where the Company maintains significant operations enacted TRAF legislation and, accordingly, the Company recorded an estimated deferred tax benefit of approximately $0.3 billion for the remeasurement of existing deferred tax liabilities offset by a related $0.2 billion increase in U.S. GILTI deferred taxes (or 1.3% net impact on the Q1 2020 effective tax rate). The Company is currently assessing and awaiting the approval for certain elective transition provisions in several cantons which include discussions with federal and cantonal tax authorities on the application of the new law. The Company has recorded the estimated impact of ~~these changes~~the transitional provisions based on the best available information ~~and guidance available at that time. Subsequent U.S. Treasury guidance on the application of these provisions allowed~~for cantons where enactment has occurred, but the Company ~~to better refine these calculations for~~has not yet received final tax rulings in all cantons. Further, authoritative guidance from the relevant Swiss tax authorities may be issued in the future and additional revisions may be required in the fiscal ~~year 2018 and when combined with the election to account for GILTI under the deferred method reduced~~period they are issued.

In the first fiscal ~~six months~~quarter of 2020, the Company reduced a contingent consideration liability related to the 2019 Auris Health acquisition that benefited the overall effective ~~income~~ tax rate by ~~approximately 2.5% versus~~1.9% (see Note 10 to the ~~first fiscal six months of 2018. This reduction was partially offset by~~Consolidated Financial Statements for more details). Additionally, the Company ~~having~~had more income in higher tax jurisdictions relative to lower tax jurisdictions ~~including the one-time impact of the ASP divestiture, which was primarily taxed in the U.S.,~~ as compared to the same period in ~~2018.~~the prior fiscal year, driven primarily by the one-time charges in the first fiscal quarter of 2019 related to the impairment of the Alios in-process research and development intangible asset taxed in the U.S. at 21.0% and additional tax benefits received from stock based compensation that were either exercised or vested during the fiscal first quarter.

As of ~~June 30, 2019,~~March 29, 2020, the Company had approximately ~~$3.3~~$3.2 billion of liabilities from unrecognized tax benefits. The Company ~~believes it is possible that~~conducts business and files tax returns in numerous countries and currently has tax audits ~~may be completed by tax authorities~~ in ~~some jurisdictions over the next twelve months. The Company is not able to provide~~progress in a ~~reasonably reliable estimate~~number of ~~the timing of any future tax payments relating to uncertain tax positions.~~jurisdictions. With respect to the United States, the IRS has completed its audit for the tax years through 2009 and is currently auditing the tax years 2010 through 2012. The Company currently expects ~~substantial~~ completion of this audit ~~within~~and settlement of the related tax liabilities in the fiscal year 2020. As of March 29, 2020, the Company has classified unrecognized tax benefits and related interest of approximately $0.2 billion as a current liability on the “Accrued taxes on Income” line of the Consolidated Balance Sheet. This is the amount expected to be paid over the next ~~twelve months.~~12 months with respect to the IRS audit. During the first fiscal quarter of 2020, the Company made a payment of approximately $0.6 billion to the U.S. Treasury with respect to the 2010-2012 tax audit in anticipation of a final settlement later in the fiscal year 2020. The ~~outcome from~~completion of this tax audit may result in additional adjustments to the ~~Company’s current estimates that may have a material impact on the Company’s current and future operating results or cash flows in the period that the audit is substantially completed.~~Company’s unrecognized tax benefit liability.

~~Swiss Tax Reform~~

On September 28, 2018 the Swiss Parliament approved the Federal Act on Tax Reform and AHV Financing (TRAF). On May 19, 2019 a public referendum was held in Switzerland that approved the federal reform proposals and subsequently announced the TRAF will become effective on January 1, 2020. In ~~the fiscal third quarter of 2019, the Swiss Federal Council enacted TRAF.~~

TRAF provides for parameters which enable the Swiss cantons to establish localized tax rates and regulations for multinational companies. The new cantonal tax parameters include favorable tax benefits for patents and an additional research and development tax deduction to encourage investment. The cantons are required to implement new local legislation by January 1, 2020 or the new federal law will be directly applied.

~~The significant cantons in which~~other major jurisdictions where the Company ~~operates have not yet enacted legislation in response~~conducts business, the years that remain open to ~~TRAF.~~tax audit go back to the year 2006. The ~~transitional provisions of TRAF are also expected to allow companies to elect~~Company believes it is possible that tax ~~basis adjustments to fair value which is used for tax depreciation and amortization purposes resulting in a deduction~~audits may be completed over the ~~transitional period. The adjustment~~next twelve months by taxing authorities in some jurisdictions outside of the ~~Company’s asset tax basis will likely require review and approval by the federal and cantonal tax agencies. The Company has not yet applied for the adjustment to the tax basis.~~

~~As TRAF was not enacted as of June 30, 2019,~~United States. However, the Company ~~has~~is not ~~reflected the financial impacts in its fiscal second quarter results. The Company estimates the impact of revaluing its deferred tax assets and liabilities as~~able to provide a result of Swiss Federal enactment of TRAF, without consideration of future cantonal tax rate changes or the transitional provisions, to result in an incremental tax expense between $0.3 billion to $0.5 billion in the fiscal third quarter of 2019. The financial impactreasonably reliable estimate of the timing of any other future ~~cantonal~~ tax ~~rate changes or the transitional provisions cannot currently be reasonably estimated but may result in a material impact~~payments relating to ~~the future results of the Company.~~uncertain tax positions.

NOTE 6 —— PENSIONS AND OTHER BENEFIT PLANS

Components of Net Periodic Benefit Cost

Net periodic benefit ~~cost~~costs for the ~~Company’s~~Company’s defined benefit retirement plans and other benefit plans for the fiscal ~~second~~first quarters of 2020and ~~the first fiscal six months of~~ 2019 ~~and 2018~~ include the following components:

Fiscal Second Quarter Ended Fiscal Six Months Ended
Retirement Plans Other Benefit Plans Retirement Plans Other Benefit Plans
(Dollars in Millions) June 30, 2019 July 1, 2018 June 30, 2019 July 1, 2018 June 30, 2019 July 1, 2018 June 30, 2019 July 1, 2018
Service cost $ 277
309
69
68
553
618
137
135
Interest cost 274
249
46
38
549
501
92
75
Expected return on plan assets (581 ) (554 ) (1 ) (2 ) (1,164 ) (1,114 ) (3 ) (4 )
Amortization of prior service cost/(credit) 1
—
(8 ) (8 ) 2
1
(16 ) (16 )
Recognized actuarial losses 146
213
33
31
290
428
65
61
Curtailments and settlements 8
—
—
—
7
(2 ) —
—
Net periodic benefit cost $ 125
217
139
127
237
432
275
251

15

Table of Contents



	Retirement Plans					Other Benefit Plans
(Dollars in Millions)	March 29, 2020			March 31, 2019		March 29, 2020		March 31, 2019
Service cost	$	326		276		72		68
Interest cost	240			275		33		46
Expected return on plan assets	(614		)	(583	)	(2	)	(2	)
Amortization of prior service cost/(credit)	—			1		(8	)	(8	)
Recognized actuarial losses	223			144		36		32
Curtailments and settlements	19			(1	)	—		—
Net periodic benefit cost	$	194		112		131		136

The service cost component of net periodic benefit cost is presented in the same line items on the Consolidated Statement of Earnings where other employee compensation costs are reported. All other components of net periodic benefit cost are presented as part of Other (income) expense, net on the Consolidated Statement of Earnings.

Company Contributions

For the fiscal ~~six months~~first quarter ended~~June 30, 2019~~March 29, 2020, the Company contributed ~~$42~~$23 million and ~~$87~~$9 million to its U.S. and international retirement plans, respectively. The Company plans to continue to fund its U.S. defined benefit plans to comply with the Pension Protection Act of 2006. International plans are funded in accordance with local regulations.

NOTE 7 —— ACCUMULATED OTHER COMPREHENSIVE INCOME

Components of other comprehensive income (loss) consist of the following:



	Foreign			Gain/(Loss)	Employee		Gain/(Loss)		Total Accumulated		Foreign			Gain/(Loss)	Employee		Gain/(Loss)		Total Accumulated
	Currency			On	Benefit		On Derivatives		Other Comprehensive		Currency			On	Benefit		On Derivatives		Other Comprehensive
(Dollars in Millions)	Translation			Securities	Plans		& Hedges		Income (Loss)		Translation			Securities	Plans		& Hedges		Income (Loss)
December 30, 2018	$	(8,869	)	—	(6,158	)	(195	)	(15,222	)
December 29, 2019											$	(8,705	)	—	(6,891	)	(295	)	(15,891	)
Net change	92			1	306		(146	)	253		(1,519		)	2	195		970		(352	)
June 30, 2019	$	(8,777	)	1	(5,852	)	(341	)	(14,969	)
March 29, 2020											$	(10,224	)	2	(6,696	)	675		(16,243	)

Amounts in accumulated other comprehensive income are presented net of the related tax impact. Foreign currency translation is not adjusted for income taxes where it relates to permanent investments in international subsidiaries. For additional details on comprehensive income see the Consolidated Statements of Comprehensive Income.

Details on reclassifications out of Accumulated Other Comprehensive Income:

Gain/(Loss) On Securities - reclassifications released to Other (income) expense, net.

Employee Benefit Plans - reclassifications are included in net periodic benefit cost. See Note 6 for additional details.

Gain/(Loss) On Derivatives && Hedges - reclassifications to earnings are recorded in the same account as the underlying transaction. See Note 4 for additional details.

Table of Contents

NOTE 8 —— EARNINGS PER SHARE

The following is a reconciliation of basic net earnings per share to diluted net earnings per share for the fiscal ~~second~~first quarters ~~and the first fiscal six months~~ ended ~~June 30, 2019~~March 29, 2020 and ~~July 1, 2018~~March 31, 2019:


	Fiscal Second Quarter Ended					Fiscal Six Months Ended				Fiscal First Quarter Ended
(Shares in Millions)	June 30, 2019			July 1, 2018		June 30, 2019		July 1, 2018		March 29, 2020			March 31, 2019
Basic net earnings per share	$	2.11		1.47		3.52		3.10		$	2.20		1.41
Average shares outstanding — basic	2,652.5			2,682.3		2,656.7		2,682.2
Average shares outstanding — basic										2,633.7			2,660.8
Potential shares exercisable under stock option plans	140.8			127.5		138.6		141.8		126.0			136.7
Less: shares which could be repurchased under treasury stock method	(102.3		)	(89.3	)	(99.0	)	(96.3	)	(89.4		)	(99.4	)
Convertible debt shares	0.7			0.8		0.7		0.8		0.7			0.7
Average shares outstanding — diluted	2,691.7			2,721.3		2,697.0		2,728.5
Average shares outstanding — diluted										2,671.0			2,698.8
Diluted net earnings per share	$	2.08		1.45		3.47		3.05		$	2.17		1.39

The diluted net earnings per share calculation for both the fiscal ~~second~~first quarters ended ~~June 30,~~March 29, 2020 and March 31, 2019 ~~and July 1, 2018~~ included the dilutive effect of convertible debt that was offset by the related reduction in interest expense. The diluted net earnings per share calculation for the fiscal ~~second~~first quarter ended ~~June 30, 2019~~March 29, 2020 excluded ~~an insignificant number of~~10 million shares related to stock options, as the exercise price of these options was greater than their average market value. The diluted net earnings per share calculation for the fiscal ~~second~~first quarter ended ~~July 1, 2018 excluded 17 million shares related to stock options, as the exercise price of these options was greater than their average market value.~~

~~The diluted net earnings per share calculation for the fiscal six months ended June 30,~~March 31, 2019 and July 1, 2018 included the dilutive effect of convertible debt that was offset by the related reduction in interest expense. The diluted net earnings per share calculation for the fiscal six months ended June 30, 2019 excluded an insignificant number of shares related to stock options, as the exercise price of these options was greater than their average market value. The diluted net earnings per share calculation for the fiscal six months ended July 1, 2018 included all shares related to stock options, as there were no0 options or other instruments which were anti-dilutive.

Table of Contents

NOTE 9 —— SEGMENTS OF BUSINESS AND GEOGRAPHIC AREAS

SALES BY SEGMENT OF BUSINESS


	Fiscal Second Quarter Ended					Fiscal Six Months Ended					Fiscal First Quarter Ended
(Dollars in Millions)	June 30, 2019		July 1, 2018	Percent Change		June 30, 2019		July 1, 2018	Percent Change		March 29, 2020		March 31, 2019	Percent Change

CONSUMER
Consumer Health*
Baby Care
U.S.	$	99	89	11.5	%	$	186	186	(0.2	)%	$	92	87	6.7	%
International	344		367	(6.3	)	651		727	(10.5	)	269		307	(12.4	)
Worldwide	443		456	(2.8	)	837		913	(8.4	)	361		394	(8.2	)
Beauty
Skin Health/Beauty
U.S.	663		637	4.1		1,251		1,248	0.3		659		588	12.1
International	539		472	14.1		1,041		945	10.1		458		502	(8.8	)
Worldwide	1,202		1,109	8.4		2,292		2,193	4.5		1,117		1,090	2.5
Oral Care
U.S.	155		157	(1.6	)	306		314	(2.5	)	176		151	16.2
International	234		236	(0.7	)	450		458	(1.7	)	219		216	1.5
Worldwide	389		393	(1.1	)	756		772	(2.0	)	395		367	7.6
OTC
U.S.	484		454	6.6		991		919	7.8		689		507	35.9
International	580		612	(5.1	)	1,160		1,219	(4.9	)	659		580	13.7
Worldwide	1,064		1,066	(0.1	)	2,151		2,138	0.6		1,348		1,087	24.1
Women's Health
U.S.	3		4	(10.3	)	6		7	(3.7	)	4		3	32.0
International	250		276	(9.5	)	472		516	(8.6	)	228		222	2.5
Worldwide	253		280	(9.5	)	478		523	(8.5	)	232		225	2.9
Wound Care/Other
U.S.	132		135	(1.9	)	234		238	(1.5	)	119		102	17.0
International	61		65	(6.4	)	114		125	(8.9	)	52		53	(1.2	)
Worldwide	193		200	(3.4	)	348		363	(4.0	)	171		155	10.7
TOTAL CONSUMER
TOTAL Consumer Health
U.S.	1,537		1,476	4.1		2,975		2,912	2.2		1,740		1,438	21.0
International	2,007		2,028	(1.0	)	3,887		3,990	(2.6	)	1,885		1,880	0.3
Worldwide	3,544		3,504	1.2		6,862		6,902	(0.6	)	3,625		3,318	9.2
* Previously referred to as Consumer

PHARMACEUTICAL
Immunology
     U.S. 2,379
2,317
2.7
4,542
4,317
5.2
     International 1,087
1,021
6.3
2,175
2,063
5.4
     Worldwide 3,466
3,338
3.8
6,717
6,380
5.3
     REMICADE^®

     U.S. 801
918
(12.7 ) 1,575
1,834
(14.1 )
     U.S. Exports 62
104
(40.3 ) 138
246
(43.9 )
     International 244
298
(18.5 ) 496
629
(21.2 )
     Worldwide 1,107
1,320
(16.2 ) 2,209
2,709
(18.5 )
     SIMPONI / SIMPONI ARIA^®

     U.S. 281
274
2.7
544
498
9.1
     International 282
274
2.7
543
568
(4.4 )
     Worldwide 563
548
2.7
1,087
1,066
1.9
     STELARA^®

     U.S. 1,058
919
15.2
1,940
1,571
23.5
     International 499
422
18.1
1,022
831
23.0
     Worldwide 1,558
1,341
16.1
2,963
2,402
23.3
     TREMFYA^®

     U.S. 176
102
72.3 344
168
*
     International 59
24
* 108
30
*
     Worldwide 235
126
86.5 452
198
*
     OTHER IMMUNOLOGY

     U.S. —
—
— —
—
—
     International 3
3
27.7 6
5
23.6
     Worldwide 3
3
27.7 6
5
23.6

Infectious Diseases
     U.S. 387
328
17.8
744
661
12.5
     International 475
521
(8.7 ) 964
1,018
(5.3 )
     Worldwide 862
849
1.5
1,708
1,679
1.7
     EDURANT^® / rilpivirine

     U.S. 12
15
(15.8 ) 24
29
(17.3 )
     International 198
196
0.5
397
392
1.4
     Worldwide 210
211
(0.6 ) 421
421
0.1
     PREZISTA^® / PREZCOBIX^® / REZOLSTA^® / SYMTUZA^®

     U.S. 344
277
24.2
659
550
19.9
     International 191
215
(11.1 ) 399
420
(5.0 )
     Worldwide 535
492
8.7
1,058
970
9.1
     OTHER INFECTIOUS DISEASES

     U.S. 31
36
(16.6 ) 61
82
(26.0 )
     International 86
110
(20.8 ) 168
206
(18.6 )
     Worldwide 117
146
(19.7 ) 229
288
(20.7 )

18

Table of Contents



PHARMACEUTICAL
Immunology
U.S.	2,410	2,163	11.4
International	1,228	1,088	12.8
Worldwide	3,638	3,251	11.9
REMICADE^®
U.S.	625	774	(19.3	)
U.S. Exports	110	76	44.3
International	256	252	1.5
Worldwide	990	1,102	(10.2	)
SIMPONI / SIMPONI ARIA^®
U.S.	272	263	3.4
International	258	261	(1.2	)
Worldwide	529	524	1.1
STELARA^®
U.S.	1,217	882	37.9
International	603	523	15.2
Worldwide	1,819	1,405	29.5
TREMFYA^®
U.S.	187	168	11.5
International	109	49	*
Worldwide	296	217	36.4
OTHER IMMUNOLOGY
U.S.	—	—	—
International	3	3	(6.9)
Worldwide	3	3	(6.9)

Infectious Diseases
U.S.	436	357	22.3
International	483	489	(1.2	)
Worldwide	920	846	8.7
EDURANT^® / rilpivirine
U.S.	12	12	0.6
International	212	199	6.4
Worldwide	224	211	6.1
PREZISTA^® / PREZCOBIX^® / REZOLSTA^® / SYMTUZA^®
U.S.	396	315	25.5
International	184	208	(11.6	)
Worldwide	579	523	10.8
OTHER INFECTIOUS DISEASES
U.S.	29	30	(3.4	)
International	87	82	6.7
Worldwide	116	112	4.0

Neuroscience
     U.S. 664
639
3.8
1,387
1,263
9.8
     International 875
889
(1.6 ) 1,780
1,824
(2.4 )
     Worldwide 1,538
1,528
0.6
3,167
3,087
2.6
     CONCERTA^® / methylphenidate

     U.S. 15
68
(78.6 ) 112
134
(16.4 )
     International 123
115
6.2
239
222
7.3
     Worldwide 137
183
(25.2 ) 351
356
(1.6 )
     INVEGA SUSTENNA^® / XEPLION^® / INVEGA TRINZA^® / TREVICTA^®

     U.S. 506
438
15.6
989
838
18.1
     International 312
282
10.4
619
578
7.0
     Worldwide 818
720
13.6
1,608
1,416
13.6
     RISPERDAL CONSTA^®

     U.S. 81
80
0.8
158
162
(3.0 )
     International 101
108
(6.5 ) 203
222
(8.4 )
     Worldwide 182
188
(3.4 ) 361
384
(6.2 )
     OTHER NEUROSCIENCE

     U.S. 62
53
16.1
128
129
(0.4 )
     International 340
384
(11.5 ) 719
802
(10.3 )
     Worldwide 401
437
(8.1 ) 847
931
(8.9 )

Oncology
     U.S. 1,013
1,085
(6.6 ) 1,975
2,018
(2.1 )
     International 1,684
1,371
22.8
3,240
2,749
17.9
     Worldwide 2,697
2,456
9.8
5,215
4,767
9.4
     DARZALEX^®

     U.S. 369
298
24.4
721
562
28.5
     International 405
213
89.5
682
381
78.7
     Worldwide 774
511
51.6
1,403
943
48.8
     IMBRUVICA^®

     U.S. 367
250
47.0
716
477
50.2
     International 463
370
25.3
898
730
23.1
     Worldwide 831
620
34.1
1,615
1,207
33.8
     VELCADE^®

     U.S. —
—
— —
—
—
     International 224
280
(20.1 ) 487
593
(17.9 )
     Worldwide 224
280
(20.1 ) 487
593
(17.9 )
     ZYTIGA^® / abiraterone acetate

     U.S. 198
486
(59.4 ) 383
893
(57.1 )
     International 500
423
18.0
994
861
15.4
     Worldwide 698
909
(23.3 ) 1,377
1,754
(21.5 )
     OTHER ONCOLOGY

     U.S. 78
51
50.5 154
86
77.7
     International 92
85
8.8
179
184
(2.5 )
     Worldwide 170
136
24.7
333
270
23.2

19

Table of Contents



Neuroscience
U.S.	748	723	3.3
International	910	905	0.5
Worldwide	1,658	1,629	1.8
CONCERTA^® / methylphenidate
U.S.	52	97	(46.1	)
International	118	116	1.5
Worldwide	171	214	(20.1	)
INVEGA SUSTENNA^® / XEPLION^® / INVEGA TRINZA^® / TREVICTA^®
U.S.	544	483	12.6
International	339	307	10.3
Worldwide	883	790	11.7
RISPERDAL CONSTA^®
U.S.	76	77	(0.3	)
International	94	102	(8.7	)
Worldwide	170	179	(5.1	)
OTHER NEUROSCIENCE
U.S.	75	66	12.5
International	360	379	(5.1	)
Worldwide	435	446	(2.5	)

Oncology
U.S.	1,175	962	22.1
International	1,839	1,556	18.2
Worldwide	3,013	2,518	19.7
DARZALEX^®
U.S.	463	352	31.8
International	474	277	70.9
Worldwide	937	629	49.0
ERLEADA^®
U.S.	119	58	*
International	24	3	*
Worldwide	143	61	*
IMBRUVICA^®
U.S.	432	349	23.9
International	599	435	37.8
Worldwide	1,031	784	31.6
VELCADE^®
U.S.	—	—	—
International	108	263	(59.0	)
Worldwide	108	263	(59.0	)
ZYTIGA^® / abiraterone acetate
U.S.	139	185	(25.2	)
International	552	494	11.7
Worldwide	690	679	1.6

Pulmonary Hypertension
     U.S. 439
429
2.2 869
790
10.0
     International 251
236
6.7 477
460
3.7
     Worldwide 690
665
3.8 1,346
1,250
7.7
     OPSUMIT^®

     U.S. 203
180
12.8 375
329
14.2
     International 146
131
11.5 279
253
10.3
     Worldwide 348
311
12.3 654
582
12.5
     TRACLEER^®

     U.S. 41
71
(41.8) 102
139
(26.3 )
     International 62
72
(14.5) 118
144
(18.7 )
     Worldwide 103
143
(28.0) 220
283
(22.4 )
     UPTRAVI^®

     U.S. 175
155
13.4 351
279
25.9
     International 28
16
62.5 50
32
53.1
     Worldwide 203
171
18.2 401
311
28.7
     OTHER

     U.S. 20
23
(18.2) 41
43
(8.4 )
     International 16
17
3.7 31
31
4.1
     Worldwide 37
40
(9.6) 72
74
(3.4 )

Cardiovascular / Metabolism / Other
     U.S. 902
1,101
(18.1 ) 1,849
2,204
(16.1 )
     International 373
417
(10.5 ) 771
831
(7.2 )
     Worldwide 1,275
1,518
(16.0 ) 2,620
3,035
(13.7 )
     XARELTO^®

     U.S. 549
679
(19.2 ) 1,091
1,257
(13.2 )
     International —
—
— —
—
—
     Worldwide 549
679
(19.2 ) 1,091
1,257
(13.2 )
     INVOKANA^® / INVOKAMET^®

     U.S. 132
169
(21.2 ) 286
373
(23.2 )
     International 43
46
(6.0 ) 92
90
2.6
     Worldwide 177
215
(17.9 ) 379
463
(18.2 )
     PROCRIT^® / EPREX^®

     U.S. 113
156
(27.5 ) 261
345
(24.3 )
     International 70
80
(13.4 ) 148
167
(11.7 )
     Worldwide 183
236
(22.7 ) 409
512
(20.2 )
     OTHER

     U.S. 107
97
9.3
211
229
(8.2 )
     International 260
291
(10.5 ) 531
574
(7.5 )
     Worldwide 368
388
(5.5 ) 742
803
(7.7 )

TOTAL PHARMACEUTICAL
     U.S. 5,783
5,899
(2.0 ) 11,365
11,253
1.0
     International 4,746
4,455
6.5
9,408
8,945
5.2
     Worldwide 10,529
10,354
1.7
20,773
20,198
2.8

20

Table of Contents



OTHER ONCOLOGY
U.S.	22	18	20.1
International	82	84	(2.7)
Worldwide	104	102	1.3

Pulmonary Hypertension
U.S.	486	430	13.0
International	260	226	14.9
Worldwide	745	656	13.7
OPSUMIT^®
U.S.	229	172	33.0
International	160	133	20.2
Worldwide	389	306	27.4
UPTRAVI^®
U.S.	212	176	20.7
International	38	22	70.2
Worldwide	250	198	26.2
OTHER PULMONARY HYPERTENSION
U.S.	44	82	(45.9)
International	62	71	(12.4)
Worldwide	106	152	(30.4)

Cardiovascular / Metabolism / Other
U.S.	806	947	(14.9	)
International	354	398	(11.0	)
Worldwide	1,160	1,345	(13.8	)
XARELTO^®
U.S.	527	542	(2.7	)
International	—	—	—
Worldwide	527	542	(2.7	)
INVOKANA^® / INVOKAMET^®
U.S.	117	154	(23.6	)
International	58	49	18.6
Worldwide	175	202	(13.5	)
PROCRIT^® / EPREX^®
U.S.	76	148	(48.5	)
International	79	78	0.4
Worldwide	155	226	(31.6	)
OTHER
U.S.	85	104	(18.0	)
International	217	271	(19.7	)
Worldwide	302	374	(19.2	)

TOTAL PHARMACEUTICAL
U.S.	6,061	5,582	8.6
International	5,073	4,662	8.8
Worldwide	11,134	10,244	8.7

MEDICAL DEVICES
Diabetes Care
     U.S. —
129
* —
246
*
     International —
226
* —
448
*
     Worldwide —
355
* —
694
*
Interventional Solutions
     U.S. 366
323
13.7
709
627
13.2
     International 385
344
11.6
774
680
13.7
     Worldwide 750
667
12.6
1,482
1,307
13.4
Orthopaedics
     U.S. 1,331
1,332
(0.1 ) 2,649
2,639
0.4
     International 894
930
(3.8 ) 1,779
1,873
(5.0 )
     Worldwide 2,224
2,262
(1.6 ) 4,428
4,512
(1.9 )
     HIPS

     U.S. 216
211
2.1
429
420
2.1
     International 147
149
(0.7 ) 295
303
(2.3 )
     Worldwide 364
360
0.9
725
723
0.3
     KNEES

     U.S. 218
229
(4.8 ) 441
457
(3.5 )
     International 153
153
0.4
299
312
(4.0 )
     Worldwide 372
382
(2.8 ) 741
769
(3.7 )
     TRAUMA

     U.S. 407
394
3.3
824
801
2.9
     International 265
281
(5.9 ) 533
570
(6.5 )
     Worldwide 672
675
(0.6 ) 1,357
1,371
(1.0 )
     SPINE & OTHER

     U.S. 490
498
(1.5 ) 955
961
(0.6 )
     International 328
347
(5.3 ) 651
688
(5.4 )
     Worldwide 818
845
(3.1 ) 1,606
1,649
(2.6 )
Surgery
     U.S. 926
1,022
(9.5 ) 1,927
2,015
(4.4 )
     International 1,427
1,493
(4.4 ) 2,821
2,923
(3.5 )
     Worldwide 2,353
2,515
(6.5 ) 4,748
4,938
(3.9 )
     ADVANCED

     U.S. 396
402
(1.7 ) 800
795
0.6
     International 633
603
5.0
1,209
1,176
2.8
     Worldwide 1,029
1,005
2.3
2,009
1,971
1.9
GENERAL

     U.S. 443
436
1.6
868
859
1.0
     International 674
733
(7.9 ) 1,339
1,437
(6.8 )
     Worldwide 1,119
1,169
(4.3 ) 2,208
2,296
(3.9 )
     SPECIALTY

     U.S. 87
184
(53.1 ) 259
361
(28.3 )
     International 120
157
(23.7 ) 273
310
(12.1 )
     Worldwide 206
341
(39.6 ) 531
671
(20.8 )

21

Table of Contents



MEDICAL DEVICES
Interventional Solutions
U.S.	365	343	6.6
International	362	389	(6.9	)
Worldwide	727	732	(0.6	)
Orthopaedics
U.S.	1,250	1,318	(5.2	)
International	788	885	(11.0	)
Worldwide	2,038	2,204	(7.5	)
HIPS
U.S.	206	213	(3.6	)
International	132	148	(11.2	)
Worldwide	337	361	(6.7	)
KNEES
U.S.	214	223	(4.2	)
International	130	146	(11.4	)
Worldwide	343	369	(7.0	)
TRAUMA
U.S.	407	417	(2.3	)
International	247	268	(8.0	)
Worldwide	654	685	(4.5	)
SPINE, SPORTS & OTHER
U.S.	423	465	(8.9	)
International	280	323	(13.3	)
Worldwide	703	788	(10.7	)
Surgery
U.S.	844	1,001	(15.7	)
International	1,257	1,394	(9.8	)
Worldwide	2,100	2,395	(12.3	)
ADVANCED
U.S.	381	404	(5.7	)
International	567	576	(1.6	)
Worldwide	948	980	(3.3	)
GENERAL
U.S.	463	597	(22.5	)
International	690	818	(15.7	)
Worldwide	1,153	1,414	(18.5	)
Vision
U.S.	439	446	(1.6	)
International	628	682	(8.0	)
Worldwide	1,067	1,129	(5.5	)
CONTACT LENSES / OTHER
U.S.	346	321	7.7
International	467	502	(7.0	)
Worldwide	814	824	(1.3	)
SURGICAL
U.S.	93	125	(25.5	)

Vision
     U.S. 461
459
0.4
907
899
1.0
     International 701
714
(2.0 ) 1,383
1,389
(0.5 )
     Worldwide 1,161
1,173
(1.0 ) 2,290
2,288
0.1
CONTACT LENSES / OTHER

     U.S. 333
320
3.9
654
629
4.0
     International 509
524
(2.9 ) 1,011
1,022
(1.0 )
     Worldwide 842
844
(0.3 ) 1,666
1,651
0.9
SURGICAL

     U.S. 128
139
(7.7 ) 253
270
(6.1 )
     International 191
190
0.7
371
367
1.0
     Worldwide 319
329
(2.8 ) 624
637
(2.0 )

TOTAL MEDICAL DEVICES
     U.S. 3,083
3,265
(5.6 ) 6,192
6,426
(3.6 )
     International 3,406
3,707
(8.1 ) 6,756
7,313
(7.6 )
     Worldwide 6,489
6,972
(6.9 ) 12,948
13,739
(5.7 )

WORLDWIDE
     U.S. 10,403
10,640
(2.2 ) 20,532
20,591
(0.3 )
     International 10,159
10,190
(0.3 ) 20,051
20,248
(1.0 )
     Worldwide $ 20,562
20,830
(1.3 )% $ 40,583
40,839
(0.6 )%
22

Table of Contents



International	160		180	(11.0	)
Worldwide	253		305	(16.9	)

TOTAL MEDICAL DEVICES
U.S.	2,898		3,109	(6.8	)
International	3,034		3,350	(9.4	)
Worldwide	5,932		6,459	(8.2	)

WORLDWIDE
U.S.	10,699		10,129	5.6
International	9,992		9,892	1.0
Worldwide	$	20,691	20,021	3.3	%

*Percentage greater than 100% or not meaningful

EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT


	Fiscal Second Quarter Ended					Fiscal Six Months Ended					Fiscal First Quarter Ended
(Dollars in Millions)	June 30, 2019		July 1, 2018	Percent Change		June 30, 2019		July 1, 2018	Percent Change		March 29, 2020		March 31, 2019	Percent Change
Consumer ⁽¹⁾	$	406	829	(51.0	)%	$	1,147	1,377	(16.7	)%
Consumer Health ⁽¹⁾											$	770	741	3.9	%
Pharmaceutical⁽²⁾	3,677		3,651	0.7		6,008		7,317	(17.9	)	3,834		2,331	64.5
Medical Devices⁽³⁾	3,189		796	*		4,686		2,375	97.3		2,025		1,497	35.3
Segment earnings before provision for taxes	7,272		5,276	37.8		11,841		11,069	7.0		6,629		4,569	45.1
Less: Expense not allocated to segments⁽⁴⁾	231		303			378		615			120		147
Worldwide income before tax	$	7,041	4,973	41.6	%	$	11,463	10,454	9.7	%	$	6,509	4,422	47.2	%

*Percentage greater than 100%

⁽¹⁾ Includes a gain of ~~$0.3~~$0.3 billion related to the Company's previously held equity investment in Ci:z Holdings Co., Ltd. ~~(Dr. Ci: Labo)~~(DR. CI: LABO) in the fiscal ~~six months~~first quarter of 2019. ~~Includes a gain of $0.3 billion from the divestiture of NIZORAL~~^®~~in the fiscal second quarter and six months of 2018.~~ Includes amortization expense of ~~$0.1~~$0.1 billion ~~and $0.1 billion~~ in both the fiscal ~~second~~first quarters of 2020 and ~~$0.2 billion and $0.1 billion in the fiscal six months of~~ 2019, ~~and 2018,~~ respectively. ~~Includes litigation expense of $0.2 billion in the fiscal second quarter and fiscal six months of 2019.~~

⁽²⁾Includes ~~an unrealized gain on securities of $0.2 billion and Actelion acquisition related costs of $0.1 billion in the fiscal second quarter of 2019. Includes an unrealized gain on securities of $0.3 billion,~~ an in-process research and development expense of ~~$0.9~~$0.9 billion related to the Alios asset in the fiscal first quarter of 2019. Includes litigation expense of $0.1 billion and $0.3 billion in the fiscal first quarter of 2020 and 2019, respectively. Includes an unrealized loss on securities of $0.3 billion in the fiscal first quarter of 2020 and an unrealized gain on securities of $0.1 billion in the fiscal first quarter of 2019. Additionally, the fiscal first quarter of 2019 includes a research and development expense of ~~$0.3~~$0.3 billion for an upfront payment related to argenx, litigation expense of $0.4 billion, and Actelion acquisition related costs of $0.1 billion in the fiscal six months of 2019. Includes Actelion acquisition related costs of $0.1 billion and $0.2 billion in the fiscal second quarter and fiscal six months of 2018, respectively and a gain of $0.1 billion from the divestiture of PANCREASE^®~~in the fiscal second quarter and six months of 2018.~~argenx. Includes amortization expense of ~~$0.8~~$0.8 billion ~~and $0.8 billion~~ in both the fiscal ~~second~~first quarters of 2020 and ~~$1.6 billion and $1.5 billion in the fiscal six months of 2019 and 2018, respectively.~~2019.

⁽³⁾Includes a ~~gain~~contingent consideration reversal of ~~$2.0~~$1.0 billion ~~from the divestiture of the ASP business~~in the fiscal ~~second~~first quarter ~~and six months~~of 2020 related to the timing of certain developmental milestones associated with the Auris Health acquisition. Includes litigation expense of $0.1 billion in the fiscal first quarter of 2019. Includes a restructuring related charge of ~~$0.1~~$0.1 billion and $0.1 billion in the fiscal second quarters of 2019 and 2018, respectively and $0.1 billion and $0.2 billion in the fiscal six months of 2019 and 2018, respectively. Includes litigation expense of $0.2 billion and $0.7 billion in the fiscal second quarters of 2019 and 2018, respectively and $0.3 billion and $0.7 billion in the fiscal six months of 2019 and 2018, respectively. Includes amortization expense of ~~$0.2~~$0.2 billion ~~and $0.3 billion~~ in both the fiscal ~~second~~first quarters of ~~2019~~2020 and ~~2018, respectively and $0.5 billion and $0.5 billion in the fiscal six months of 2019 and 2018, respectively.~~2019.

⁽⁴⁾ Amounts not allocated to segments include interest income/expense and general corporate income/expense.

SALES BY GEOGRAPHIC AREA


	Fiscal Second Quarter Ended					Fiscal Six Months Ended					Fiscal First Quarter Ended
(Dollars in Millions)	June 30, 2019		July 1, 2018	Percent Change		June 30, 2019		July 1, 2018	Percent Change		March 29, 2020		March 31, 2019	Percent Change
United States	$	10,403	10,640	(2.2	)%	$	20,532	20,591	(0.3	)%	$	10,699	10,129	5.6	%
Europe	4,733		4,810	(1.6	)	9,342		9,607	(2.8	)	4,827		4,609	4.7
Western Hemisphere, excluding U.S.	1,455		1,540	(5.5	)	2,958		3,107	(4.8	)	1,502		1,503	(0.1	)
Asia-Pacific, Africa	3,971		3,840	3.4		7,751		7,534	2.9		3,663		3,780	(3.1	)
Total	$	20,562	20,830	(1.3	)%	$	40,583	40,839	(0.6	)%	$	20,691	20,021	3.3	%

Table of Contents

NOTE ~~10—~~10— BUSINESS COMBINATIONS AND DIVESTITURES

During the fiscal first quarter of 2020, the Company completed the acquisition of all rights to the investigational compound bermekimab, which has multiple dermatological indications, along with certain employees from XBiotech Inc., for a purchase price of $0.8 billion. The fair value of the acquisition was allocated primarily to non-amortizable intangible assets, primarily IPR&D, for $0.8 billion. XBiotech may be eligible to receive additional payments upon the receipt of certain commercialization authorizations. The transaction was accounted for as a business combination and included in the Pharmaceutical segment. Additionally, the Company completed the acquisition of all outstanding shares in Verb Surgical Inc., a company with world-class robotics and data science capabilities, including those shares previously held by Verily.

The transaction was accounted for as a business combination and included in the Medical Devices segment. The fair value of the acquisition was allocated primarily to non-amortizable intangible assets, primarily IPR&D, for $0.4 billion, goodwill for $0.2 billion, other assets of $0.2 billion and liabilities assumed of $0.3 billion. The fair value of the Company's previously held equity investment in Verb Surgical Inc. was $0.4 billion.

On April 1, 2019, the Company completed the acquisition of Auris Health, Inc. for approximately ~~$3.4~~$3.4 billion, net of cash acquired. Additional contingent payments of up to ~~$2.35~~$2.35 billion, in the aggregate, may be payable upon reaching certain predetermined milestones. Auris Health was a privately held developer of robotic technologies, initially focused in lung cancer, with an FDA-cleared platform currently used in bronchoscopic diagnostic and therapeutic procedures. The Company treated this transaction as a business combination and included it in the Medical Devices segment. The fair value of the acquisition was allocated primarily to amortizable and non-amortizable intangible assets, primarily IPR~~&D,~~&D, for ~~$3.0~~$3.0 billion, goodwill for ~~$2.0~~$2.0 billion, marketable securities of ~~$0.2~~$0.2 billion and liabilities assumed of ~~$1.8~~$1.8 billion, which includes the fair value of the contingent payments mentioned above, subject to any subsequent valuation adjustments within the measurement period. ~~The~~As of

March 29, 2020, there were no valuation adjustments to the assets acquired but during the fiscal first quarter of 2020, the Company recorded Other income of $1.0 billion for the reversal of the contingent consideration related to the timing of certain developmental and commercial milestones, which are not expected to be met based on the Company’s current timelines. As of March 29, 2020, the fair value of the remaining contingent consideration ~~was $1.1 billion. A probability~~is $0.2 billion. Further, the Company re-assessed the current value of ~~success factor ranging from 55% to 95% was used~~the Auris IPR&D assets in connection with the modified development timeline and determined the fair value ~~calculation to reflect inherent regulatory and commercial risk of~~still exceeds the contingent payments and IPR&D. The discount rate applied was approximately 10%. The goodwill is primarily attributable to synergies expected to arise from the business acquisition and is not expected to be deductible for tax purposes.carrying value.

On ~~April 1,~~January 17, 2019, the Company completed the divestiture of its ASP business to Fortive Corporation for an aggregate value of approximately $2.8 billion, consisting of $2.7 billion of cash proceeds and $0.1 billion of retained net receivables. The Company recognized a pre-tax gain recorded in Other (income) expense, net, of approximately $2.0 billion.

~~On October 23, 2018, the Company entered into an agreement to acquire Ci:z Holdings Co., Ltd., (DR.CI:LABO)~~acquired DR. CI:LABO, a Japanese company focused on the marketing, development and distribution of a broad range of dermocosmetic, cosmetic and skincare products for a total purchase price of approximately ~~¥230~~¥230 billion, which equates to approximately ~~$2.1~~$2.1 billion, using the exchange rate of 109.06 Japanese Yen to each U.S. Dollar on January 16, 2019. The acquisition was completed on January 17, 2019, through a series of transactions that included an all-cash tender offer to acquire the publicly held shares not already held by the Company for ¥5,900 per share. The Company previously held a 20% ownership in Ci:z Holdings Co., Ltd. As of June 2019, the Company became the legal owner of Ci:z Holdings with the completion of the tender offer procedure in Japan. The acquired company was then delisted from the Tokyo Stock Exchange. Additionally, in the fiscal first quarter of 2019, the Company recognized a pre-tax gain recorded in Other (income) expense, net, of approximately ~~$0.3~~$0.3 billion related to the Company's previously held equity investment in ~~Ci:z Holdings Co., Ltd.~~DR. CI:LABO.

The Company treated this transaction as a business combination and included it in the Consumer Health segment. ~~On June 30, 2019,~~During the fiscal first quarter of 2020, the Company finalized the purchase price allocation. At March 29, 2020, the fair value of the acquisition was allocated primarily to amortizable intangible assets for ~~$1.5~~$1.5 billion, goodwill for ~~$1.2~~$1.2 billion and liabilities assumed of ~~$0.5~~$0.4 billion ~~subject to any subsequent valuation adjustments within the measurement period.~~. The adjustments made since the date of acquisition were ~~$0.1~~$0.1 billion to ~~the~~ intangible assets, accrued liabilities, deferred taxes on income and property, plant and equipment with the offset to goodwill. The amortizable intangible assets were comprised of brand/trademarks and customer relationships with a weighted average life of 15.3 ~~years.~~years. The goodwill

is primarily attributable to synergies expected to arise from the business acquisition and is not expected to be deductible for tax purposes.

During the fiscal third quarter of 2018, the Company accepted a binding offer to form a strategic collaboration with Jabil Inc., one of the ~~world’s~~world’s leading manufacturing services providers for health care products and technology products. The Company is expanding a 12-year relationship with Jabil Inc. to produce a range of products within the Ethicon Endo-Surgery and DePuy Synthes businesses. This transaction includes the transfer of certain employees and manufacturing sites. ~~Certain manufacturing sites~~The majority of the transfers were ~~transferred to Jabil~~completed in ~~the first fiscal six months of~~ 2019 ~~and additional sites are expected to transfer~~with a minor amount remaining in ~~the remainder of 2019.~~2020. As of ~~June 30, 2019,~~March 29, 2020, the assets held for sale on the Consolidated Balance Sheet were ~~$0.2~~$0.1 billion of ~~inventory.~~inventory and property, plant and equipment, net. For additional details on the global supply chain restructuring see Note 12 to the Consolidated Financial Statements.

~~During the fiscal second quarter~~

Table of ~~2018, the Company completed the acquisition BeneVir Biopharm, Inc. (BeneVir), a privately-held, biopharmaceutical company specializing in the development of oncolytic immunotherapies.~~Contents

~~Additionally, during the fiscal second quarter of 2018, the Company completed the divestitures of NIZORAL~~^®~~, PANCREASE~~^®~~and VALCHLOR~~^®~~products.~~

NOTE 11 —— LEGAL PROCEEDINGS

Johnson && Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability; intellectual property; commercial; supplier indemnification and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of their business. Due to the ongoing impacts of the COVID-19 pandemic, certain trials have been rescheduled or delayed. The Company continues to monitor its legal proceedings as the situation develops.

The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of ~~June 30, 2019,~~March 29, 2020, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts already accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and ~~assumptions.~~assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; or there are numerous parties involved. To the extent adverse verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.

In the Company's opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Company's balance sheet, is not expected to have a material adverse effect on the Company's financial position. However, the resolution of, or increase in accruals for, one or more of these matters in any reporting period may have a material adverse effect on the Company's results of operations and cash flows for that period.

PRODUCT LIABILITY

Johnson && Johnson and certain of its subsidiaries are involved in numerous product liability claims and lawsuits involving multiple products. Claimants in these cases seek substantial compensatory and, where available, punitive damages. While the Company believes it has substantial defenses, it is not feasible to predict the ultimate outcome of litigation. From time to time, even if it has substantial defenses, the Company considers isolated settlements based on a variety of circumstances. The Company has established accruals for product liability claims and lawsuits in compliance with ASC 450-20 based on currently available information, which in some cases may be limited. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. For certain of these matters, the Company has accrued additional amounts such as estimated costs associated with settlements, damages and other losses. ~~To the extent adverse verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.~~ Product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns. Changes to the accruals may be required in the future as additional information becomes available.

The most significant of these cases include: the DePuy ~~ASR™~~ASR™ XL Acetabular System and DePuy ~~ASR™~~ASR™ Hip Resurfacing System; the PINNACLE^®® Acetabular Cup System; pelvic meshes; RISPERDAL^®®; XARELTO^®®; body powders containing talc,

primarily JOHNSONS^®® Baby Powder; INVOKANA^®®; and ETHICON PHYSIOMESH^®®Flexible Composite Mesh. As of ~~June 30, 2019,~~March 29, 2020, in the United States there were approximately ~~1,500~~940 plaintiffs with direct claims in pending lawsuits regarding injuries allegedly due to the DePuy ~~ASR™~~ASR™ XL Acetabular System and DePuy ~~ASR™~~ASR™ Hip Resurfacing System; ~~10,500~~9,500 with respect to the PINNACLE^®® Acetabular Cup System; ~~24,800~~16,500 with respect to pelvic meshes; ~~13,400~~10,900 with respect to RISPERDAL^®®; ~~31,700~~24,600 with respect to XARELTO^®®; ~~15,500~~19,400 with respect to body powders containing talc; ~~1,000~~300 with respect to INVOKANA^®®;and ~~2,900~~3,500 with respect to ETHICON PHYSIOMESH^®® Flexible Composite Mesh.

In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR^™™ XL Acetabular System and DePuy ASR^™™ Hip Resurfacing System used in hip replacement surgery. Claims for personal injury have been made against DePuy and Johnson && Johnson. The number of pending lawsuits is expected to fluctuate as certain lawsuits are settled or dismissed and additional lawsuits are filed. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Canada, Australia, Ireland, Germany, India and Italy. In

Table of Contents

November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip System plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States who had surgery to replace their ASR Hips, known as revision surgery, as of August 31, 2013. DePuy reached additional agreements in February 2015 and March 2017, which further extended the settlement program to include ASR Hip patients who had revision surgeries after August 31, 2013 and prior to February 15, 2017. This settlement program has resolved more than 10,000 claims, therefore bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. In Australia, a class action settlement was reached that resolved the claims of the majority of ASR Hip patients in that country. In Canada, the Company has reached agreements to settle two pending class actions which have been approved by the ~~Qué~~Québec Superior Court and the Supreme Court of British Columbia. The British Columbia order is currently the subject of ~~an appeal.~~the Company's appeal to broaden the scope of participants. The Company continues to receive information with respect to potential additional costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and DePuy ASR^™™ Hip-related product liability litigation.

Claims for personal injury have also been made against DePuy Orthopaedics, Inc. and Johnson && Johnson (collectively, DePuy) relating to the PINNACLE^®® Acetabular Cup System used in hip replacement surgery. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas. Litigation has also been filed in some state courts and in countries outside of the United States. Several adverse verdicts have been rendered against DePuy, one of which was reversed on appeal and remanded for retrial. During the first quarter of 2019, DePuy established a United States settlement program to resolve these cases. As part of the settlement program, adverse verdicts have been settled. The Company has established an accrual for product liability litigation associated with the PINNACLE^®® Acetabular Cup System and the related settlement program.

Claims for personal injury have been made against Ethicon, Inc. (Ethicon) and Johnson && Johnson arising out of Ethicon's pelvic mesh devices used to treat stress urinary incontinence and pelvic organ prolapse. The Company continues to receive information with respect to potential costs and additional cases. Cases filed in federal courts in the United States ~~have~~had been organized as a multi-district litigation (MDL) in the United States District Court for the Southern District of West Virginia. The MDL Court is remanding cases for trial to the jurisdictions where the case was originally filed and additional pelvic mesh lawsuits have been filed, and remain, outside of the MDL. The Company has settled or otherwise resolved a majority of the United States cases and the estimated costs associated with these settlements and the remaining cases are reflected in the Company's accruals. In addition, class actions and individual personal injury cases or claims have been commenced in various countries outside of the United States, including claims and cases in the United Kingdom, the Netherlands and Belgium, and class actions in Israel, Australia and Canada, seeking damages for alleged injury resulting from Ethicon's pelvic mesh devices. In November 2019, the Federal Court of Australia issued a ~~trial~~judgment regarding its findings with respect to liability in relation to the three Lead Applicants and generally in relation to the design, manufacture, pre and post-market assessments and testing, and supply and promotion of the devices in Australia used to treat stress urinary incontinence and pelvic organ prolapse. In March 2020, the Court entered damages awards to the three Lead Applicants. With respect to other group members, there will be an individual case assessment process which will require proof of use and causally related loss. The class ~~action issues has been completed and~~actions in Canada are expected to be discontinued in 2020 as a result of a settlement of a group of cases, subject to court approval of the ~~parties are awaiting a decision.~~discontinuance. The Company has established accruals with respect to product liability litigation associated with Ethicon's pelvic mesh products.

Following a June 2016 worldwide market withdrawal of ETHICON PHYSIOMESH^®® Flexible Composite Mesh, claims for personal injury have been made against Ethicon, Inc. and Johnson && Johnson alleging personal injury arising out of the use of this hernia mesh device. Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) has also been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., and lawsuits pending outside the United States.

Along with ETHICON PHYSIOMESH^®® lawsuits, there were a number of filings related to the PROCEED^®® Mesh and PROCEED^®® Ventral Patch products. In March 2019, the New Jersey Supreme Court entered an order consolidating all PROCEED^®® and PROCEED^®® Ventral Patch cases as an MCL in Atlantic County Superior Court. ~~Product liability lawsuits continue to be~~Additional cases have been filed in various federal and state courts in the

US, and in jurisdictions outside the US. The Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has established accruals with respect to product liability litigation associated with ETHICON PHYSIOMESH^®®Flexible Composite Mesh, PROCEED^®® Mesh

Table of Contents

and PROCEED^®® Ventral Patch products. In September 2019, plaintiffs’ attorney filed an application with the New Jersey Supreme Court seeking centralized management of 107 PROLENE™ Polypropylene Hernia System cases. The New Jersey Supreme Court granted plaintiffs application in January 2020 and those will be transferred to an MCL in Atlantic County Superior Court.

Claims for personal injury have been made against Janssen Pharmaceuticals, Inc. and Johnson && Johnson arising out of the use of RISPERDAL^®®, and related compounds, indicated for the treatment of schizophrenia, acute manic or mixed episodes associated with bipolar I disorder and irritability associated with ~~autism, and related compounds.~~autism. Lawsuits have been primarily filed in state courts in Pennsylvania, California, and Missouri. Other actions are pending in various courts in the United States and Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has successfully defended a number of these cases but there have been verdicts against the Company, including a recent verdict in October 2019 of $8 billion of punitive damages related to one single plaintiff which was subsequently reduced in January 2020 to $6.8 million by the trial judge. The Company will appeal the final judgment. The Company has settled or otherwise resolved many of the United States cases and the costs associated with these settlements are reflected in the Company's accruals.

Claims for personal injury arising out of the use of XARELTO^®®, an oral anticoagulant, have been made against Janssen Pharmaceuticals, Inc. (JPI); Johnson ~~& Johnson;~~& Johnson (J&J); and ~~JPI's~~JPI’s collaboration partner for XARELTO^®®, Bayer AG and certain of its affiliates. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Eastern District of Louisiana. In addition, cases have been filed in state courts across the United States. Many of these cases have been consolidated into a state mass tort litigation in Philadelphia, Pennsylvania and in a coordinated proceeding in Los Angeles, California. Class action lawsuits also have been filed in Canada. In March 2019, ~~the Company~~JPI and J&J announced an agreement in principle to the settle the XARELTO^®® cases in the United States; ~~such~~the settlement agreement was ~~finalized and~~ executed in May 2019, ~~establishing a~~the settlement became final in December 2019, and the settlement was funded in January 2020. This resolved the majority of cases pending in the United ~~States settlement program.~~States. The Company has established accruals for ~~the~~its costs associated with the United States settlement program and XARELTO^®® related product liability litigation.

Personal injury claims alleging that talc causes cancer have been made against Johnson && Johnson Consumer Inc. and Johnson && Johnson arising out of the use of body powders containing talc, primarily ~~JOHNSON’S~~JOHNSON’S^®® Baby Powder. The number of pending product liability lawsuits continues to increase, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Lawsuits have been primarily filed in state courts in Missouri, New Jersey and California, as well as outside the United States. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the District of New Jersey. In the multi-district litigation, the parties have moved to exclude experts, known as Daubert motions. The Court ~~began conducting~~held Daubert hearings in mid-July ~~2019.~~2019 and a final round of briefing was submitted to the Court. In April 2020, the Court issued rulings which limit the scope of testimony, including some theories and testing methods, for certain plaintiff expert witnesses and denied the attempt to limit the scope of testimony of certain of the Company’s witnesses. The Company has successfully defended a number of these cases but there have been verdicts against the Company, including a verdict in July 2018 of ~~$4.7 billion.~~$4.7 billion. The Company believes that it has strong grounds on appeal to overturn these verdicts. The Company has established an accrual primarily for defense costs ~~only~~ in connection with product liability litigation associated with body powders containing talc.

In February 2019, the ~~Company’s~~Company’s talc supplier, Imerys Talc America, Inc. and two of its affiliates, Imerys Talc Vermont, Inc. and Imerys Talc Canada, Inc. (collectively, ~~“Imerys”)~~Imerys) filed a voluntary chapter 11 petition commencing a reorganization under the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware ~~("Imerys Bankruptcy")~~(Imerys Bankruptcy). The Imerys Bankruptcy relates to Imerys’ potential liability ~~on account of Imerys’s sales of talc, including~~for personal injury from exposure to ~~the Company for the Company’s body powders.~~talcum powder sold by Imerys (Talc Claims). In its bankruptcy filing, Imerys noted certain claims it ~~alleged~~alleges it ~~had~~has against the Company for indemnification and rights to joint insurance proceeds. Based on such claims as well as indemnity and insurance claims the Company has against Imerys, the Company ~~has~~ petitioned the United States District Court for the District of Delaware to establish federal jurisdiction of the state court talc lawsuits under the ~~“related to” jurisdictional provisions of the~~ Bankruptcy Code. The Company's petition was denied and the state court talc lawsuits that have been removed to federal court on such basis ~~will be~~have been remanded. The Company previously proposed to resolve Imerys' (and the Company’s) obligations arising out of the Talc Claims by agreeing to assume the defense of litigation of all Talc Claims involving the Company's products, waiving the Company’s indemnification claims against Imerys, and lifting the automatic stay to enable the Talc Claims to proceed outside the bankruptcy forum with the Company agreeing to settle or pay any judgment against Imerys. In addition, the Company has objected to Imerys’ fourth request to extend the time during which the debtor has the exclusive right to file a Chapter 11 plan.

In February 2018, a securities class action lawsuit was filed against Johnson && Johnson and certain named officers in the United States District Court for the District of New Jersey, alleging that Johnson && Johnson violated the federal securities laws by failing to ~~adequately~~ disclose ~~the~~ alleged asbestos contamination in body powders containing talc, primarily JOHNSON'S^®® Baby Powder,

Table of Contents

and that purchasers of Johnson ~~& Johnson’s~~& Johnson’s shares suffered losses as a result. Plaintiffs are seeking damages. In April 2019, the Company moved to dismiss the complaint and briefing on the motion was complete as of August 2019. In December 2019, the Court denied, in part, the motion to dismiss. In March 2020, Defendants answered the complaint.

In October 2018, a shareholder derivative lawsuit was filed against Johnson && Johnson as the nominal defendant and its current directors as defendants in the United States District Court for the District of New Jersey, alleging a breach of fiduciary duties related to the alleged asbestos contamination in body powders containing talc, primarily ~~JOHNSON’S~~JOHNSON’S^®® Baby Powder, and that Johnson && Johnson has suffered damages as a result of those alleged breaches. In June 2019, the shareholder filed an additional complaint initiating a summary proceeding in New Jersey state court for a books and records inspection. In August 2019, Johnson & Johnson responded to the books and records complaint and filed a cross motion to dismiss. In September 2019, Plaintiff ~~is seeking damages~~replied and ~~an order~~the Court heard oral argument. The Court has not yet ruled in the books and records action. In September 2019, the United States District Court for the District of New Jersey granted defendants’ motion to dismiss the shareholder derivative lawsuit, and dismissed the complaint without prejudice. In October 2019, the shareholder filed a notice of appeal with the United States Court of Appeals for the Third Circuit. In January 2020, the shareholder voluntarily dismissed his appeal, with prejudice. Four additional shareholder derivative lawsuits have been filed in New Jersey making similar allegations against the Company and its current directors and certain officers. In February 2020, these four cases were consolidated into a single action under the caption In re Johnson & Johnson Talc Stockholder Derivative Litigation, and the shareholders have until May 2020 to ~~reform its internal policies and procedures.~~ file a consolidated complaint or identify a previously filed complaint as the operative complaint.

In January 2019, two ERISA class action lawsuits were filed by participants in the Johnson && Johnson Savings Plan against Johnson && Johnson, its Pension and Benefits Committee, and certain named officers in the United States District Court for the District of New Jersey, alleging that the defendants breached their fiduciary duties by offering Johnson && Johnson stock as a Johnson && Johnson Savings Plan investment option when it was imprudent to do so because of failures to disclose alleged asbestos contamination in body powders containing talc, primarily ~~JOHNSON’S~~JOHNSON’S^{® ®}Baby Powder. Plaintiffs are seeking damages and injunctive relief. Defendants filed a motion to dismiss. In April 2020, the Court granted the motion to dismiss but granted leave to amend.

A lawsuit is pending in the Superior Court of California for the County of San Diego alleging violations of California’s Consumer Legal Remedies Act relating to JOHNSON’S^® Baby Powder. In that lawsuit, the plaintiffs allege that Johnson & Johnson violated the CLRA by failing to provide required Proposition 65 warnings. In July 2019, the Company filed a notice of removal to the United

States District Court for the ~~Central~~Southern District of California ~~alleging violations of Proposition 65, California’s Unfair Competition Law~~ and ~~False Advertising Law. In June 2019,~~ plaintiffs filed a second amended complaint shortly thereafter. In October 2019, the Company moved to dismiss the second amended complaint for failure to state a claim upon which relief may be granted. In response to those motions, plaintiffs filed a third amended complaint. In December 2019, the Company moved to dismiss the third amended complaint for failure to state a claim upon which relief may be granted. In April 2020, the Court granted the motion ~~for voluntary dismissal of this~~to dismiss but granted leave to amend.

In January 2020, the Abtahi Law Group filed an action under Proposition 65 against Johnson & Johnson and Johnson & Johnson Consumer Inc. as well as a number of other alleged talcum powder manufacturers and distributors, including one California company. In that action, the plaintiff alleges contamination of talcum powder products with unsafe levels of arsenic, hexavalent chromium and ~~the Company opposed such motion to the extent it would allow plaintiffs’ counsel to refile such claims with new plaintiffs.~~lead. The plaintiff seeks civil penalties and injunctive relief.

In addition, the Company has received preliminary inquiries and subpoenas to produce documents regarding these matters from Senator Murray, a member of the Senate Committee on Health, Education, Labor and Pensions, the Department of Justice, the Securities and Exchange Commission and the U.S. Congressional Subcommittee on Economic and Consumer Policy. The Company is cooperating with ~~these~~ government inquiries and continues to produce documents in response.

Claims for personal injury have been made against a number of Johnson && Johnson companies, including Janssen Pharmaceuticals, Inc. and Johnson && Johnson, arising out of the use of INVOKANA^®®, a prescription medication indicated to improve glycemic control in adults with Type 2 diabetes. Lawsuits filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the District of New Jersey. Cases have also been filed in ~~various~~ state ~~courts including Pennsylvania and Louisiana.~~courts. Class action lawsuits have been filed in Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has settled or otherwise resolved many of the cases and claims in the United States and the costs associated with these settlements are reflected in the Company's accruals.

Table of Contents

INTELLECTUAL PROPERTY

Certain subsidiaries of Johnson && Johnson are subject, from time to time, to legal proceedings and claims related to patent, trademark and other intellectual property matters arising out of their businesses. Many of these matters involve challenges to the coverage and/or validity of the patents on various products and allegations that certain of the ~~Company’s~~Company’s products infringe the patents of third parties. Although these subsidiaries believe that they have substantial defenses to these challenges and allegations with respect to all significant patents, there can be no assurance as to the outcome of these matters. A loss in any of these cases could adversely affect the ability of these subsidiaries to sell their products, result in loss of sales due to loss of market exclusivity, require the payment of past damages and future royalties, and may result in a non-cash impairment charge for any associated intangible asset. The most significant of these matters are described below.

Medical Devices

In June 2009, Rembrandt Vision Technologies, L.P. (Rembrandt) filed a patent infringement lawsuit against Johnson & Johnson Vision Care, Inc. (JJVCI) in the United States District Court for the Eastern District of Texas alleging that JJVCI's manufacture and sale of its ACUVUE^® ~~ADVANCE and ACUVUE OASYS~~^® Hydrogel Contact Lenses infringed Rembrandt’s United States Patent No. 5,712,327 and seeking monetary relief. The case was transferred to the United States District Court for the Middle District of Florida, where a trial in May 2012 resulted in a verdict of non-infringement that was subsequently upheld on appeal. In July 2014, Rembrandt sought a new trial based on alleged new evidence, which the district court denied. In April 2016, the Court of Appeals overturned that ruling and remanded the case to the district court for a new trial. A new trial was held in August 2017, and the jury returned a verdict of non-infringement in favor of JJVCI. Rembrandt has appealed the verdict to the United States Court of Appeals for the Federal Circuit (CAFC). In February 2019, the CAFC affirmed the judgment in favor of JJVCI. In May 2019, the district court awarded costs in favor of JJVCI.

In March 2013, Medinol Ltd. (Medinol) filed a patent infringement lawsuit against Cordis Corporation (Cordis) and Johnson && Johnson in the United States District Court for the Southern District of New York alleging that ~~Cordis’s~~Cordis’s sales of the CYPHER^™™ and CYPHER SELECT^™™ stents made in the United States since 2005 willfully infringed four of Medinol's patents directed to the geometry of articulated stents. ~~Medinol is seeking damages and attorneys’ fees.~~ Although Johnson && Johnson has since sold Cordis, it has retained liability for this case. After the trial in January 2014, the district court dismissed the case, finding Medinol unreasonably delayed bringing its claims (the laches defense). In September 2014, the district court denied a motion by Medinol to vacate the judgment and grant it a new trial. Medinol appealed the decision to the United States Court of Appeals for the Federal Circuit. In March 2017, the United States Supreme Court held that the laches defense is not available in patent cases. In April 2018, the United States Court of Appeals for the Federal Circuit remanded the case back to the district court to reconsider ~~Medinol’s~~Medinol’s motion for a new trial. In March 2019, the district court denied ~~Medinol’s~~Medinol’s motion for a new trial. In April 2019, Medinol ~~filed~~appealed, and the appellate court will conduct a ~~notice of appeal.~~hearing in June 2020.

In November 2016, MedIdea, L.L.C. (MedIdea) filed a patent infringement lawsuit against DePuy Orthopaedics, Inc. in the United States District Court for the Northern District of Illinois alleging infringement by the ATTUNE^®® Knee System. In April 2017, MedIdea filed an amended complaint adding DePuy Synthes Products, Inc. and DePuy Synthes Sales, Inc. as named defendants (collectively, DePuy). MedIdea alleges infringement of United States Patent Nos. 6,558,426 ~~(’426)~~(’426); 8,273,132 ~~(’132)~~(’132); 8,721,730 ~~(’730)~~(’730) and 9,492,280 ~~(’280)~~(’280) relating to posterior stabilized knee systems. Specifically, MedIdea alleges that the SOFCAM^TM Contact feature of the ATTUNE^®® posterior stabilized knee products infringes the patents-in-suit. MedIdea is

seeking monetary damages and injunctive relief. In June 2017, the case was transferred to the United States District Court for the District of Massachusetts. A claim construction hearing was held in October 2018, and a claim construction order was issued in November 2018. In December 2018, MedIdea stipulated to non-infringement of the ~~’132, ’730~~’132, ’730 and ~~’280~~’280 patents, based on the district ~~court’s~~court’s claim construction and reserving its right to appeal that construction, leaving only the ~~’426~~’426 patent at issue before the district court. In January 2019, the district court stayed the case pending a decision in the Inter Partes Review proceeding on the ~~’426~~’426 patent (see below). In December 2017, DePuy Synthes Products, Inc. filed a petition for Inter Partes Review with the United States Patent and Trademark Office (USPTO), seeking to invalidate the two claims of the ~~’426~~’426 patent asserted in the district court litigation, and in June 2018, the USPTO instituted review of those claims. A hearing was held in March 2019, andand in April 2019, the USPTO issued its decision upholding the validity of the patent. In May 2019, DePuy filed a motion for summary judgment of non-infringement of the claims of the ~~’426~~’426 patent. In November 2019, judgment was entered in favor of DePuy. In December 2019, MedIdea filed a notice of appeal.

In December 2016, Ethicon Endo-Surgery, Inc. and Ethicon Endo-Surgery, LLC (now known as Ethicon LLC) sued Covidien, Inc. in the United States District Court for the District of Massachusetts seeking a declaration that United States Patent Nos. 6,585,735 (the ~~’735~~’735 patent); 7,118,587; 7,473,253; 8,070,748 and 8,241,284 (the ~~’284~~’284 patent), are either invalid or not infringed by ~~Ethicon’s~~Ethicon’s ENSEAL^®® X1 Large Jaw Tissue Sealer product. In April 2017, Covidien LP, Covidien Sales LLC, and Covidien AG (collectively, Covidien) answered and counterclaimed, denying the allegations, asserting willful infringement of the ~~’735~~’735 patent, the ~~’284~~’284 patent and United States Patent Nos. 8,323,310 (the ~~’310~~’310 patent); 9,084,608; 9,241,759 (the ~~’759~~’759 patent) and 9,113,882, and seeking damages and an injunction. Covidien filed a motion for preliminary injunction, which was denied in October 2017. The parties have entered joint stipulations such that only the ~~’310~~’310 patent and the ~~’759~~’759 patent remain in dispute. ~~The~~A bench trial ~~is scheduled to begin~~concluded in ~~September 2019.~~March 2020. In April 2020, the district court issued a decision in Ethicon’s favor, finding that the ENSEAL^® X1 device does not infringe any asserted claim.

In December 2016, Dr. Ford Albritton sued Acclarent, Inc. (Acclarent) in United States District Court for the Northern District of Texas alleging that ~~Acclarent’s~~Acclarent’s RELIEVA^®® Spin and RELIEVEA SpinPlus^®® products infringe U.S. Patent No. 9,011,412 (the ~~’412~~’412 patent). Dr. Albritton also alleges breach of contract, fraud and that he is the true owner of ~~Acclarent’s~~Acclarent’s U.S. Patent No. 8,414,473. In December 2016, Acclarent filed a petition for Inter Partes Review (IPR) with the United States Patent and Trademark Office (USPTO) challenging the validity of the ~~’412~~’412 patent. The USPTO instituted the IPR in July 2017. In July

Table of Contents

2018, the USPTO ruled in favor of Albritton in the IPR, finding that Acclarent had not met its burden of proof that the challenged claims were invalid. ~~Acclarent appealed~~In October 2019, the ~~IPR decision~~Court of Appeals affirmed the USPTO’s Patent Trial and Appeal Board. In June 2019, the parties filed cross motions for summary judgment in ~~September 2018. A second IPR petition was not instituted.~~the district court. The district court denied most motions for summary judgment, and trial will go forward on all of Dr. Albritton’s claims. The trial is scheduled for October 2019. In June 2019, Albritton filed a motion for summary judgment that the asserted patent is not invalid. In June 2019, Acclarent filed a motion for summary judgment that the asserted claims are not infringed and that Albritton’s non-patent claims are barred by, among other things, the statute of limitations.to begin in September 2020.

In November 2017, Board of Regents, The University of Texas System and ~~Tissuegen,~~TissueGen, Inc. (collectively, UT) filed a lawsuit in the United States District Court for the Western District of Texas against Ethicon, Inc. and Ethicon US, LLC alleging the manufacture and sale of VICRYL^®® Plus Antibacterial Sutures, MONOCRYL^®® Plus Antibacterial Sutures, PDS^®® Plus Antibacterial Sutures, STRATAFIX^®® ~~POS~~PDS^®® Antibacterial Sutures and STRATAFIX^®® MONOCRYL^®®Plus Antibacterial Sutures infringe ~~plaintiffs’~~plaintiffs’ United States Patent Nos. 6,596,296 and 7,033,603 (the ~~’603~~’603 patent) directed to implantable polymer drug releasing biodegradable fibers containing a therapeutic agent. UT is seeking damages and an injunction. In December 2018, Ethicon filed petitions with the USPTO, seeking Inter Partes Review (IPR) of both asserted patents. Those petitions have been stayed by the USPTO pending a decision by the U.S. Supreme Court ~~of Appeals for the Federal Circuit~~ in an unrelated case. ~~In June 2019, the~~The stay ~~on the IPRs was~~has been lifted and athe USPTO’s institution decision ~~on institution~~ is ~~due~~expected in ~~November 2019.~~June 2020. UT dismissed the ~~’603~~’603 patent from the ~~suit.~~suit and no longer accuses PDS^® Plus Antibacterial Sutures or STRATAFIX^® PDS^® Plus Antibacterial Sutures of infringement. The district court trial is scheduled for June 2020.

~~Pharmaceutical~~

In August ~~2016, Sandoz Ltd~~2018, Intuitive Surgical, Inc. and Hexal AG (collectively, Sandoz) filed a lawsuit in the English High Court against G.D. Searle LLC, a Pfizer company (Searle) and Janssen Sciences Ireland UC (JSI) alleging that Searle’s supplementary protection certificate SPC/GB07/038 (SPC), which is exclusively licensed to JSI, is invalid and should be revoked. Janssen-Cilag Limited sells PREZISTA^® (darunavir) in the United Kingdom pursuant to this license. In October 2016, Searle and JSI counterclaimed against Sandoz for threatened infringement of the SPC based on statements of its plans to launch generic darunavir in the United Kingdom. Sandoz admitted that its generic darunavir product would infringe the SPC if it is found valid. Searle and JSI are seeking an order enjoining Sandoz from marketing its generic darunavir before the expiration of the SPC. Following a trial in April 2017, the court entered a decision holding that the SPC is valid and granting a final injunction. Sandoz has appealed the court’s decision and the injunction is stayed pending the appeal. In January 2018, the court referred the issue on appeal to the Court of Justice for the European Union (CJEU) and stayed the proceedings pending the CJEU’s ruling on the issue.

~~In April 2018, Acerta Pharma B.V., AstraZeneca UK Ltd and AstraZeneca Pharmaceuticals LP~~Intuitive Surgical Operations, Inc. (“Intuitive”) filed a patent infringement ~~lawsuit~~suit against Auris Health, Inc. (“Auris”) in United States District Court for the District of Delaware. In the suit, Intuitive alleges willful infringement of U.S. Patent Nos. 6,246,200 (’200 patent); 6,491,701 (’701 patent); 6,522,906 (’906 patent); 6,800,056 (’056 patent); 8,142,447 (’447 patent); 8,620,473 (’473 patent); 8,801,601 (’601 patent); and 9,452,276 (’276 patent) based on Auris’ Monarch™ Platform. Auris filed Petitions for Inter Partes Review with the USPTO regarding the ’200, ’056, ’601 ’701, ’447, ’276 and ’906 patents. Intuitive subsequently dropped the ’200 and ’701 patents from the suit. In December 2019, the USPTO instituted review of the ’601 patent and denied review of the ’056 patent. In February and March 2020, the USPTO instituted review of the ’200, ’447, ’701 and ’906 patents and denied review of the ’276 patent. The district court trial is scheduled to begin in January 2021.

In August 2019, RSB Spine LLC (“RSB Spine”) filed a patent infringement suit against DePuy Synthes, Inc. in United States District Court for the District of Delaware. In October 2019, RSB Spine amended the complaint to change the named defendants to DePuy Synthes Sales, Inc. and DePuy Synthes Products, Inc. In the suit, RSB Spine alleges willful infringement of United States Patent Nos. 6,984,234 and 9,713, 537 by one or more of the following products: ZERO-P-VA™ Spacer, ZERO-P^® Spacer, ZERO-P NATURAL™ Plate, SYNFIX^® LR Spacer and SYNFIX^® Evolution System. RSB Spine seeks monetary damages and injunctive relief. In November 2019, the suit was consolidated for pre-trial purposes with other patent infringement suits brought by RSB Spine in the United States District Court for the District of Delaware against ~~Pharmacyclics~~Life Spine, Inc., Medacta USA, Inc., Precision Spine, Inc., and Xtant Medical Holdings, Inc.

In March 2020, Osteoplastics, LLC filed a patent infringement suit against DePuy Synthes, Inc., DePuy Synthes Products, Inc., Medical Device Business Services, Inc., and ~~Abbvie~~Synthes, Inc. ~~(collectively, Abbvie), alleging that~~in the ~~manufacture~~United States District Court for the District of Delaware. In the suit, Osteoplastics alleges willful infringement of U.S. Patent Nos. 8,781,557; 9,929,920; 9,330,206; 9,626,756; 9,672,617; 9,672,302; and ~~sale of IMBRUVICA~~9,275,191 based on the PROPLAN CMF^®®Virtual Surgical Planning Services and the TruMatch^® ~~infringes~~CMF Personalize Solutions. In April 2020, Osteoplastics filed an amended complaint to substitute U.S. Patent No. ~~7,459,554. Janssen~~9, 292,920 for U.S. Patent No. 9,929,920. Osteoplastics seeks monetary damages and injunctive relief.

~~Biotech, Inc., which commercializes IMBRUVICA~~Pharmaceutical^® ~~jointly with Abbvie, intervened in the action in November 2018. A trial is scheduled to begin in January 2021.~~

REMICADE^®® Related Cases

In August 2014, Celltrion Healthcare Co. Ltd. and Celltrion Inc. (collectively, Celltrion) filed an application with the United States Food and Drug Administration (FDA) for approval to make and sell its own infliximab biosimilar. In March 2015, Janssen Biotech, Inc. (JBI) filed a lawsuit in the United States District Court for the District of Massachusetts against Celltrion and Hospira Healthcare Corporation (Hospira), which has exclusive marketing rights for ~~Celltrion’s~~Celltrion’s infliximab biosimilar in the United States, seeking, among other things, a declaratory judgment that their biosimilar product infringes or potentially infringes several JBI patents, including United States Patent No. 6,284,471 relating to REMICADE^®®(infliximab) (the ~~’471~~’471 patent) and United States Patent No. 7,598,083 (the ~~’083~~’083 patent) directed to the cell culture media used to make ~~Celltrion’s~~Celltrion’s biosimilar. In August 2016, the district court granted both ~~Celltrion’s~~Celltrion’s and ~~Hospira’s~~Hospira’s motions for summary judgment of invalidity of the ~~’471~~’471 patent. JBI appealed those decisions to the United States Court of Appeals for the Federal Circuit. In January 2018, the Federal Circuit dismissed the appeal as moot based on its affirmance of a decision by the ~~USPTO’s~~USPTO’s Patent Trial and Appeal Board affirming invalidity of the ~~’471~~’471 patent.

Table of Contents

In June 2016, JBI filed two additional patent infringement lawsuits asserting the ~~’083~~’083 patent, one against Celltrion and Hospira in the United States District Court for the District of Massachusetts and the other against HyClone Laboratories, Inc., the manufacturer of the cell culture media that Celltrion uses to make its biosimilar product, in the United States District Court for the District of Utah. JBI seeks monetary damages and other relief. In October 2017, the district court in the Massachusetts action denied Celltrion and Hospira’s motion to dismiss for lack of standing. In July 2018, the district court in the Massachusetts action granted ~~Celltrion’s~~Celltrion’s motion for summary judgment of non-infringement and entered an order dismissing the ~~’083~~’083 lawsuit against Celltrion and Hospira. JBI appealed to the United States Court of Appeals for the Federal ~~Circuit. The litigation~~Circuit, and Celltrion and Hospira cross-appealed on the standing issue. In November 2019, the United States District Court for the District of Utah administratively closed the case against ~~HyClone in Utah is stayed pending~~HyClone. In March 2020, the ~~outcome~~United States Court of Appeals for the Federal Circuit affirmed the decision of the ~~Massachusetts actions.~~United States District Court for the District of Massachusetts.

The FDA approved the first infliximab biosimilar for sale in the United States in 2016, and a number of such products have been launched.

Litigation Against Filers of Abbreviated New Drug Applications (ANDAs)

The following summarizes lawsuits pending against generic companies that have filed Abbreviated New Drug Applications (ANDAs) with the FDA or undertaken similar regulatory processes outside of the United States, seeking to market generic forms of products sold by various subsidiaries of Johnson && Johnson prior to expiration of the applicable patents covering those products. These ANDAs typically include allegations of non-infringement and invalidity of the applicable patents. In the event the subsidiaries are not successful in an action, or the automatic statutory stay of the ANDAs expires before the United States District Court rulings are obtained, the third-party companies involved would have the ability, upon approval of the FDA, to introduce generic versions of their products to the market, resulting in the potential for substantial market share and revenue losses for the applicable products, and which may result in a non-cash impairment charge in any associated intangible asset. In addition, from time to time, subsidiaries may settle these types of actions and such settlements can involve the introduction of generic versions of the products at issue to the market prior to the expiration of the relevant patents. The Inter Partes Review (IPR) process with the United States Patent and Trademark Office (USPTO), created under the 2011 America Invents Act, is also being used at times by generic companies in conjunction with ANDAs and lawsuits, to challenge the applicable patents.

ZYTIGA^®®

In July 2015, Janssen Biotech, Inc., Janssen Oncology, Inc. and Janssen Research & Development, LLC (collectively, Janssen) and BTG International Ltd. (BTG) initiated a patent infringement lawsuit (the main action) in the United States District Court for the District of New Jersey against a number of generic companies (and certain of their affiliates and/or suppliers) who filed ANDAs seeking approval to market a generic version of ZYTIGA^® 250mg before the expiration of United States Patent No. 8,822,438 (the ’438 patent). The generic companies include Amneal Pharmaceuticals, LLC and Amneal Pharmaceuticals of New York, LLC (collectively, Amneal); Apotex Inc. and Apotex Corp. (collectively, Apotex); Citron Pharma LLC (Citron); Dr. Reddy’s Laboratories, Ltd. and Dr. Reddy’s Laboratories, Inc. (collectively, Dr. Reddy’s); Mylan Pharmaceuticals Inc. and Mylan Inc. (collectively, Mylan); Par Pharmaceuticals, Inc. and Par Pharmaceutical Companies, Inc. (collectively, Par); Teva Pharmaceuticals USA, Inc. (Teva); Wockhardt Bio A.G.; Wockhardt USA LLC and Wockhardt Ltd. (collectively, Wockhardt); West-Ward Pharmaceutical Corp. (West-Ward) and Hikma Pharmaceuticals, LLC (Hikma).

Janssen and BTG also initiated patent infringement lawsuits in the United States District Court for the District of New Jersey against Amerigen Pharmaceuticals Limited (Amerigen) in May 2016, and Glenmark Pharmaceuticals, Inc. (Glenmark) in June

~~2016, each of whom filed an ANDA seeking approval to market its generic version of ZYTIGA~~^® ~~before the expiration of the ’438 patent. These lawsuits were consolidated with the main action.~~

In August 2015, Janssen and BTG filed an additional jurisdictional protective lawsuit against the Mylan defendants in the United States District Court for the Northern District of West Virginia, which has been stayed.

In August 2017, Janssen and BTG initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Teva, who filed an ANDA seeking approval to market a generic version of ZYTIGA^® ~~500mg before the expiration of the ’438 patent. This lawsuit has been consolidated with the main action.~~

~~In December 2017, Janssen and BTG entered into a settlement agreement with Glenmark.~~

In February 2018, Janssen and BTG filed a patent infringement lawsuit against MSN Pharmaceuticals, Inc. and MSN Laboratories Private Limited (collectively, MSN) in United States District Court for the District of New Jersey based on its ANDA seeking approval for a generic version of ZYTIGA^® ~~prior to the expiration of the ’438 patent. In February 2019, the action was stayed pending the outcome of the main action.~~

~~In April 2018, Janssen and BTG entered into a settlement agreement with Apotex.~~

In October 2018, the United States District Court for the District of New Jersey issued a ruling invalidating all asserted claims of the ’438 patent. The court held that the patent claims would be infringed if the patent were valid. Janssen appealed the court’s decision.

In November 2018, Janssen and BTG initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Qilu Pharmaceutical Co., Ltd. and Qilu Pharma, Inc. (collectively, Qilu), who filed an ANDA seeking approval to market a generic version of ZYTIGA^® ~~before the expiration of the ’438 patent. Janssen is seeking an order enjoining Qilu from marketing its generic version of ZYTIGA~~^® ~~before the expiration of the ’438 patent.~~

~~In November 2018, the United States Court of Appeals for the Federal Circuit denied Janssen’s request for an injunction pending appeal. As a result, several generic versions of ZYTIGA~~^® ~~have entered the market.~~

Several generic companies including Amerigen, Argentum Pharmaceuticals LLC (Argentum), Mylan, Wockhardt, Actavis, Amneal, Dr. Reddy’s, Sun, Teva, West-Ward and Hikma filed Petitions for Inter Partes Review (IPR) with the USPTO, seeking to invalidate the ’438 patent. In January 2018, the USPTO issued decisions finding the ’438 patent claims unpatentable, and Janssen requested rehearing. In December 2018, the USPTO denied Janssen’s request for rehearing of the IPR decisions. Janssen filed an appeal, which was consolidated with the above-mentioned appeal of the decision of the United States District Court for the District of New Jersey. In May 2019, the Federal Circuit issued a decision affirming the USPTO's decision in the Wockhardt IPR that the ’438 patent claims are unpatentable and dismissed the remaining appeals as moot. Subsequently, Janssen dismissed its lawsuits against MSN and Qilu.

In November 2017, Janssen initiated a Notice of Application under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Apotex Inc. (Apotex) and the Minister of Health in Canada in response to ~~Apotex’s~~Apotex’s filing of an Abbreviated New Drug Submission (ANDS) seeking approval to market a generic version of ZYTIGA^®®before the expiration of Canadian Patent No. ~~2,661,422.~~2,661,422 (the ’422 patent). The ~~Final Hearing~~final hearing concluded in May 2019. In October 2019, the court issued an order prohibiting the Canadian Minister of Health from approving Apotex’s ANDS until the expiration of the ’422 patent. In November 2019, Apotex filed an appeal.

In January 2019, Janssen initiated a ~~Notice~~Statement of ~~Application~~Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Apotex and the Minister of Health in Canada in response to ~~Apotex’s~~Apotex’s filing of an Abbreviated New Drug Submission (ANDS) seeking approval to market a film-coated generic version of ZYTIGA^®® before the expiration of ~~Canadian Patent No. 2,661,422.~~the ’422 patent. The ~~Final Hearing~~final hearing is scheduled to begin in October 2020.

In January 2019, Janssen initiated a ~~Notice~~Statement of ~~Application~~Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Pharmascience Inc. (Pharmascience) and the Minister of Health in Canada in response to ~~Pharmascience’s~~Pharmascience’s filing of an Abbreviated New Drug Submission (ANDS) seeking approval to market a generic version of ZYTIGA^®®250 mg,before the expiration of ~~Canadian Patent No. 2,661,422.~~the ’422 patent. The ~~Final Hearing~~final hearing is scheduled to begin in October 2020.

In ~~January~~November 2019, Janssen initiated a ~~Notice~~Statement of ~~Application~~Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against ~~Sandoz Canada Inc. (Sandoz)~~Pharmascience and the Minister of Health in Canada in response to ~~Sandoz’s~~Pharmascience’s filing of an ~~Abbreviated New Drug Submission (ANDS)~~ANDS seeking approval to market a generic version of ZYTIGA^{® ®}, 500 mg, before the expiration of ~~Canadian Patent No. 2,661,422.~~the ’422 patent. The ~~Final Hearing~~final hearing is scheduled to begin in October 2020.

In June 2019, Janssen initiated a ~~Notice~~Statement of ~~Application~~Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Dr. Reddy's Laboratories Ltd. and Dr. Reddy's Laboratories, Inc. (collectively, DRL) and the Minister of Health in Canada in response to ~~Apotex’s~~Apotex’s filing of an Abbreviated New Drug Submission (ANDS) seeking approval to market a generic version of ZYTIGA^��® before the expiration of ~~Canadian Patent No. 2,661,422~~the ’422 patent. The final hearing is scheduled to begin in October 2020.

Table of Contents

In each of these Canadian actions, Janssen is seeking an order ~~prohibiting~~enjoining the ~~Minister~~defendants from marketing their generic versions of ~~Health from issuing a Notice of Compliance with respect to the defendants’ ANDSs~~ZYTIGA^® before the expiration of ~~Janssen’s~~the ’422 patent.

XARELTO^®®

B~~eginning~~Beginning in October 2015, Janssen Pharmaceuticals, Inc. (JPI) and Bayer Pharma AG and Bayer Intellectual Property GmbH (collectively, Bayer) filed patent infringement lawsuits in the United States District Court for the District of Delaware against a number of generic companies who filed ANDAs seeking approval to market generic versions of XARELTO^®® before expiration of ~~Bayer’s~~Bayer’s United States Patent Nos. 7,157,456, 7,585,860 and 7,592,339 relating to XARELTO^®®. JPI is the exclusive sublicensee of the asserted patents. The following generic companies ~~are~~were named defendants: Aurobindo Pharma Limited and Aurobindo Pharma USA, Inc. (collectively, Aurobindo); Breckenridge Pharmaceutical, Inc. (Breckenridge); InvaGen Pharmaceuticals Inc. (InvaGen); Micro Labs USA Inc. and Micro Labs Ltd (collectively, Micro); Mylan Pharmaceuticals Inc. (Mylan); Prinston Pharmaceuticals, Inc.; Sigmapharm Laboratories, LLC (Sigmapharm); Torrent Pharmaceuticals, Limited and Torrent Pharma Inc. (collectively, Torrent). The trial concluded in April 2018. In July 2018 the district court entered judgment against Mylan and Sigmapharm, holding that the asserted compound patent is valid and infringed. In September 2018, the district court entered judgment against the remaining defendants. None of the defendants appealed the judgment.

Beginning in April 2017, JPI and Bayer Intellectual Property GmbH and Bayer AG (collectively, Bayer AG) filed patent infringement lawsuits in the United States District Court for the District of Delaware against a number of generic companies who filed ANDAs seeking approval to market generic versions of XARELTO^®® before expiration of Bayer ~~AG’s~~AG’s United States Patent No. 9,539,218 ~~(’218)~~(’218) relating to XARELTO^®®. JPI is the exclusive sublicensee of the asserted patent. The following generic companies are named defendants: Alembic Pharmaceuticals Limited, Alembic Global Holding SA and Alembic Pharmaceuticals, Inc. (Alembic); Aurobindo; Breckenridge; InvaGen; Lupin Limited and Lupin Pharmaceuticals, Inc. (collectively, Lupin); Micro; Mylan; Sigmapharm; Taro Pharmaceutical Industries Ltd. and Taro Pharmaceuticals U.S.A., Inc. (collectively, Taro) and Torrent. Lupin counterclaimed for declaratory judgment of noninfringement and invalidity of United States Patent No. 9,415,053, but Lupin dismissed its counterclaims after it was provided a covenant not to sue on that patent. Aurobindo, Taro, Torrent, Micro, Breckenridge, InvaGen, Sigmapharm, Lupin and Alembic have agreed to have their cases stayed and to be bound by the outcome of any final judgment rendered against any of the other defendants. The ~~’218~~’218 cases have been consolidated for discovery and trial. The trial began in April 2019 and closing arguments were heard in June 2019.

In December 2018, JPI and Bayer AG filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd. (collectively, Teva) who filed an ANDA seeking approval to market a generic version of XARELTO^®® before expiration of Bayer ~~AG’s ’218~~AG’s ’218 patent. The case against Teva has been consolidated with the other ~~’218~~’218 cases for all purposes, and Teva has agreed to have its case stayed and to be bound by the outcome of any final judgment rendered against any of the other defendants.

In May 2018, Mylan filed a Petition for Inter Partes Review with the USPTO, seeking to invalidate the ’218 patent. In December 2018, the USPTO issued a decision denying institution of Mylan’s Petition for Inter Partes Review.

~~In May 2019,~~March 2020, JPI and Bayer ~~filed suit against Macleods Pharmaceuticals Ltd.~~entered into settlement agreements with each of Alembic and Macleods Pharma USA, Inc. (collectively, Macleods) alleging infringement of the ’218 patent. The case against Macleods has been consolidated with the other ’218 cases for all purposes, and Macleods has agreed to have its case stayed and to be bound by the outcome of any final judgment rendered against any of the other defendants.

Lupin. In ~~June 2019,~~April 2020, JPI and Bayer ~~filed suit against Accord Healthcare Inc., Accord Healthcare Ltd.,~~entered into settlement agreements with each of Aurobindo and ~~Intas Pharmaceuticals Ltd. (collectively, Accord) alleging infringement of the ’218 patent.~~Teva.

The consolidated ’218 cases involving InvaGen and Taro have been stayed.

In each of these lawsuits, JPI is seeking an order enjoining the defendants from marketing their generic versions of XARELTO^®® before the expiration of the relevant patents.

PREZISTA^®®

In ~~May 2018,~~January 2020, Janssen Products, L.P. and Janssen Sciences Ireland UCUnlimited Company (collectively, Janssen) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against ~~Dr. Reddys Laboratories,~~Zydus Pharmaceuticals (USA), Inc.~~, Dr. Reddys Laboratories, Ltd., Laurus Labs,~~ and Cadila Healthcare Ltd. ~~and Pharmaq, Inc.~~ (collectively, ~~DRL)~~Zydus), who filed an ANDA seeking approval to market a generic ~~versions~~version of PREZISTA^®® before the expiration of United States Patent Nos. ~~8,518,987; 7,126,015; and 7,595,408. In February 2019, the parties entered into a settlement agreement.~~

In December 2018, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Amneal Pharmaceuticals, LLC, Amneal Pharmaceuticals Company GmbH, Amneal Pharmaceuticals of New York, LLC, Amneal Pharmaceuticals Pvt Ltd., and Raks Pharma Pvt. Ltd. (collectively, Amneal), who filed an ANDA seeking approval to market generic versions of PREZISTA^® ~~before the expiration of United States Patent Nos. 8,518,987; 7,126,015;~~7,700,645, 8,518,987, 7,126,015 and 7,595,408. Janssen is seeking an order enjoining ~~Amneal~~Zydus from marketing its generic ~~versions~~version of PREZISTA^®® before the expiration of the relevant patents.

In April ~~2019,~~2020, Janssen initiated a Statement of Claim under Section 6 of the ~~parties entered into~~Patented Medicines (Notice of Compliance) Regulations against Marcan Pharmaceuticals Inc. (Marcan) and the Minister of Health in Canada in response to Marcan’s filing of an ANDS seeking approval to market a ~~settlement.~~generic version of Prezista before the expiration of Canadian Patent No. 2,485,834

Table of Contents

(the ’834 patent). Janssen is seeking an order enjoining Marcan from marketing its generic version of PREZISTA^® before the expiration of the ’834 patent.

INVOKANA^®®/INVOKAMET^®®/INVOKAMET XR^®®

Beginning in July 2017, Janssen Pharmaceuticals, Inc., Janssen Research && Development, LLC, Cilag GmbH International and Janssen Pharmaceutica NV (collectively, Janssen) and Mitsubishi Tanabe Pharma Corporation (MTPC) filed patent infringement lawsuits in the United States District Court for the District of New Jersey ~~the United States District Court for the District of Colorado and the United States District Court for the District of Delaware~~ against a number of generic companies who filed ANDAs seeking approval to market generic versions of INVOKANA^®®, INVOKAMET^® and/or INVOKAMET^{® ®} XR before expiration of ~~MTPC’s~~MTPC’s United States Patent Nos. 7,943,582 (the ~~’582~~’582 patent) and/or 8,513,202 (the ~~’202~~’202 patent) relating to INVOKANA^®®, INVOKAMET^® ~~and~~and/or INVOKAMET^®®. XR. Janssen is the exclusive licensee of the asserted patents. The following generic companies ~~are~~were named as defendants: Apotex Inc. and Apotex Corp. (Apotex); Aurobindo Pharma USA Inc. (Aurobindo); Macleods Pharmaceuticals Ltd. and Macleods Pharma USA, Inc.; InvaGen Pharmaceuticals, Inc. (InvaGen); Prinston Pharmaceuticals Inc.; Dr. ~~Reddy’s~~Reddy’s Laboratories, Inc. and Dr. ~~Reddy’s~~Reddy’s Laboratories ~~Ltd;~~Ltd (DRL); Hetero USA, Inc., Hetero Labs Limited ~~Unit-V~~Unit V and Hetero Labs Limited; MSN Laboratories Private Ltd. and MSN Pharmaceuticals, Inc. (MSN); Laurus Labs Ltd.; Indoco Remedies Ltd.; Zydus Pharmaceuticals (USA) Inc. (Zydus); Sandoz, Inc. (Sandoz); Teva Pharmaceuticals USA, Inc.; and Lupin Ltd. and Lupin Pharmaceuticals, Inc. (Lupin). These cases were consolidated into one action (Polymorph Main Action), which is scheduled for trial starting in June 2020. In February 2020, the lawsuit against Macleods and DRL was dismissed.

Beginning in July 2017, Janssen and MTPC filed patent infringement lawsuits in the United States District Court for the District of New Jersey ~~and the United States District Court for the District~~against a number of ~~Colorado against Sandoz and InvaGen,~~generic companies who filed ANDAs seeking approval to market generic versions of INVOKANA^®®, INVOKAMET^® and/or INVOKAMET^®® XRbefore expiration of ~~MTPC’s~~MTPC’s United States Patent No. 7,943,788 (the ~~’788~~’788 patent), 8,222,219 (the ’219 patent) and/or 8,785,403 (the ’403 patent) relating to INVOKANA^® ~~and INVOKAMET~~^®~~and against Zydus, who filed ANDAs seeking approval to market generic versions of INVOKANA~~^® ~~and INVOKAMET~~^®~~before expiration of the ’788 patent, MTPC's United States Patent No. 8,222,219 relating to INVOKANA~~^® ~~and INVOKAMET~~^®~~and MTPC’s United States Patent No. 8,785,403 relating to INVOKAMET~~^®®, ~~and against Aurobindo, who filed an ANDA seeking approval to market a generic version of INVOKANA~~INVOKAMET^®®and/or INVOKAMET^® ~~before expiration of the ’788 patent and the ’219 patent relating to INVOKANA~~^®.XR Janssen is the exclusive licensee of the asserted patents. ~~In October 2017, the Colorado lawsuits~~The following generic companies were named as defendants: Sandoz, Zydus and Aurobindo. These cases were consolidated into one action (Compound Main Action), which was scheduled for trial in May 2020 but is being rescheduled. The lawsuit against Sandoz ~~were dismissed. In December 2017, the Delaware lawsuits against Apotex and Teva were dismissed.~~was dismissed in February 2020.

In April 2018, Janssen and MTPC filed a patent infringement lawsuit in the United States District Court for the District of New Jersey against Prinston, who filed an ANDA seeking approval to market a generic version of INVOKANA^® ~~before expiration of the ’788 patent relating to INVOKANA~~^®.

~~In February~~July 2019, Janssen and MTPC filed a patent infringement lawsuit in the United States District Court for the District of New Jersey against ~~Lupin,~~MSN, who filed an ANDA seeking approval to market a generic version of INVOKAMET XR^®® before expiration of the ~~’582~~’582 patent and ~~’202~~’202 patent relating to INVOKAMET XR^®®. In October 2019, Janssen and MTPC initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against MSN, who filed ANDAs seeking approval to market generic versions of INVOKANA^® and INVOKAMET XR^® before expiration of the ’788 patent. In October 2019, Janssen and MTPC initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against DRL, who filed an ANDA seeking approval to market a generic version of INVOKAMET^® before expiration of the ’788 patent. In March 2020, Janssen and MTPC initiated patent infringement lawsuits in the United States District Court for the District of New Jersey against Aurobindo, who filed an ANDA seeking approval to market a generic version of INVOKAMET XR^® before expiration of the ’788 patent, ’219 patent, ’403 patent, ’582 patent, and ’202 patent. These lawsuits have not been consolidated with the Main Actions.

~~A trial on the ’582~~Janssen and ~~’202 patents is scheduled to begin~~MTPC entered into a settlement agreement with Indoco in ~~April 2020, and a trial on the ’788, ’219 and ’403 patents is scheduled to begin in May~~March 2020.

In each of these lawsuits, Janssen and MTPC are seeking an order enjoining the defendants from marketing their generic versions of INVOKANA^®®, INVOKAMET^®® and/or, , INVOKAMET XR^®®before the expiration of the relevant patents.

OPSUMIT^®®

In January 2018, Actelion Pharmaceuticals Ltd (Actelion) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Zydus Pharmaceuticals (USA) Inc. (Zydus) and Amneal Pharmaceuticals LLC

(Amneal), each of whom filed an ANDA seeking approval to market a generic version of OPSUMIT^®®before the expiration of United States Patent No. ~~7,094,781.~~7,094,781 (the ’781 patent). In the lawsuit, Actelion is seeking an order enjoining Zydus and Amneal from marketing generic versions of OPSUMIT^®® before the expiration of the patent. Amneal and Zydus have stipulated to infringement. In February 2020, Actelion and Amneal entered into a settlement agreement. The trial against Zydus is scheduled to commence in October 2020.

In July 2019, Actelion Pharmaceuticals Ltd. filed suit against Aurobindo Pharma USA Inc. and Aurobindo Pharma Limited (Aurobindo). Aurobindo filed an ANDA seeking approval to market a generic version of OPSUMIT^® before the expiration of

Table of Contents

the ’781 patent. Actelion is seeking an order enjoining Defendants from marketing a generic version of OPSUMIT^® before the expiration of the ’781 patent. Trial against Aurobindo is scheduled to commence in July 2021.

INVEGA SUSTENNA^®®

In January 2018, Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc. (collectively, Janssen) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Teva Pharmaceuticals USA, Inc. (Teva), who filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA^®® before the expiration of United States Patent No. ~~9,439,906.~~ 9,439,906 (the ’906 patent). Trial was scheduled to begin in June 2020 but is being rescheduled.

In August 2019, Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc. (collectively, Janssen) initiated a patent infringement lawsuit in the ~~lawsuit, Janssen is~~United States District Court for the District of New Jersey against Mylan Laboratories Limited (Mylan), who filed an ANDA seeking ~~an order enjoining Teva from marketing~~approval to market a generic version of INVEGA SUSTENNA^®® before the expiration of the ’906 patent. In February 2020, Mylan filed a Petition for Inter Partes Review with the USPTO seeking to invalidate the ’906 patent.

In December 2019, Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc. (collectively, Janssen) initiated a patent infringement lawsuit in the United States District Courts for the Districts of New Jersey and Delaware against Pharmascience Inc., Mallincrodt PLC and Specgx LLC (collectively, Pharmascience), who filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA^® before the expiration of the ’906 patent.

In February 2018, Janssen Inc. and Janssen Pharmaceutica NV (collectively, Janssen) initiated a ~~Notices~~Statement of ~~Application~~Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Teva Canada Limited (Teva) and the Minister of Health in response to Teva's filing of an Abbreviated New Drug Submission (ANDS) seeking approval to market a generic version of INVEGA SUSTENNA^®® before the expiration of Canadian Patent Nos. 2,309,629 (the ’629 patent) and 2,655,335 (the ’335 patent). Janssen subsequently discontinued the portion of the lawsuit relating to the ’629 patent. The final hearing took place in February 2020. In April 2020, the Canadian Federal Court issued a Draft CONFIDENTIAL Judgment and Reasons (Draft Judgment) declaring that Teva’s generic version of INVEGA SUSTENNA^®, if approved, would infringe claims of the ’335 patent and that the claims of the ’335 patent are not invalid for obviousness. The Draft Judgment will be made final after the parties have made submissions on the redaction of any confidential information.

In April 2020, Janssen Inc. and Janssen Pharmaceutica NV (together, Janssen) initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Pharmascience Inc. (Pharmascience) and the Minister of Health in response to Pharmascience's filing of an Abbreviated New Drug Submission (ANDS) seeking approval to market a generic version of INVEGA SUSTENNA^® before the expiration of Canadian Patent No. 2,655,335.

In each of these lawsuits, Janssen is seeking an order ~~prohibiting~~enjoining the ~~Minister~~defendant from marketing a generic version of ~~Health from issuing a Notice of Compliance with respect to Teva’s ANDS~~INVEGA SUSTENNA^® before the expiration of ~~these patents. The Final Hearing is scheduled to begin in September 2019.~~the patent.

IMBRUVICA^®®

Beginning in January 2018, Pharmacyclics LLC (Pharmacyclics) and Janssen Biotech, Inc. (JBI) filed patent infringement lawsuits in the United States District Court for the District of Delaware against a number of generic companies who filed ANDAs seeking approval to market generic versions of IMBRUVICA^®®140 mg capsulesbefore expiration of ~~Pharmacyclics’~~Pharmacyclics’ United States Patent Nos. 8,008,309, 7,514,444, 8,697,711, 8,735,403, 8,957,079, 9,181,257, 8,754,091, 8,497,277, 8,925,015, 8,476,284, 8,754,090, 8,999,999, 9,125,889, 9,801,881, 9,801,883, 9,814,721, 9,795,604, 9,296,753, 9,540,382, 9,713,617 and/or 9,725,455 relating to IMBRUVICA^®®. JBI is the exclusive licensee of the asserted patents. The following generic companies are named defendants: Cipla Limited and Cipla USA Inc. (Cipla); Fresenius Kabi USA, LLC, Fresenius Kabi USA, Inc., and Fresenius Kabi Oncology Limited (Fresenius Kabi); Sandoz Inc. and Lek Pharmaceuticals d.d. (Sandoz); Shilpa Medicare Limited (Shilpa); Sun Pharma Global FZE and Sun Pharmaceutical Industries Limited (Sun); Teva Pharmaceuticals USA, Inc. (Teva); and Zydus Worldwide DMCC and Cadila Healthcare Limited (Zydus). The trial is scheduled to begin in October 2020.

In October 2018, Pharmacyclics and JBI filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Sun asserting United States Patent No. 10,004,746.

In November 2018, Pharmacyclics and JBI filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Hetero Labs Limited, Hetero Labs Limited Unit-1, Hetero Labs Limited Unit-V, and Hetero USA Inc. (“Hetero”), who filed an ANDA seeking approval to market a generic version of IMBRUVICA
^®~~140 mg capsules, asserting infringement of United States Patent Nos. 8,754,090, 9,296,753, 9,540,382, 9,713,617 and 9,725,455.~~

~~In January 2019, Pharmacyclics and JBI amended their complaints against Fresenius Kabi, Zydus, Teva and Sandoz to further allege infringement of U.S. Patent Nos. 10,106,548, and 10,125,140.~~

In January 2019, Pharmacyclics and JBI filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Zydus, who filed an ANDA seeking approval to market a generic version of IMBRUVICA^®® 70 mg before

Table of Contents

the expiration of U.S. Patent Nos. 7,514,444, 8,003,309, 8,476,284, 8,497,277, 8,697,711, 8,753,403, 8,754,090, 8,754,091, 8,952,015, 8,957,079, 9,181,257, 9,296,753, 9,540,382, 9,713,617, 9,725,455, 10,106,548, and 10,125,140.

In January 2019, Pharmacyclics and JBI filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Hetero asserting infringement of United States Patent No. 10,106,548.

In February 2019, Pharmacyclics and JBI amended their complaints against Cipla, Shilpa, and Sun to allege infringement of United States Patent Nos. 10,106,548, and 10,125,140.

~~In February 2019, Pharmacyclics and JBI entered into settlement agreements with Teva and Hetero. In March 2019, Pharmacyclics and JBI entered into a settlement agreement with Shilpa.~~

In March 2019, Pharmacyclics and JBI filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Alvogen Pine Brook LLC and Natco Pharma Ltd. (Alvogen), who filed an ANDA seeking approval to market generic versions of IMBRUVICA^®® tablets, asserting infringement of United States Patent Nos. 7,514,444, 8,003,309, 8,476,284, 8,497,277, 8,697,711, 8,753,403, 8,754,090, 8,754,091, 8,952,015, 8,957,079, 9,181,257, 9,296,753, 9,655,857, 9,725,455, 10,010,507, 10,106,548, and 10,125,140.

In May 2019, Pharmacyclics and JBI amended their complaints against Cipla to further allege infringement of United States Patent No. 10,016,435. In June 2019, Pharmacyclics and JBI amended their complaints against Alvogen to further allege infringement of United States Patent No. 10,213,386.

In August 2019, Pharmacyclics and JBI amended their complaints against Cipla, Fresenius, and Sandoz to further allege infringement of U.S. Patent Nos. 10,294,231 and 10,294,232 and amended their complaint against Sun to further allege infringement of U.S. Patent No. 10,294,232.

In March 2019, Sandoz filed an Inter Partes Review (IPR) in the USPTO, seeking to invalidate United States Patent No. 9,795,604.

In February 2020, Pharmacyclics and JBI entered into settlement agreements with Fresenius Kabi.

In March 2020, Pharmacyclics and JBI filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Alvogen, Zydus, Sun and Sandoz asserting infringement of United States Patent No. 10,478,439.

In April 2020, Pharmacyclics and JBI filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Zydus, who filed an ANDA seeking approval to market generic versions of IMBRUVICA^® tablets, asserting infringement of United States Patent Nos. 7,514,444, 8,003,309, 8,476,284, 8,497,277, 8,697,711, 8,753,403, 8,754,090, 8,754,091, 8,952,015, 8,957,079, 9,181,257, 9,296,753, 9,655,857, 9,725,455, 10,010,507, 10,106,548, 10,125,140, 10,213,286 and 10,478,439.

In each of the lawsuits, Pharmacyclics and JBI are seeking an order enjoining the defendants from marketing generic versions of IMBRUVICA^®®before the expiration of the relevant patents.

~~In March 2019, Sandoz filed an Inter Partes Review (IPR) in the USPTO, seeking to invalidate United States Patent No. 9,795,604.~~

TRACLEER^®®

In ~~May~~December 2019, Actelion Pharmaceuticals Ltd and Actelion Pharmaceuticals US, Inc. initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against ~~Natco Pharma~~Zydus Pharmaceuticals (USA), Inc. and Cadila Healthcare Limited ~~and Syneos Health LLC~~ (collectively, ~~Natco)~~Zydus), who filed an ANDA seeking approval to market a generic version of TRACLEER^®®, 32 mg, before the expiration of U.S. Patent No. 8,309,126 (the ~~’126~~’126 patent). ~~In the lawsuit,~~ Actelion is seeking an order enjoining ~~Natco~~Zydus from marketing its generic version of TRACLEER^®® before the expiration of the ~~’126~~’126 patent.

UPTRAVI^®

In April 2020, Actelion Pharmaceuticals Ltd and Nippon Shinyaku Co., Ltd. initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against a number of generic companies who filed ANDAs seeking approval to market generic versions of UPTRAVI^®before expiration of Nippon Shinyaku’s United States Patent Nos. 7,205,302; 8,791,122; and 9,284,280 relating to UPTRAVI^®. Actelion is the exclusive licensee of the asserted patents. The following generics are named defendants in the complaint: Alembic Pharmaceuticals Limited and Alembic Pharmaceuticals Inc. (Alembic); MSN Laboratories Private Limited and MSN Pharmaceuticals Inc. (MSN); Aizant Drug Research Solutions Private Limited (Aizant); VGYAAN Pharmaceuticals LLC (VGYAAN); and Zydus Pharmaceuticals (USA), Inc. and Zydus Worldwide DMCC (Zydus)

Actelion and Nippon Shinyaku are seeking an order enjoining the defendants from marketing generic versions of UPTRAVI^®before the expiration of the relevant patents.

Table of Contents

GOVERNMENT PROCEEDINGS

Like other companies in the pharmaceutical, consumer and medical devices industries, Johnson && Johnson and certain of its subsidiaries are subject to extensive regulation by national, state and local government agencies in the United States and other countries in which they operate. As a result, interaction with government agencies is ongoing. The most significant litigation brought by, and investigations conducted by, government agencies are listed below. It is possible that criminal charges and substantial fines and/or civil penalties or damages could result from government investigations or litigation.

Average Wholesale Price (AWP) Litigation

Johnson && Johnson and several of its pharmaceutical subsidiaries (the J&J&J AWP Defendants), along with numerous other pharmaceutical companies, were named as defendants in a series of lawsuits in state and federal courts involving allegations that the pricing and marketing of certain pharmaceutical products amounted to fraudulent and otherwise actionable conduct because, among other things, the companies allegedly reported an inflated Average Wholesale Price (AWP) for the drugs at issue. Payors alleged that they used those AWPs in calculating provider reimbursement levels. The plaintiffs in these cases included three classes of private persons or entities that paid for any portion of the purchase of the drugs at issue based on AWP, and state government entities that made Medicaid payments for the drugs at issue based on AWP. Many of these cases, both federal actions and state actions removed to federal court, were consolidated for pre-trial purposes in a multi-district litigation in the United States District Court for the District of Massachusetts, where all claims against the J&J&J AWP Defendants were ultimately dismissed. The J&J&J AWP Defendants also prevailed in a case brought by the Commonwealth of Pennsylvania. Other AWP cases have been resolved through court order or settlement. ~~Two cases remain pending. A~~The case brought by Illinois was ~~tried in May 2019 and post-trial briefing is underway.~~settled after trial. In New Jersey, a putative class action based upon AWP allegations is pending against Centocor, Inc. and Ortho Biotech Inc. (both now Janssen Biotech, Inc.), Johnson && Johnson and ALZA Corporation. All other cases have been resolved.

~~Opioids~~Opioid Litigation

Beginning in 2014 and continuing to the present, Johnson && Johnson and Janssen Pharmaceuticals, Inc. (JPI), along with other pharmaceutical companies, have been named in more than ~~2,000~~2,900 lawsuits ~~brought by certain state and local governments~~ related to the marketing of opioids, including DURAGESIC^®®, NUCYNTA^®® and NUCYNTA^®® ER. The suits also raise allegations related to previously owned active pharmaceutical ingredient supplier subsidiaries, Tasmanian Alkaloids Pty, Ltd. and Noramco, Inc. (both subsidiaries were divested in 2016). The majority of the cases have been filed by state and local governments. Similar lawsuits have also been filed by private plaintiffs and organizations, including but not limited to the following: individual plaintiffs on behalf of children suffering from Neonatal Abstinence Syndrome; hospitals; and health insurers/payors. To date, complaints against pharmaceutical companies, including Johnson && Johnson and JPI, have been filed ~~in state court~~ by the state Attorneys General in Arkansas, Florida, Idaho, Illinois, Kentucky, Louisiana, Mississippi, Missouri, New Hampshire, New Jersey, New Mexico, New York, Ohio, Oklahoma, South Dakota, Texas, Washington and ~~South Dakota.~~

West Virginia. Complaints against the manufacturers also have been filed in state or federal court by city, county and local government agencies in the following states: ~~Alabama; Arkansas; California; Connecticut; Florida; Georgia; Illinois; Kentucky; Louisiana; Maine; Maryland; Massachusetts; Mississippi; Missouri; Nevada;~~Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Illinois, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Mississippi, Missouri, Nevada, New ~~Hampshire;~~Hampshire, New ~~Jersey;~~Jersey, New ~~Mexico;~~Mexico, New ~~York;~~York, North Carolina; ~~Ohio; Oklahoma; Oregon; Pennsylvania;~~Ohio, Oklahoma, Oregon, Pennsylvania, Rhode ~~Island;~~Island, South ~~Carolina;~~Carolina, South ~~Dakota; Tennessee; Texas; Utah; Virginia; Washington;~~Dakota, Tennessee, Texas, Utah, Virginia, Washington, West Virginia and Wisconsin. The Government of Puerto Rico filed suit in Superior Court of San Juan. There are more than 370 cases pending in various state courts. There are over 2,600 federal cases coordinated in a federal Multi-District Litigation (MDL) pending in the U.S. District Court for the Northern District of Ohio (MDL No. 2804). In addition, the Province of British Columbia filed suit in Canada. In October 2019, an anti-trust complaint was filed by private plaintiffs in federal court in Tennessee and is pending transfer to the MDL. These actions allege a variety of claims related to ~~opioids~~opioid marketing practices, including false advertising, unfair competition, public nuisance, consumer fraud violations, deceptive acts and practices, false claims and unjust enrichment. The suits generally seek penalties and/or injunctive and monetary relief and, in some of the suits, the plaintiffs are seeking joint and several liability among the defendants. The case filed by the Oklahoma Attorney General started trial in May 2019. Additionally, over 2,000 federal cases have been coordinated in a federal Multi-District Litigation (MDL) pending in the U.S. District Court for the Northern District of Ohio (MDL No. 2804). The first trial date in the MDL has been set for October 2019. An adverse judgment in any of these lawsuits could result in the imposition of large monetary penalties and significant damages including, punitive damages, cost of abatement, substantial fines, equitable remedies and other sanctions.

The trial in the matter filed by the Oklahoma Attorney General resulted in a judgment against Johnson & Johnson and JPI in the amount of $572 million, subject to a final order to be issued by the court. The court issued a final judgment reducing the amount to $465 million. Johnson & Johnson and JPI have appealed the judgment. The Company believes that it has strong grounds to overturn this judgment. In October 2019 Johnson & Johnson and JPI announced a settlement of the first case set for trial in the MDL with two counties in Ohio.

Table of Contents

Johnson && Johnson, JPI and other pharmaceutical companies have also received subpoenas or requests for information related to opioids marketing practices from the following state Attorneys General: Alaska, Indiana, Montana, New Hampshire, South Carolina, Tennessee, Texas and Washington. In September 2017, Johnson && Johnson and JPI were contacted by the Texas and Colorado Attorney ~~General’s~~General’s Offices on behalf of approximately 38 states regarding a multi-state Attorney General investigation. In October 2019, the Company announced a proposed agreement in principle that would include the Company paying $4 billion as settlement of these lawsuits, subject to various conditions and an agreement being finalized. This agreement in principle is not an admission of liability or wrong-doing and would resolve opioid lawsuits filed and future claims by states, cities and counties. The ~~multi-state coalition served~~Company cannot predict if or when the agreement will be finalized and individual cases are ongoing.

In August 2019, Johnson && Johnson received a grand jury subpoena from the United States Attorney’s Office for the Eastern District of New York for documents related to the Company’s anti-diversion policies and ~~JPI with~~procedures and distribution of its opioid medications, in what the Company understands to be part of a broader investigation into manufacturers’ and distributors’ monitoring programs and reporting under the Controlled Substances Act. In September 2019, Johnson & Johnson received subpoenas from the New York State Department of Financial Services (NYDFS) as part of an industry-wide inquiry into the ~~investigation.~~effect of opioid prescriptions on New York health insurance premiums. The Company is cooperating and producing documents in response to the various subpoenas and requests for information.

In November 2019, a shareholder filed a derivative complaint against Johnson & Johnson as the nominal defendant and certain current and former directors and officers as defendants in the Superior Court of New Jersey. The complaint alleges breaches of fiduciary duties related to the marketing of opioids, and that Johnson & Johnson has suffered damages as a result of those alleged breaches. In December 2019, two additional shareholders filed two separate derivative complaints making similar allegations against Johnson & Johnson as the nominal defendant and certain current and former directors and officers as defendants in the United States District for the District of New Jersey. The parties to those two cases are conferring regarding consolidation and a scheduling stipulation.

Other

In August 2012, DePuy Orthopaedics, Inc., DePuy, Inc. (now known as DePuy Synthes, Inc.), and Johnson && Johnson Services, Inc. (collectively DePuy) received an informal request from the United States Attorney's Office for the District of Massachusetts and the Civil Division of the United States Department of Justice (the United States) for the production of materials relating to the DePuy ~~ASR™~~ASR™ XL Hip device. In July 2014, the United States notified the United States District Court for the District of Massachusetts that it had declined to intervene in a qui tam case filed pursuant to the False Claims Act against the companies. In February 2016, the district court granted the ~~companies’~~companies’ motion to dismiss with prejudice, unsealed the qui tam complaint, and denied the qui tam ~~relators’~~relators’ request for leave to file a further amended complaint. The qui tam relators appealed the case to the United States Court of Appeals for the First Circuit. In July 2017, the First Circuit affirmed the district ~~court’s~~court’s dismissal in part, reversed in part, and affirmed the decision to deny the ~~relators’~~relators’ request to file a third amended complaint. The ~~relators’~~relators’ remaining claims are now pending before the district ~~court, and fact~~court. The Court has granted the relators’ motion to stay discovery ~~is currently scheduled to close in September 2019.~~pending adjudication of outstanding motions.

In October 2012, Johnson && Johnson was contacted by the California Attorney General's office regarding a multi-state Attorney General investigation of the marketing of surgical mesh products for hernia and urogynecological purposes by Johnson && Johnson's subsidiary, Ethicon, Inc. (Ethicon). Johnson & Johnson and Ethicon have since entered into a series of tolling agreements with the 47 states and the District of Columbia participating in the multi-state investigation and have responded to Civil Investigative Demands served by certain of the participating states. The states are seeking monetary and injunctive relief. In May 2016, California and Washington filed civil complaints against Johnson && Johnson, Ethicon and Ethicon US, LLC alleging violations of their consumer protection statutes. Similar complaints were filed against the companies by the following states: Kentucky, Mississippi, West Virginia and Oregon. In April 2019, Johnson && Johnson and Ethicon settled the Washington case. The California case started trial in July ~~2019. Similar complaints were filed against the companies by Kentucky~~2019 and concluded in ~~August 2016 and by Mississippi in October 2017.~~September 2019. The trial date for the Kentucky case was scheduled for September 2019 but has been adjourned and no new trial date has been scheduled. The trial date for the Mississippi case is scheduled for April 2021. In October 2019, Johnson && Johnson and Ethicon ~~have entered into a new tolling agreement~~settled the multi-state investigation with ~~the remaining 43~~41 other states and the District of Columbia. In January 2020, the Court in California issued a statement of decision, finding in favor of the State of California, and awarded civil penalties in the amount of $344 million. The Company intends to appeal the decision. In April 2020, the Company settled the West Virginia case.

In December 2012, Therakos, Inc. (Therakos), formerly a subsidiary of Johnson && Johnson and part of the Ortho-Clinical Diagnostics, Inc. (OCD) franchise, received a letter from the civil division of the United States Attorney's Office for the Eastern District of Pennsylvania informing Therakos that the United States Attorney's Office was investigating the sales and marketing of Uvadex^®® (methoxsalen) and the Uvar Xts^®® and Cellex^®® Systems during the period 2000 to the present. The United States Attorney's Office requested that OCD and Johnson && Johnson preserve documents that could relate to the investigation. Therakos was subsequently acquired by an affiliate of Gores Capital Partners III, L.P. in January 2013, and OCD was divested

Table of Contents

in June 2014. Following the divestiture of OCD, Johnson && Johnson retains ~~OCD’s~~OCD’s portion of any liability that may result from the investigation for activity that occurred prior to the sale of Therakos. In March 2014 and March 2016, the United States ~~Attorney’s~~Attorney’s Office requested that Johnson && Johnson produce certain documents, and Johnson && Johnson is cooperating with those requests.

In June 2014, the Mississippi Attorney General filed a complaint in Chancery Court of The First Judicial District of Hinds County, Mississippi against Johnson && Johnson and Johnson && Johnson Consumer Companies, Inc. (now known as Johnson && Johnson Consumer Inc.) (JJCI). The complaint alleges that defendants ~~failed~~violated the Mississippi Consumer Protection Act by

failing to disclose alleged health risks associated with female consumers' use of talc contained in JOHNSON'S^®® Baby Powder and JOHNSON'S^®® Shower to Shower (a product divested in 2012) and seeks injunctive and monetary relief. The ~~trial~~matter is stayed pending interlocutory appeal of a December 2018 denial of Johnson & Johnson and JJCI's motion for summary judgment. The Mississippi Supreme Court granted J&J and JJCI's request to file an interlocutory appeal of the denial of the motion for summary judgment in late 2019.

In January 2020, the State of New Mexico filed a consumer protection case alleging that the Company deceptively marketed and sold its talcum powder products by making misrepresentations about the safety of the products and the presence of carcinogens, including asbestos. The State of New Mexico filed an Amended Complaint in March 2020.

Forty-one states have commenced a joint investigation into the Company’s marketing of its talcum powder products. At this time, the multi-state group has not asserted any claims against the Company, nor has the multi-state group sought any documents or other information.

In March 2016, Janssen Pharmaceuticals, Inc. (JPI) received a Civil Investigative Demand from the United States ~~Attorney’s~~Attorney’s Office for the Southern District of New York related to ~~JPI’s~~JPI’s contractual relationships with pharmacy benefit managers over the period from January 1, 2006 to the present with regard to certain of JPI's pharmaceutical products. The demand was issued in connection with an investigation under the False Claims Act.

In July 2016, Johnson && Johnson and Janssen Products LP were served with a qui tam complaint pursuant to the False Claims Act filed in the United States District Court for the District of New Jersey alleging the off-label promotion of two HIV products, PREZISTA^®® and INTELENCE^®®, and anti-kickback violations in connection with the promotion of these products. The complaint was filed under seal in December 2012. The federal and state governments have declined to intervene, and the lawsuit is being prosecuted by the relators.

In January 2017, Janssen Pharmaceuticals, Inc. (JPI) received a Civil Investigative Demand from the United States Department of Justice relating to allegations concerning the sales and marketing practices of OLYSIO^®. In December 2017, Johnson & Johnson and JPI were served with a whistleblower lawsuit filed in the United States District Court for the Central District of California alleging the off-label promotion of OLYSIO^® ~~and additional products, including NUCYNTA~~^®~~, XARELTO~~^®~~, LEVAQUIN~~^® ~~and REMICADE~~^®. At this time, the federal and state governments have declined to intervene and the lawsuit, which is related to the Civil Investigative Demand, is being prosecuted by a former company employee. The United States District Court for the Central District of California dismissed the claim in April 2018. In May 2018, the relator filed a notice of appeal to the United States Court of Appeals for the Ninth Circuit.

In November 2018, a second whistleblower lawsuit was unsealed in the United States District Court for the Central District of California. The lawsuit was substantially similar to the lawsuit under appeal but was brought in the name of the original relator. The federal and state governments declined to intervene in the second suit, and the relator moved to dismiss the lawsuit without prejudice. In April 2019, the court granted the relator's motion and dismissed the complaint without prejudice.

In March 2017, Janssen Biotech, Inc. received a Civil Investigative Demand from the United States Department of Justice regarding a False Claims Act investigation concerning management and advisory services provided to rheumatology and gastroenterology practices that purchased REMICADE^®® or SIMPONI ARIA^®®. In August 2019, the Unites States Department of Justice notified Janssen Biotech, Inc. that it was closing the investigation. Subsequently, the United States District Court for the District of Massachusetts unsealed a qui tam False Claims Act complaint, which was served on the Company. The Department of Justice had declined to intervene in the qui tam lawsuit in August 2019. The Company has filed a motion to dismiss the relator’s complaint.

In April and September 2017, Johnson && Johnson received subpoenas from the United States Attorney for the District of Massachusetts seeking documents broadly relating to pharmaceutical copayment support programs for DARZALEX^®®, OLYSIO^®®, REMICADE^®®, SIMPONI^®®, STELARA^®®and ZYTIGA^®®. The subpoenas also seek documents relating to Average Manufacturer Price and Best Price reporting to the Center for Medicare and Medicaid Services related to those products, as well as rebate payments to state Medicaid agencies.

In June 2017, Johnson && Johnson received a subpoena from the United States Attorney's Office for the District of Massachusetts seeking information regarding practices pertaining to the sterilization of DePuy Synthes, Inc. spinal implants at three hospitals in Boston as well as interactions of employees of Company subsidiaries with physicians at these hospitals. Johnson && Johnson and DePuy Synthes, Inc. have produced documents in response to the subpoena and are fully cooperating with the ~~government’s~~government’s investigation.

In July 2018 the Public Prosecution Service in Rio de Janeiro and representatives from the Brazilian antitrust authority CADE inspected the offices of more than 30 companies including Johnson && Johnson do Brasil ~~Indú~~Indústria e ~~Comé~~Comércio de Produtos para ~~Saú~~Saúde Ltda. The authorities appear to be investigating allegations of possible anti-competitive behavior and possible improper payments in the medical device industry. The United States Department of Justice and the United States Securities and Exchange Commission have made additional ~~preliminary~~ inquiries, ~~about the inspection in Brazil,~~ and Johnson && Johnson do Brasil ~~Indú~~Indústria e ~~Comé~~Comércio de Produtos para ~~Saú~~Saúde Ltda. is cooperating with those requests.

Table of Contents

From time to time, the Company has received requests from a variety of United States Congressional Committees to produce information relevant to ongoing congressional inquiries. It is the policy of Johnson && Johnson to cooperate with these inquiries by producing the requested information.

GENERAL LITIGATION

In May 2014, two purported class actions were filed in federal court, one in the United States District Court for the Central District of California and one in the United States District Court for the Southern District of Illinois, against Johnson && Johnson and Johnson && Johnson Consumer Companies, Inc. (now known as Johnson && Johnson Consumer Inc.) (JJCI) alleging violations of state consumer fraud statutes based on nondisclosure of alleged health risks associated with talc contained in JOHNSON'S^®®Baby Powder and JOHNSON'S^®® Shower to Shower (a product no longer sold by JJCI). Both cases seek injunctive relief and monetary damages; neither includes a claim for personal injuries. In October 2016, both cases were transferred to the United States District Court for the District Court of New Jersey as part of a newly created federal multi-district litigation. In July 2017, the district court granted Johnson && Johnson's and ~~JJCI’s~~JJCI’s motion to dismiss one of the cases. In September 2018, the United States Court of Appeals for the Third Circuit affirmed this dismissal. In September 2017, the plaintiff in the second case voluntarily dismissed the complaint. In March 2018, the plaintiff in the second case refiled in Illinois State Court.

In August 2014, United States Customs and Border Protection (US CBP) issued a Penalty Notice against Janssen Ortho LLC (Janssen Ortho), assessing penalties for the alleged improper classification of darunavir ethanolate (the active pharmaceutical ingredient in PREZISTA^®®) in connection with its importation into the United States. In October 2014, Janssen Ortho submitted a Petition for Relief in response to the Penalty Notice. In May 2015, US CBP issued an Amended Penalty Notice assessing substantial penalties and Janssen Ortho filed a Petition for Relief in July 2015. In May 2019, US CBP issued its Mitigation Decision and determined that Janssen Ortho had negligently misrepresented that darunavir ethanolate is entitled to duty free treatment. In June 2019, Janssen Ortho filed a Supplemental Petition for Relief. The Penalties Proceeding will be impacted by the related Classification Litigation pending in the United States Court of International Trade. The Classification Litigation will determine whether darunavir ethanolate was properly classified as exempt from duties upon importation into the United States. The trial in the Classification Litigation ~~commenced~~was held in July 2019. In February 2020, the Court ruled that darunavir ethanolate is eligible for duty free treatment. In April 2020, the United States filed a Notice of Appeal to the United States Court of Appeals for the Federal Circuit.

In March and April 2015, over 30 putative class action complaints were filed by contact lens patients in a number of courts around the United States against Johnson && Johnson Vision Care, Inc. (JJVCI) and other contact lens manufacturers, distributors, and retailers, alleging vertical and horizontal conspiracies to fix the retail prices of contact lenses. The complaints allege that the manufacturers reached agreements with each other and certain distributors and retailers concerning the prices at which some contact lenses could be sold to consumers. The plaintiffs are seeking damages and injunctive relief. All of the class action cases were transferred to the United States District Court for the Middle District of Florida in June 2015. The plaintiffs filed a consolidated class action complaint in November 2015. In December 2018, the district court granted the plaintiffs' motion for class certification. Defendants filed two motions for interlocutory appeal of class certification to the United States Court of Appeals for the Eleventh Circuit. Both motions were denied. Defendants' motions for summary judgment ~~are pending~~were denied in ~~the District Court.~~November 2019.

In August 2015, two third-party payors filed a purported class action in the United States District Court for the Eastern District of Louisiana against Janssen Research && Development, LLC, Janssen Ortho LLC, Janssen Pharmaceuticals, Inc., Ortho-McNeil-Janssen Pharmaceuticals, Inc. and Johnson && Johnson (as well as certain Bayer entities), alleging that the defendants improperly marketed and promoted XARELTO^®® as safer and more effective than less expensive alternative medications while failing to fully disclose its risks. The complaint seeks damages.

In May 2017, Lonza Sales AG (Lonza) filed a Request for Arbitration with the London Court of International Arbitration against Janssen Research & Development, LLC (Janssen R&D). Lonza alleges that Janssen R&D breached a 2005 agreement between the parties by sublicensing certain Lonza technology used in the manufacture of daratumumab without Lonza’s consent. Lonza seeks monetary damages. In May 2019, the arbitration award was issued and the matter has been resolved.

In September 2017, Pfizer, Inc. (Pfizer) filed an antitrust complaint against Johnson && Johnson and Janssen Biotech, Inc. (collectively, Janssen) in United States District Court for the Eastern District of Pennsylvania. Pfizer alleges that Janssen has violated federal antitrust laws through its contracting strategies for REMICADE^®®. The complaint seeks damages and injunctive relief. Discovery is ongoing.

Beginning in September 2017, multiple purported class actions of direct and indirect purchasers were filed against Johnson && Johnson and Janssen Biotech, Inc. (collectively, Janssen) alleging that ~~Janssen’s~~Janssen’s REMICADE^®® contracting strategies violated federal and state antitrust and consumer laws and seeking damages and injunctive relief. In November 2017, the cases were consolidated for pre-trial purposes in United States District Court for the Eastern District of Pennsylvania as In re Remicade Antitrust Litigation. ~~A motion to compel arbitration of the direct purchaser case was denied and is on appeal to the United States Court of Appeals for the Third Circuit.~~ Motions to dismiss were denied in both the direct and indirect purchaser cases. A motion to compel

Table of Contents

arbitration of the direct purchaser case was denied by the district court. The United States Court of Appeals for the Third Circuit reversed the district court's ruling.

In June 2018, Walgreen Co. and Kroger Co, filed an antitrust complaint against Johnson && Johnson and Janssen Biotech, Inc. (collectively, Janssen) in the United States District Court for the Eastern District of Pennsylvania. The complaint alleges that Janssen has violated federal antitrust laws through its contracting strategies for REMICADE^®®. The complaint seeks damages and injunctive relief. In March 2019, summary judgment was granted in favor of Janssen. ~~This ruling is on appeal to~~In February 2020, the United States Court of Appeals for the Third ~~Circuit.~~Circuit reversed the District Court’s decision.

In June 2019, the United States Federal Trade Commission ~~(“FTC”)~~(FTC) issued a Civil Investigative Demand to Johnson && Johnson in connection with its investigation of whether ~~Janssen’s~~Janssen’s REMICADE^®® contracting practices violate federal antitrust laws. The Company has produced documents and information responsive to the Civil Investigative Demand.

In October 2017, certain United States service members and their families brought a complaint against a number of pharmaceutical and medical devices companies, including Johnson && Johnson and certain of its subsidiaries, alleging that the defendants violated the United States Anti-Terrorism Act. The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health. In January ~~2019, plaintiffs' motion to file~~2020, plaintiffs filed a ~~Second~~Third Amended Complaint adding further plaintiffs to the ~~lawsuit was granted.~~lawsuit. In ~~April 2019,~~February 2020, the Company moved to dismiss the ~~Second~~Third Amended Complaint.

In October 2018, two separate putative class actions were filed against Actelion Pharmaceutical Ltd., Actelion Pharmaceuticals US, Inc., and Actelion Clinical Research, Inc. (collectively ~~“Actelion”)~~Actelion) in United States District Court for the District of Maryland and United States District Court for the District of Columbia. The complaints allege that Actelion violated state and federal antitrust and unfair competition laws by allegedly refusing to supply generic pharmaceutical manufacturers with samples of TRACLEER^®®. TRACLEER^®® is subject to a Risk Evaluation and Mitigation Strategy, which imposes restrictions on distribution of the product. In January 2019, the plaintiffs dismissed the District of Columbia case and filed a consolidated complaint in the United States District Court for the District of Maryland. In ~~February~~October 2019, the Court granted Actelion ~~filed a~~’s motion to dismiss the amended complaint. Plaintiffs have appealed the decision.

In December 2018, Janssen Biotech, Inc., Janssen Oncology, Inc, Janssen Research && Development, LLC, and Johnson && Johnson (collectively, Janssen) were served with a qui tam complaint filed on behalf of the United States, 28 states, and the District of Columbia. The complaint, which was filed in December 2017 in United States District Court for the Northern District of California, alleges that Janssen violated the federal False Claims Act and state law when providing pricing information for ZYTIGA^®® to the government in connection with direct government sales and government-funded drug reimbursement programs. At this time, the federal and state governments have declined to intervene. The case has been transferred to United States District Court for the District of New Jersey. Janssen has moved to dismiss the complaint.

In April 2019, Blue Cross && Blue Shield of Louisiana and HMO Louisiana, Inc. filed a class action complaint against Janssen Biotech, Inc, Janssen Oncology, Inc, Janssen Research && Development, LLC and BTG International Limited in the United States District Court for the Eastern District of Virginia. Several additional complaints were filed thereafter in Virginia and New Jersey. The ~~complaint alleges~~complaints generally allege that the defendants violated ~~the Sherman Act and~~ the antitrust and consumer protections laws of several states and the Sherman Act by pursuing patent litigation relating to ZYTIGA^®®in order to delay generic entry. The ~~case has~~Virginia cases have been transferred to the United States District Court for the District of New ~~Jersey.~~Jersey and consolidated with the New Jersey case for pretrial purposes.

In May 2019, a class action antitrust complaint was filed against Janssen R&D Ireland (Janssen) and Johnson & Johnson in the United States District Court for the Northern District of California. The complaint alleges that Janssen violated federal and state antitrust and consumer protection laws by agreeing to exclusivity provisions in its agreements with Gilead concerning the development and marketing of combination antiretroviral therapies (cART) to treat HIV. The complaint also alleges that Gilead entered into similar agreements with Bristol-Myers-Squibb and Japan Tobacco. In March 2020, the Court granted in part and denied in part defendants’ motions to dismiss. Plaintiffs filed an amended complaint in April 2020.

In October 2019, Innovative Health, LLC filed a complaint against Biosense Webster, Inc. (BWI) in the United States District Court for the Middle District of California. The complaint alleges that certain of BWI’s business practices and contractual terms violate the antitrust laws of the United States and the State of California by restricting competition in the sale of High Density Mapping Catheters and Ultrasound Catheters. BWI filed a motion to dismiss the complaint.

In November 2019, Johnson & Johnson received a demand for indemnification from Pfizer Inc., pursuant to the 2006 Stock and Asset Purchase Agreement between the Company and Pfizer. Also in November 2019, Johnson & Johnson, Inc. received a

Table of Contents

demand for indemnification from Sanofi Consumer Health, Inc., pursuant to the 2016 Asset Purchase Agreement between J&J, Inc. and Sanofi. In January 2020, Johnson && Johnson received a demand for indemnification from Boehringer Ingelheim Pharmaceuticals, Inc., pursuant to the 2006 Asset Purchase Agreement among the Company, Pfizer, and Boehringer Ingelheim. The notices seek indemnification for legal claims related to over-the-counter Zantac (ranitidine) products. Plaintiffs in the underlying actions allege that Zantac and other over-the-counter ranitidine medications contain unsafe levels of NDMA (N-nitrosodimethylamine) and can cause and/or have caused various cancers in patients using the products, and seek injunctive and monetary relief.

Johnson & Johnson or its subsidiaries are also parties to a number of proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as Superfund, and comparable state, local or foreign laws in which the primary relief sought is the cost of past and/or future remediation.

NOTE ~~12—~~12— RESTRUCTURING

~~On April 17, 2018, the~~The Company announced plans to implement a series of actions across its Global Supply Chain that are intended to focus resources and increase investments in the critical capabilities, technologies and solutions necessary to manufacture and supply its product portfolio, enhance agility and drive growth. The Global Supply Chain actions will include expanding the use of strategic collaborations and bolstering initiatives to reduce complexity, improve cost-competitiveness, enhance capabilities and optimize the Supply Chain network. For additional details on the global supply chain restructuring strategic collaborations see Note 10 to the Consolidated Financial Statements. In the fiscal ~~second~~first quarter of ~~2019,~~2020, the Company recorded a pre-tax charge of ~~$142~~$118 million, which is included on the following lines of ~~which $38~~the Consolidated Statement of Earnings, $58 million ~~was included~~ in restructuring, $15 million in cost of products sold and ~~$47~~$45 million was included in other (income) expense. In the first fiscal six months of 2019, the Company recorded a pre-tax charge of $232 million, of which $61 million was included in cost of products sold and $78 million was included in other (income) expense. Total project costs of approximately ~~$500 million~~$1.0 billion have been recorded since the restructuring was announced. See the following table for additional details on the restructuring program.

In total, the Company expects ~~these~~the Global Supply Chain actions to generate approximately ~~$0.6~~$0.6 billion to ~~$0.8~~$0.8 billion in annual pre-tax cost savings that will be substantially delivered by 2022. The Company expects to record pre-tax restructuring charges of approximately ~~$1.9~~$1.9 billion to ~~$2.3~~$2.3 billion, over the 4 to 5 year period of this activity. These costs are associated with network optimizations, exit costs and accelerated depreciation and amortization.

The following table summarizes the severance related reserves and the associated spending through the fiscal first ~~fiscal six months~~quarter of ~~2019:~~2020:


(Dollars in Millions)	Severance			Asset Write-offs		Other**		Total		Severance			Asset Write-offs		Other⁽²⁾			Total
Reserve balance, December 30, 2018	$	194		—		48		242
Reserve balance, December 29, 2019										$	164		—		16			180

Current year activity:
Charges	—			61		171		232		—			11		107			118
Cash payments	(7		)	—		(204	)	(211	)	(6		)	—		(99	)		(105	)
Settled non cash	—			(61	)	—		(61	)	—			(11	)	(17	)	⁽³⁾	(28	)

Reserve balance, June 30, 2019*	$	187		—		15		202

Reserve balance, March 29, 2020⁽¹⁾										$	158		—		7			165

*⁽¹⁾Cash outlays for severance are expected to be substantially paid out over the next 2 years in accordance with the Company's plans and local laws.

**⁽²⁾Other includes project expense such as salaries for employees supporting ~~the initiative~~these initiatives and consulting expenses.

⁽³⁾Relates to pension related actuarial losses associated with the transfer of employees to Jabil Inc. as part of the strategic collaboration.

The Company continuously reevaluates its severance reserves related to restructuring and the timing of payments due to the planned release of associates regarding several longer-term projects. The Company believes that the existing severance reserves are sufficient to cover the Global Supply Chain plans given the period over which the actions will take place. The Company will continue to assess and make adjustments as necessary if additional amounts become probable and estimable.

Table of Contents


Item 1A.	RISK FACTORS

The Company faces a number of uncertainties and risks that are difficult to predict and many of which are outside of the Company's control. For a detailed discussion of the risks that affect our business, please refer to Part I, Item IA, “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 29, 2019. There have been no material changes to the risk factors as previously disclosed in the Company's Annual Report on Form 10-K, except as follows:

Global health crises and pandemics, such as the global outbreak of the novel coronavirus (COVID-19), could cause disruptions in our business.

The recent global outbreak of COVID-19 could cause disruptions to the Company's business and have a negative impact on the Company's revenues and operating results. While the Company has robust business continuity plans in place across its global supply chain network to help mitigate the impact of COVID-19, these efforts may not completely prevent its business from being adversely affected. The extent to which COVID-19 impacts the Company's operations will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the outbreak and any prolonged restrictive measures implemented in order to control the spread of the disease. In particular, the continued global spread of COVID-19 could adversely impact the Company's operations, including, among other things, its manufacturing operations, supply chain, sales and marketing and clinical trial operations. Any of these factors could adversely affect the Company's business, operating results or financial condition.

Table of Contents

Item 2 ~~— MANAGEMENT’S~~— MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

RESULTS OF OPERATIONS

Sales to Customers

Analysis of Consolidated Sales

For the ~~first~~ fiscal ~~six months~~first quarter of ~~2019,~~2020, worldwide sales were ~~$40.6~~$20.7 billion, a total ~~decrease~~increase of ~~0.6%~~3.3%, including operational growth of ~~2.7%~~4.8% as compared to ~~2018~~2019 fiscal ~~six months~~first quarter sales of ~~$40.8 billion.~~$20.0 billion. Currency fluctuations had a negative impact of ~~3.3%~~1.5% for the ~~first~~ fiscal ~~six months~~first quarter of ~~2019.~~2020. In the ~~first~~ fiscal ~~six months~~first quarter of ~~2019,~~2020, the net impact of acquisitions and divestitures on worldwide operational sales growth was a negative ~~1.9%~~0.8%. The estimated impact of COVID-19 on worldwide operational sales was approximately negative 1.0%.

Sales by U.S. companies were ~~$20.5~~$10.7 billion in the ~~first~~ fiscal ~~six months~~first quarter of ~~2019,~~2020, which represented ~~a decrease~~an increase of ~~0.3%~~5.6% as compared to the prior year. In the ~~first~~ fiscal ~~six months~~first quarter of ~~2019,~~2020, the net impact of acquisitions and divestitures on the U.S. operational sales growth was a negative ~~1.8%~~1.1%. Sales by international companies were ~~$20.1~~$10.0 billion ~~a decrease~~, an increase of 1.0%, including operational growth of ~~5.8%~~4.0%, offset by a negative currency impact of ~~6.8%~~3.0% as compared to the ~~first~~ fiscal ~~six months~~first quarter sales of ~~2018.~~2019. In the ~~first~~ fiscal ~~six months~~first quarter of ~~2019,~~2020, the net impact of acquisitions and divestitures on the international operational sales growth was a negative ~~1.9%~~0.5%.

In the ~~first~~ fiscal ~~six months~~first quarter of ~~2019,~~2020, sales by companies in Europe ~~experienced a decline~~achieved growth of ~~2.8%~~4.7%, which included operational growth of ~~4.6%~~7.5% partially offset by a negative currency impact of ~~7.4%~~2.8%. Sales by companies in the Western Hemisphere, excluding the U.S., experienced a sales decline of ~~4.8%~~0.1%, which included operational growth of ~~6.5%~~8.5%, offset by a negative currency impact of ~~11.3%~~8.6%. Sales by companies in the Asia-Pacific, Africa region ~~achieved growth~~experienced a sales decline of ~~2.9%~~3.1%, including an operational ~~growth~~decline of ~~7.0%~~1.9% and a negative currency impact of ~~4.1%~~1.2%.

Note: values may have been rounded

Table of Contents

For the fiscal second quarter of 2019, worldwide sales were $20.6 billion, a total decrease of 1.3%, including operational growth of 1.6% as compared to 2018 fiscal second quarter sales of $20.8 billion. Currency fluctuations had a negative impact of 2.9% for the fiscal second quarter of 2019. In the fiscal second quarter of 2019, the net impact of acquisitions and divestitures on worldwide operational sales growth was a negative 2.1%.

Sales by U.S. companies were $10.4 billion in the fiscal second quarter of 2019, which represented a decrease of 2.2% as compared to the prior year. In the fiscal second quarter of 2019, the net impact of acquisitions and divestitures on the U.S. operational sales growth was a negative 2.2%. Sales by international companies were $10.2 billion, a decrease of 0.3%, including operational growth of 5.5%, offset by a negative currency impact of 5.8% as compared to the fiscal second quarter sales of 2018. In the fiscal second quarter of 2019, the net impact of acquisitions and divestitures on the international operational sales growth was a negative 2.1%.

In the fiscal second quarter of 2019, sales by companies in Europe experienced a decline of 1.6%, which included operational growth of 4.7% offset by a negative currency impact of 6.3%. Sales by companies in the Western Hemisphere, excluding the U.S., experienced a sales decline of 5.5%, which included operational growth of 4.2%, offset by a negative currency impact of 9.7%. Sales by companies in the Asia-Pacific, Africa region achieved growth of 3.4%, including operational growth of 7.2% and a negative currency impact of 3.8%.

~~Note: values may have been rounded~~

Analysis of Sales by Business Segments

Consumer Health*

Consumer Health segment sales in the ~~first~~ fiscal ~~six months~~first quarter of ~~2019~~2020 were ~~$6.9~~$3.6 billion ~~a decrease~~, an increase of ~~0.6%~~9.2% as compared to the same period a year ago, including operational growth of ~~3.4%~~11.3% and a negative currency impact of ~~4.0%~~2.1%. U.S. Consumer Health segment sales increased by ~~2.2%~~21.0%. International Consumer Health segment sales ~~decreased~~increased by ~~2.6%~~0.3%, including an operational ~~increase~~growth of ~~4.3% and~~3.9% partially offset by a negative currency impact of ~~6.9%~~3.6%. In the ~~first~~ fiscal ~~six months~~first quarter of ~~2019,~~2020, the net impact of acquisitions and divestitures on the Consumer Health segment operational sales growth was a positive ~~1.9%.~~

~~Major Consumer Franchise Sales — Fiscal Six Months Ended~~

(Dollars in Millions) June 30, 2019 July 1, 2018 Total
Change Operations
Change Currency
Change
Beauty $ 2,292
$ 2,193
4.5 % 7.2 % (2.7 )%
OTC 2,151
2,138
0.6
4.2
(3.6 )
Baby Care 837
913
(8.4 ) (2.6 ) (5.8 )
Oral Care 756
772
(2.0 ) 1.9
(3.9 )
Women’s Health 478
523
(8.5 ) 1.2
(9.7 )
Wound Care/Other 348
363
(4.0 ) (2.3 ) (1.7 )
Total Consumer Sales $ 6,862
$ 6,902
(0.6 )% 3.4 % (4.0 )%

Consumer segment sales in the fiscal second quarter of 2019 were $3.5 billion, an increase of 1.2% as compared to the same period a year ago, including operational growth of 4.6% and a negative currency impact of 3.4%0.3%. U.S. Consumer segment sales increased by 4.1%. International Consumer segment sales decreased by 1.0%, including operational growth of 4.9% offset by a negative currency impact of 5.9%. In the fiscal second quarter of 2019, theThe estimated net impact of ~~acquisitions and divestitures~~COVID-19 on the Consumer Health segment operational sales growth was a positive ~~2.3%.~~7.0% primarily driven by increased stocking.

Major Consumer Health* Franchise Sales —— Fiscal ~~Second~~First Quarter Ended


(Dollars in Millions)	June 30, 2019		July 1, 2018		Total Change		Operations Change		Currency Change		March 29, 2020		March 31, 2019		Total Change		Operations Change		Currency Change
Beauty	$	1,202	$	1,109	8.4	%	10.7	%	(2.3	)%
OTC	1,064		1,066		(0.1	)	2.8		(2.9	)	$	1,348	$	1,087	24.1	%	25.8	%	(1.7	)%
Skin Health/Beauty**											1,117		1,090		2.5		3.5		(1.0	)
Oral Care											395		367		7.6		9.8		(2.2	)
Baby Care	443		456		(2.8	)	2.2		(5.0	)	361		394		(8.2	)	(4.9	)	(3.3	)
Oral Care	389		393		(1.1	)	2.5		(3.6	)
Women’s Health	253		280		(9.5	)	(1.4	)	(8.1	)
Women’s Health											232		225		2.9		9.2		(6.3	)
Wound Care/Other	193		200		(3.4	)	(1.9	)	(1.5	)	171		155		10.7		11.8		(1.1	)
Total Consumer Sales	$	3,544	$	3,504	1.2	%	4.6	%	(3.4	)%
Total Consumer Health* Sales											$	3,625	$	3,318	9.2	%	11.3	%	(2.1	)%

* Previously referred to as Consumer

** Previously referred to as Beauty

The ~~Beauty~~OTC franchise achieved operational growth of ~~10.7%~~25.8% as compared to the prior year fiscal ~~second~~first quarter. Growth was primarily driven by COVID-19 related demand, TYLENOL^®and MOTRIN^®in analgesics, upper respiratory including ZYRTEC^®, digestive health and ZARBEES^®Naturals.

The Skin Health/Beauty franchise achieved operational growth of 3.5% as compared to the prior year fiscal first quarter. Growth was primarily driven by sales from ~~the recent acquisition of DR. CI: LABO as well as~~ NEUTROGENA^®®, and AVEENO^®®~~and OGX~~^® ~~products. Growth was~~products partially offset by COVID-19 related impacts in the ~~divestitures of RoC~~^®~~and NIZORAL~~^®.Asia Pacific region.

~~The OTC franchise achieved operational growth of 2.8% as compared to the prior year fiscal second quarter. Growth was primarily driven by sales from the recent acquisition of ZARBEES~~^®~~as well as ZYRTEC~~^®~~andMOTRIN~~^® ~~products.~~

~~The Baby Care franchise achieved operational growth of 2.2% as compared to the prior year fiscal second quarter. Growth was primarily due to prior year comparisons related to the JOHNSON'S~~^® ~~U.S. relaunch partially offset by AVEENO~~^®~~baby.~~

The Oral Care franchise achieved operational growth of ~~2.5%~~9.8% as compared to the prior year fiscal ~~second~~first quarter primarily ~~driven by~~due to market growth for LISTERINE^®mouthwash due to COVID-19 as well as new U.S. product ~~launches outside the U.S.~~innovation.

The ~~Women’s Health~~Baby Care franchise experienced an operational decline of ~~1.4%~~4.9% as compared to the prior year fiscal ~~second quarter driven~~first quarter. The decline was primarily due to COVID-19 related impacts in the Asia Pacific and Europe regions and the U.S. Baby Center divestiture partially offset by ~~competitive pressures outside the U.S.~~strength in AVEENO^®baby.

The ~~Wound Care/Other~~Women’s Health franchise ~~experienced an~~achieved operational ~~decline~~growth of ~~1.9%~~9.2% as compared to the prior year fiscal ~~second~~first quarter driven by o.b. increased COVID-19 related demand in Germany and growth in napkins primarily in Latin America.

The Wound Care/Other franchise achieved operational growth of 11.8% as compared to the ~~divestiture of COMPEED~~prior year fiscal first quarter. Growth was primarily due to U.S. market growth in NEOSPORIN^®®.and BAND-AID^®Brand Adhesive Bandages due to increased demand related to COVID-19.

~~Pharmaceutical~~

Table of Contents

Pharmaceutical

Pharmaceutical segment sales in the ~~first~~ fiscal ~~six months~~first quarter of ~~2019~~2020 were ~~$20.8~~$11.1 billion, an increase of ~~2.8%~~8.7% as compared to the same period a year ago, with an operational increase of ~~6.1%~~10.1% and a negative currency impact of ~~3.3%~~1.4%. U.S. Pharmaceutical sales increased ~~1.0%~~8.6% as compared to the same period a year ago. International Pharmaceutical sales increased by ~~5.2%~~8.8%, including operational growth of ~~12.5%~~12.0% and a negative currency impact of ~~7.3%~~3.2%. In the ~~first~~ fiscal ~~six months~~first quarter of ~~2019,~~2020, the net impact of acquisitions and divestitures on the Pharmaceutical segment operational sales growth was ~~negligible.~~a negative 0.1%. Adjustments to previous reserve estimates, as compared to the prior year, positively impacted the Pharmaceutical segment operational growth by approximately 1.0%, primarily in the Immunology, Infectious Diseases and Oncology therapeutic areas. The estimated net impact of COVID-19 on the Pharmaceutical segment operational sales growth was a positive 1.0% primarily driven by increased prescriptions being filled to ensure there is access to essential medicines.

Major Pharmaceutical Therapeutic Area Sales* — — Fiscal ~~Six Months~~First Quarter Ended

(Dollars in Millions) June 30, 2019 July 1, 2018
Total
Change

Operations
Change

Currency
Change
Total Immunology $ 6,717
$ 6,380
5.3 % 7.6 % (2.3 )%
     REMICADE^®
2,209
2,709
(18.5 ) (17.1 ) (1.3 )
     SIMPONI^®/ SIMPONI ARIA^®
1,087
1,066
1.9
5.4
(3.5 )
     STELARA^®
2,963
2,402
23.3
26.1
(2.8 )
     TREMFYA^®
452
198
** ** **
     Other Immunology 6
5
23.6
24.0
(0.4 )
Total Infectious Diseases 1,708
1,679
1.7
6.5
(4.8 )
     EDURANT^®/rilpivirine
421
421
0.1
6.8
(6.7 )
     PREZISTA^®/ PREZCOBIX^®/ REZOLSTA^®/ SYMTUZA^®
1,058
970
9.1
12.7
(3.6 )
     Other Infectious Diseases 229
288
(20.7 ) (15.1 ) (5.6 )
Total Neuroscience 3,167
3,087
2.6
6.4
(3.8 )
     CONCERTA^®/methylphenidate
351
356
(1.6 ) 2.5
(4.1 )
     INVEGA SUSTENNA^®/ XEPLION^®/ INVEGA TRINZA^®/ TREVICTA^®
1,608
1,416
13.6
16.7
(3.1 )
     RISPERDAL CONSTA^®
361
384
(6.2 ) (2.0 ) (4.2 )
     Other Neuroscience 847
931
(8.9 ) (4.1 ) (4.8 )
Total Oncology 5,215
4,767
9.4
14.3
(4.9 )
     DARZALEX^®
1,403
943
48.8
54.6
(5.8 )
     IMBRUVICA^®
1,615
1,207
33.8
39.8
(6.0 )
     VELCADE^®
487
593
(17.9 ) (12.9 ) (5.0 )
     ZYTIGA^®/ abiraterone acetate
1,377
1,754
(21.5 ) (18.0 ) (3.5 )
     Other Oncology 333
270
23.2
28.6
(5.4 )
Pulmonary Hypertension 1,346
1,250
7.7
10.2
(2.5 )
     OPSUMIT^®
654
582
12.5
15.8
(3.3 )
     TRACLEER^®
220
283
(22.4 ) (20.3 ) (2.1 )
     UPTRAVI^®
401
311
28.7
29.7
(1.0 )
     Other 72
74
(3.4 ) 1.0
(4.4 )
Cardiovascular / Metabolism / Other 2,620
3,035
(13.7 ) (12.1 ) (1.6 )
     XARELTO^®
1,091
1,257
(13.2 ) (13.2 ) —
     INVOKANA^®/ INVOKAMET^®
379
463
(18.2 ) (16.9 ) (1.3 )
     PROCRIT^®/EPREX^®
409
512
(20.2 ) (18.7 ) (1.5 )
     Other 742
803
(7.7 ) (3.4 ) (4.3 )
Total Pharmaceutical Sales $ 20,773
$ 20,198
2.8 % 6.1 % (3.3 )%



(Dollars in Millions)	March 29, 2020		March 31, 2019		Total Change		Operations Change		Currency Change
Immunology	$	3,638	$	3,251	11.9	%	13.1	%	(1.2	)%
REMICADE^®	990		1,102		(10.2	)	(9.3	)	(0.9	)
SIMPONI^®/ SIMPONI ARIA^®	529		524		1.1		3.0		(1.9	)
STELARA^®	1,819		1,405		29.5		30.6		(1.1	)
TREMFYA^®	296		217		36.4		37.3		(0.9	)
Other Immunology	3		3		(6.9	)	(5.6	)	(1.3	)
Infectious Diseases	920		846		8.7		11.0		(2.3	)
EDURANT^®/rilpivirine	224		211		6.1		8.7		(2.6	)
PREZISTA^®/ PREZCOBIX^®/ REZOLSTA^®/SYMTUZA^®	579		523		10.8		12.8		(2.0	)
Other Infectious Diseases	116		112		4.0		6.6		(2.6	)
Neuroscience	1,658		1,629		1.8		3.1		(1.3	)
CONCERTA^®/ methylphenidate	171		214		(20.1	)	(19.0	)	(1.1	)
INVEGA SUSTENNA^®/ XEPLION^®/ INVEGA TRINZA^®/TREVICTA^®	883		790		11.7		12.9		(1.2	)
RISPERDAL CONSTA^®	170		179		(5.1	)	(3.5	)	(1.6	)
Other Neuroscience	435		446		(2.5	)	(0.8	)	(1.7	)
Oncology	3,013		2,518		19.7		21.8		(2.1	)
DARZALEX^®	937		629		49.0		51.6		(2.6	)
ERLEADA^®(1)	143		61		*		*		*
IMBRUVICA^®	1,031		784		31.6		34.1		(2.5	)
VELCADE^®	108		263		(59.0	)	(58.2	)	(0.8	)
ZYTIGA^®/ abiraterone acetate	690		679		1.6		3.5		(1.9	)
Other Oncology	104		102		1.3		4.1		(2.8	)
Pulmonary Hypertension	745		656		13.7		14.7		(1.0	)
OPSUMIT^®	389		306		27.4		28.8		(1.4	)
UPTRAVI^®	250		198		26.2		26.8		(0.6	)
Other Pulmonary Hypertension⁽²⁾	106		152		(30.4	)	(29.6	)	(0.8	)
Cardiovascular / Metabolism / Other	1,160		1,345		(13.8	)	(13.1	)	(0.7	)
XARELTO^®	527		542		(2.7	)	(2.7	)	—
INVOKANA^®/ INVOKAMET^®	175		202		(13.5	)	(12.9	)	(0.6	)
PROCRIT^®/ EPREX^®	155		226		(31.6	)	(31.0	)	(0.6	)
Other	302		374		(19.2	)	(17.4	)	(1.8	)
Total Pharmaceutical Sales	$	11,134	$	10,244	8.7	%	10.1	%	(1.4	)%

*Certain prior year amounts have been reclassified to conform to current year presentation

**Percentage greater than 100% or not meaningful

~~Pharmaceutical segment sales in the fiscal second quarter~~

Table of 2019 were $10.5 billion, an increase of 1.7% as compared to the same period a year ago, with an operational increase of 4.4% and a negative currency impact of 2.7%. U.S. Pharmaceutical sales decreased 2.0% as compared to the same period a year ago. International Pharmaceutical sales increased by 6.5%, including operational growth of 12.9% and a negative currency impact of 6.4%. In the fiscal second quarter of 2019, the net impact of acquisitions and divestitures on the Pharmaceutical segment operational sales growth was negligible.Contents

~~Major Pharmaceutical Therapeutic Area Sales* —~~ ⁽¹⁾~~Fiscal Second Quarter Ended~~Previously included in Other Oncology

(Dollars in Millions) June 30, 2019 July 1, 2018
Total
Change

Operations
Change

Currency
Change
Total Immunology $ 3,466
$ 3,338
3.8 % 5.7 % (1.9 )%
     REMICADE^®
1,107
1,320
(16.2 ) (15.1 ) (1.1 )
     SIMPONI^®/ SIMPONI ARIA^®
563
548
2.7
5.6
(2.9 )
     STELARA^®
1,558
1,341
16.1
18.3
(2.2 )
     TREMFYA^®
235
126
86.5
88.9
(2.4 )
     Other Immunology 3
3
27.7
27.0
0.7
Total Infectious Diseases 862
849
1.5
5.4
(3.9 )
     EDURANT^®/rilpivirine
210
211
(0.6 ) 5.0
(5.6 )
     PREZISTA^®/ PREZCOBIX^®/ REZOLSTA^®/SYMTUZA^®
535
492
8.7
11.6
(2.9 )
     Other Infectious Diseases 117
146
(19.7 ) (15.1 ) (4.6 )
Total Neuroscience 1,538
1,528
0.6
3.9
(3.3 )
     CONCERTA^®/ methylphenidate
137
183
(25.2 ) (21.5 ) (3.7 )
     INVEGA SUSTENNA^®/ XEPLION^®/ INVEGA TRINZA^®/TREVICTA^®
818
720
13.6
16.3
(2.7 )
     RISPERDAL CONSTA^®
182
188
(3.4 ) 0.3
(3.7 )
     Other Neuroscience 401
437
(8.1 ) (4.4 ) (3.7 )
Total Oncology 2,697
2,456
9.8
14.1
(4.3 )
     DARZALEX^®
774
511
51.6
57.3
(5.7 )
     IMBRUVICA^®
831
620
34.1
39.2
(5.1 )
     VELCADE^®
224
280
(20.1 ) (16.1 ) (4.0 )
     ZYTIGA^®/ abiraterone acetate
698
909
(23.3 ) (20.3 ) (3.0 )
     Other Oncology 170
136
24.7
29.3
(4.6 )
Pulmonary Hypertension 690
665
3.8
6.0
(2.2 )
     OPSUMIT^®
348
311
12.3
15.0
(2.7 )
     TRACLEER^®
103
143
(28.0 ) (26.2 ) (1.8 )
     UPTRAVI^®
203
171
18.2
19.1
(0.9 )
     Other 37
40
(9.6 ) (5.8 ) (3.8 )
Cardiovascular / Metabolism / Other 1,275
1,518
(16.0 ) (14.7 ) (1.3 )
     XARELTO^®
549
679
(19.2 ) (19.2 ) —
     INVOKANA^®/ INVOKAMET^®
177
215
(17.9 ) (16.9 ) (1.0 )
     PROCRIT^®/ EPREX^®
183
236
(22.7 ) (21.4 ) (1.3 )
     Other 368
388
(5.5 ) (1.5 ) (4.0 )
Total Pharmaceutical Sales $ 10,529
$ 10,354
1.7 % 4.4 % (2.7 )%
⁽²⁾Inclusive of TRACLEER^®which was previously disclosed separately

*Certain prior year amounts have been reclassified to conform to current year presentation

Immunology products achieved operational growth of ~~5.7%~~13.1% as compared to the same period a year ago driven by strong uptake of STELARA^®® (ustekinumab) in Crohn's disease ~~the strong launch of~~and increased COVID-19 related demand, strength in TREMFYA^®®(guselkumab), in Psoriasis, expanded indications of SIMPONI ARIA^®® (golimumab), and U.S. immunology market growth. Immunology was negatively impacted by lower sales of REMICADE^®®(infliximab) due to increased discounts/rebates and biosimilar competition.

The patents for REMICADE^®®(infliximab)in certain countries in Europe expired in February 2015. Biosimilar versions of REMICADE^®® have been introduced in certain markets outside the United States, resulting in a reduction in sales of REMICADE^®® in those markets. Additional biosimilar competition will likely result in a further reduction in REMICADE^®® sales in markets outside the United States. In the United States, a biosimilar version of REMICADE^®® was introduced in 2016, and additional competitors continue to enter the market. Continued infliximab biosimilar competition in the U.S. market will result in a further reduction in U.S. sales of REMICADE^®®. See Note 11 to the Consolidated Financial Statements for a description of legal matters regarding the REMICADE^®®patents.

Infectious disease products achieved operational growth of ~~5.4%~~11.0% as compared to the same period a year ago. Strong sales of SYMTUZA^®®,JULUCA^®and~~the launch of JULUCA~~increased^®COVID-19 related demand were partially offset by lower sales of PREZISTA^®®and PREZCOBIX^®®/REZOLSTA^®® due to increased competition and loss of exclusivity of PREZISTA^®®in certain countries outside the U.S.

Neuroscience products achieved operational sales growth of ~~3.9%~~3.1% as compared to the same period a year ago. Paliperidone long-acting injectables growth was driven by strong sales of INVEGA ~~TRINZA~~^®~~/TREVICTA~~^®~~and INVEGA~~ SUSTENNA^®®/XEPLION^®® (paliperidone palmitate) and INVEGA TRINZA^®/TREVICTA^® from new patient starts and persistence, was partially offset by cannibalization of RISPERDAL CONSTA^®®(risperidone)~~. The decline of U.S.~~ and generic competition on CONCERTA^®®/~~methylphenidate sales was due to generic competition.~~methylphenidate.

Oncology products achieved strong operational sales growth of ~~14.1%~~21.8% as compared to the same period a year ago. Contributors to the growth were strong sales of DARZALEX^®® (daratumumab) ~~and~~driven by patient uptake in all lines of therapy, IMBRUVICA^®® (ibrutinib) due to increased patient uptake ~~globally. DARZALEX~~globally and increased COVID-19 related demand and the launch uptake of ERLEADA^{® ®} (apalutamide). Additionally, strong sales ~~included one-time adjustments related to the completion~~and share growth of ~~pricing and reimbursement discussions in certain European countries which positively impacted worldwide DARZALEX~~ZYTIGA^®®~~growth~~(abiraterone acetate) outside the U.S. was partially offset by ~~approximately 16%. Growth was negatively impacted from~~ a decline in U.S. sales ~~of ZYTIGA~~^®~~(abiraterone acetate)~~ driven by generic ~~competition partially offset by increased~~competition. Lower sales ~~outside the U.S. Additionally, sales from the launch~~ of ~~ERLEADA™ (apalutamide) contributed~~VELCADE^®(bortezomib) were due to ~~the growth.~~generic competition.

Pulmonary Hypertension achieved operational sales growth of ~~6.0%~~14.7% as compared to the same period a year ago. Sales growth of OPSUMIT^®® (macitentan) and UPTRAVI^®® (selexipag) were due to continued market growth, increased share and increased ~~share while sales~~COVID-19 related demand. Sales of TRACLEER^®® ~~(bosetan)~~(bosentan) were negatively impacted by ~~increased use of~~generics and cannibalization from OPSUMIT^{® ®}~~and generics.~~.

Cardiovascular / Metabolism / Other products experienced an operational decline of ~~14.7%~~13.1% as compared to the same period a year ago. Lower sales of ~~XARELTO~~^®~~(rivaroxaban) were driven by higher discounts and rebates, lower sales of~~ INVOKANA^®®/INVOKAMET^®® (canagliflozin) were due to share loss from competitive pressure and a safety label update in the U.S. and lower sales of PROCRIT^®®/ EPREX^®®(epoetin alfa) were due to biosimilar competition.

Increased market growth and COVID-19 related demand of XARELTO^®(rivaroxaban) was offset by higher discounts and rebates.

Table of Contents

Medical Devices

The Medical Devices segment sales in the ~~first~~ fiscal ~~six months~~first quarter of ~~2019~~2020 were ~~$12.9~~$5.9 billion, a decrease of ~~5.7%~~8.2% as compared to the same period a year ago, with an operational decline of ~~2.6%~~6.9% and a negative currency impact of ~~3.1%~~1.3%. U.S. Medical Devices sales decreased ~~3.6%~~6.8%. International Medical Devices sales decreased by ~~7.6%~~9.4%, including an operational decline of ~~1.6%~~6.9% and a negative currency impact of ~~6.0%~~2.5%. In the ~~first~~ fiscal ~~six months~~first quarter of ~~2019,~~2020, the net impact of acquisitions and divestitures on the Medical Devices segment operational sales growth was a negative ~~6.4% of which, the divestitures of LifeScan and ASP had an impact of approximately 5.1% and 1.1%~~2.1%, ~~respectively.~~

~~Major Medical Devices Franchise Sales — Fiscal Six Months Ended~~

(Dollars in Millions) June 30, 2019 July 1, 2018
Total
Change

Operations
Change

Currency
Change
Surgery $ 4,748
$ 4,938
(3.9 )% 0.0 % (3.9 )%
     Advanced 2,009
1,971
1.9
5.9
(4.0 )
     General 2,208
2,296
(3.9 ) 0.1
(4.0 )
     Specialty 531
671
(20.8 ) (17.8 ) (3.0 )
Orthopaedics 4,428
4,512
(1.9 ) 0.7
(2.6 )
     Hips 725
723
0.3
3.0
(2.7 )
     Knees 741
769
(3.7 ) (1.3 ) (2.4 )
     Trauma 1,357
1,371
(1.0 ) 1.5
(2.5 )
     Spine & Other 1,606
1,649
(2.6 ) (0.1 ) (2.5 )
Vision 2,290
2,288
0.1
3.2
(3.1 )
     Contact Lenses/Other 1,666
1,651
0.9
4.2
(3.3 )
     Surgical 624
637
(2.0 ) 0.6
(2.6 )
Interventional Solutions 1,482
1,307
13.4
16.7
(3.3 )
Diabetes Care⁽¹⁾
—
694
* * *
Total Medical Devices Sales $ 12,948
$ 13,739
(5.7 )% (2.6 )% (3.1 )%

*Percentage greater than 100% or not meaningful

⁽¹⁾~~LifeScan was divested in the fiscal fourth quarter of 2018~~

~~The Medical Devices segment sales in the fiscal second quarter of 2019 were $6.5 billion, a decrease of 6.9% as compared~~primarily due to the ~~same period a year ago, with an operational decline~~divestiture of 4.1% and a negative currency impact of 2.8%. U.S. Medical Devices sales decreased 5.6%. International Medical Devices sales decreased by 8.1%, including an operational decline of 2.9% and a negative currency impact of 5.2%. In the ~~fiscal second quarter of 2019, the~~Advanced Sterilization Products (ASP) business. The estimated net impact of ~~acquisitions and divestitures~~COVID-19 on the Medical Devices segment operational sales growth was a negative ~~7.3% of which, the divestitures of LifeScan and ASP had an impact of approximately 5.1% and 2.0%, respectively.~~7.5% - 8.0% primarily related to reduced procedures.

Major Medical Devices Franchise ~~Sales —~~Sales* — Fiscal ~~Second~~First Quarter Ended


(Dollars in Millions)	June 30, 2019		July 1, 2018		Total Change		Operations Change		Currency Change		March 29, 2020		March 31, 2019		Total Change		Operations Change		Currency Change
Surgery	$	2,353	$	2,515	(6.5	)%	(3.0	)%	(3.5	)%	$	2,100	$	2,395	(12.3	)%	(10.5	)%	(1.8	)%
Advanced	1,029		1,005		2.3		6.1		(3.8	)	948		980		(3.3	)	(1.4	)	(1.9	)
General(1)	1,119		1,169		(4.3	)	(0.9	)	(3.4	)	1,153		1,414		(18.5	)	(16.8	)	(1.7	)
Specialty	206		341		(39.6	)	(37.1	)	(2.5	)
Orthopaedics	2,224		2,262		(1.6	)	0.6		(2.2	)	2,038		2,204		(7.5	)	(6.5	)	(1.0	)
Hips	364		360		0.9		3.3		(2.4	)	337		361		(6.7	)	(5.6	)	(1.1	)
Knees	372		382		(2.8	)	(0.7	)	(2.1	)	343		369		(7.0	)	(6.1	)	(0.9	)
Trauma	672		675		(0.6	)	1.7		(2.3	)	654		685		(4.5	)	(3.5	)	(1.0	)
Spine & Other	818		845		(3.1	)	(0.9	)	(2.2	)
Spine, Sports & Other⁽²⁾											703		788		(10.7	)	(9.8	)	(0.9	)
Vision	1,161		1,173		(1.0	)	1.5		(2.5	)	1,067		1,129		(5.5	)	(4.5	)	(1.0	)
Contact Lenses/Other	842		844		(0.3	)	2.4		(2.7	)	814		824		(1.3	)	(0.3	)	(1.0	)
Surgical	319		329		(2.8	)	(0.8	)	(2.0	)	253		305		(16.9	)	(15.9	)	(1.0	)
Interventional Solutions	750		667		12.6		15.6		(3.0	)	727		732		(0.6	)	0.4		(1.0	)
Diabetes Care⁽¹⁾	—		355		*		*		*
Total Medical Devices Sales	$	6,489	$	6,972	(6.9	)%	(4.1	)%	(2.8	)%	$	5,932	$	6,459	(8.2	)%	(6.9	)%	(1.3	)%

*~~Percentage greater than 100% or not meaningful~~Certain prior year amounts have been reclassified to conform to current year presentation

⁽¹⁾~~LifeScan~~IncludesSpecialty Surgery which was ~~divested in the fiscal fourth quarter of 2018~~previously disclosed separately

⁽²⁾ Previously referred to as Spine & Other

The Surgery franchise experienced an operational sales decline of ~~3.0%~~10.5% as compared to the prior year fiscal ~~second~~first quarter. ~~Operational growth~~The operational decline in Advanced Surgery was primarily driven by the negative impact of COVID-19 and competitive pressures in the U.S. partially offset by new product growth in endocutters, biosurgery, and ~~growth~~energy products primarily outside the U.S. in energy products driven by share gains and new products. Growth was partially offset by a sales decline in biosurgery due to an isolated supply disruption. The decline in General Surgery was primarily driven by mechanical products due to a temporary stapler recall partially offset by growth of wound closure products. The operational decline in ~~Specialty~~General Surgery was primarily driven by the divestiture of the ~~Advanced Sterilization Products (ASP)~~ASP business ~~partially offset by growth~~in 2019 and the negative impact of ~~Mentor products.~~COVID-19.

The Orthopaedics franchise ~~achieved~~experienced an operational sales ~~growth~~decline of ~~0.6%~~6.5% as compared to the prior year fiscal ~~second~~first quarter. ~~Operational growth in hips and trauma was primarily due to the continued uptake of new products. Spine & Other~~The operational decline in ~~sales~~hips was driven by ~~declines in spine~~the negative impact of COVID-19 partially offset by ~~growth~~leadership position in ~~Sports.~~the anterior approach, strong market demand for the ACTIS^® stem and enabling technologies such as the KINCISE™ surgical automated system and VELYS™ Hip Navigation. The operational decline in knees was ~~due to competitive pressure in~~driven by the ~~U.S.~~negative impact of COVID-19 partially offset by ~~continued~~the global uptake from new products. The operational decline in Trauma was driven by the negative impact of COVID-19 and market softness. The operational decline in Spine, Sports & Other was driven by the ~~ATTUNE~~^® ~~Revision knee system~~negative impact of COVID-19 and base business declines in Spine partially offset by share growth in Sports outside the U.S. ~~from new products.~~

The Vision franchise ~~achieved~~experienced an operational sales ~~growth~~decline of ~~1.5%~~4.5% as compared to the prior year fiscal ~~second~~first quarter. ~~Operational~~The operational decline in Contact Lenses/Other was due to the negative impact of COVID-19 partially offset by double-digit U.S. growth ~~was primarily driven by strength of~~in daily ~~disposables and Astigmatism~~disposable lenses in the ~~OASYS~~ACUVUE^®®OASYS contact lenses category. The Surgical operational decline was primarily driven by the negative impact of COVID-19 and competitive pressures in the U.S. partially offset by ~~strength of cataracts~~new product growth outside the U.S.

The Interventional Solutions franchise achieved ~~strong~~ operational sales growth of ~~15.6%~~0.4% as compared to the prior year fiscal ~~second~~first quarter. ~~Strong operational~~Operational growth in the electrophysiology business was driven by Atrial Fibrillation ~~procedure volume. Growth in~~procedures coupled with strong diagnostic catheter sales and new products partially offset by the ~~Cerenovus business was driven by new product innovation and market growth.~~negative impact of COVID-19.

Table of Contents

ANALYSIS OF CONSOLIDATED EARNINGS BEFORE PROVISION FOR TAXES ON INCOME

Consolidated earnings before provision for taxes on income for the first fiscal six months of 2019 was $11.5 billion representing 28.2% of sales as compared to $10.5 billion in the first fiscal six months of 2018, representing 25.6% of sales.

Consolidated earnings before provision for taxes on income for the fiscal ~~second~~first quarter of ~~2019~~2020 was ~~$7.0~~$6.5 billion representing ~~34.2%~~31.5% of sales as compared to ~~$5.0~~$4.4 billion in the fiscal ~~second~~first quarter of ~~2018,~~2019, representing ~~23.9%~~22.1% of sales.

Cost of Products Sold

~~Consolidated costs~~(Dollars in billions. Percentages in chart are as a percent to total sales)

Q1 2020 versus Q1 2019

Cost of products sold ~~for the first fiscal six months of 2019~~ increased as a percent to ~~33.4% from 33.2% of~~ sales as compared to the same period a year ago. Consolidated costs of products sold for the fiscal second quarter of 2019 increased to 33.8% from 33.3% of sales as compared to the same period a year ago. The unfavorable increase in both periods was primarily driven ~~by unfavorable product mix and the negative impact of currency in the Pharmaceutical business.~~ by:


•	Product mix in the Medical Devices business


•	Establishment of incremental inventory reserves associated with the impact of COVID-19 in the Medical Devices business

The intangible asset amortization expense included in cost of products sold for each of the fiscal ~~second~~first quarters of ~~2019~~2020 and ~~2018~~2019 was $1.1 billion. ~~The intangible asset amortization expense for each of the first fiscal six months of 2019 and 2018 was $2.2 billion.~~

Selling, Marketing and Administrative Expenses

~~Consolidated selling, marketing~~

(Dollars in billions. Percentages in chart are as a percent to total sales)

Q1 2020 versus Q1 2019

Selling, Marketing and ~~administrative expenses for the first fiscal six months of 2019~~Administrative Expenses decreased ~~to 26.5% from 27.0% of sales~~ as ~~compared to the same period~~ a year ago. Consolidated selling, marketing and administrative expenses for the fiscal second quarter of 2019 decreased to 27.0% from 27.5% of sales as compared to the same period a year ago. The decrease in both periods was primarily due to favorable segment mix and lower costs relativepercent to sales ~~growth in the Pharmaceutical business. Additionally, planned optimization in the Consumer business and expense leveraging in the Pharmaceutical business was~~ driven by:


•	Leveraging in the Pharmaceutical business


•	Planned prioritization and reduced brand marketing expense in the Consumer Health business


•	Favorable product mix with a higher percentage of sales coming from the Pharmaceutical business

partially offset ~~by increased investment spending in the Medical Device business in the fiscal second quarter of 2019.~~by:


•	Deleveraging in the Medical Devices business resulting from the COVID-19 impact on sales

Research and Development Expense

(Dollars in billions. Percentages in chart are as a percent to total sales)

~~Worldwide costs~~

Table of research and development activities for the first fiscal six months of 2019 increased to 13.6% from 12.3% of sales as compared to the same period a year ago. The increase in the fiscal six months was due to higher upfront payments, primarily related to argenx and increased investment to advance the pipeline. Worldwide costs of research and development activities for the fiscal second quarter of 2019 increased to 13.0% from 12.7% of sales as compared to the same period a year ago. The increase in the fiscal second quarter was due to increased investment in the Medical Device business related to robotics and digital programs.Contents

Q1 2020 versus Q1 2019

Research and Development decreased as a percent to sales driven by:


•	Higher upfront payments in the fiscal first quarter of 2019, primarily related to the argenx collaboration

partially offset by:


•	Increased investment in the Medical Devices business related to robotics and digital programs

In-Process Research and Development (IPR~~&D)~~&D)

There was no IPR&D charge in the fiscal first quarter of 2020. In the fiscal first quarter of 2019, the Company recorded an IPR&D&D charge of $0.9 billion for the remaining intangible asset value related to the development program of AL-8176, an investigational drug for the treatment of Respiratory Syncytial Virus (RSV) and human metapneumovirus (hMPV) acquired with the 2014 acquisition of Alios Biopharma Inc. The impairment charge was based on additional information, including clinical data, which became available and led to the Company's decision to abandon the development of AL-8176. There was no IPR&D charge in the fiscal six months of 2018. A partial impairment charge of $0.8 billion was previously recorded in the fiscal third quarter of 2018 related to the development program of AL-8176.

Interest (Income) Expense

Interest (Income) Expense in the fiscal first ~~fiscal six months and fiscal second~~ quarter of ~~2019~~2020 was a net interest income as compared to an expense in the same ~~periods~~period a year ago. This was primarily due to the positive effect of net investment hedging arrangements and certain cross currency ~~swaps, a higher average interest rate~~swaps. This was partially offset by areduced interest income resulting from lower ~~average~~rates of interest earned on cash ~~cash equivalents and marketable securities balance and a lower average debt balance.~~balances. The balance of cash, cash equivalents and current marketable securities was $18.0 billion at the end of the fiscal first quarter of 2020 as compared to $15.3 billion at the end of the fiscal ~~second~~first quarter of ~~2019~~2019. The Company’s debt position was $27.6 billion as of March 29, 2020 as compared to ~~$18.1 billion at the end of the fiscal second quarter of 2018. The Company’s debt position was~~ $29.4 ~~billion as of June 30, 2019 as compared to $32.1~~ billion the same period a year ago.

Other (Income) Expense, Net

Q1 2020 versus Q1 2019

Other (income) expense, net for the fiscal first ~~fiscal six months and fiscal second~~ quarter of ~~2019~~2020 was favorable by $2.1 billion and $2.0 billion, respectively, as compared to the same period a year ago. This was primarily attributable to a gain of $2.0 billion related to the divestiture of the ASP business. In addition the fiscal six months of 2019 included an equity step-up gain of $0.3 billion related to the Company's previously held equity investment in Ci:z Holdings (Dr. Ci: Labo) and higher unrealized gains on securities of $0.3$0.7 billion as compared to the ~~same period a~~prior year ago. This was partially offset by higher litigation expense of $0.8 billion in the fiscal six months of 2019 as compared to $0.7 billion in the fiscal six months of 2018. The fiscal six months of 2018 included divestiture gains of $0.4 billion, primarily ~~NIZORAL~~^®. The fiscal second quarter of 2019 included lower litigation expense of $0.4 billion as compared to $0.7 billion in the fiscal second quarter of 2018 and higher unrealized gains on securities of $0.1 billion as compareddue to the ~~same period~~following:



First Quarter
(Dollars in Billions)(Income)/Expense	2020			2019		Change
Litigation expense	$	0.1		0.4		(0.3	)
Acquisition and Integration related*	(1.0		)	0.1		(1.1	)
Unrealized (gains)/losses on securities	0.3			(0.2	)	0.5
Equity step-up gain related to DR. CI:LABO	0.0			(0.3	)	0.3
Divestiture Gains	0.0			(0.1	)	0.1
Other	(0.1		)	0.1		(0.2	)
Total Other (Income) Expense, Net	$	(0.7	)	0.0		(0.7	)

* 2020 is primarily driven by a ~~year ago. The fiscal second quarter~~contingent consideration reversal of ~~2018 included divestiture gains~~approximately $1.0 billion related to the timing of ~~$0.4 billion, primarily NIZORAL~~^®.certain developmental milestones associated with the Auris Health acquisition.

Table of Contents

EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT

Income before tax by segment of business for the ~~first~~ fiscal ~~six months~~first quarters were as follows:


	Income Before Tax				Segment Sales				Percent of Segment Sales				Income Before Tax				Segment Sales				Percent of Segment Sales
(Dollars in Millions)	June 30, 2019		July 1, 2018		June 30, 2019		July 1, 2018		June 30, 2019		July 1, 2018		March 29, 2020		March 31, 2019		March 29, 2020		March 31, 2019		March 29, 2020		March 31, 2019
Consumer	$	1,147	$	1,377	$	6,862	$	6,902	16.7	%	20.0	%
Consumer Health													$	770	$	741	$	3,625	$	3,318	21.2	%	22.3	%
Pharmaceutical	6,008		7,317		20,773		20,198		28.9		36.2		3,834		2,331		11,134		10,244		34.4		22.8
Medical Devices	4,686		2,375		12,948		13,739		36.2		17.3		2,025		1,497		5,932		6,459		34.1		23.2
Segment total	11,841		11,069		40,583		40,839		29.2		27.1
Segment earnings before tax													6,629		4,569		20,691		20,021		32.0		22.8
Less: Expenses not allocated to segments ⁽¹⁾	378		615										120		147
Worldwide total	$	11,463	$	10,454	$	40,583	$	40,839	28.2	%	25.6	%
Worldwide income before tax													$	6,509	$	4,422	$	20,691	$	20,021	31.5	%	22.1	%

⁽¹⁾ Amounts not allocated to segments include interest (income) expense and general corporate (income) expense.

~~Income before tax by segment of business for the fiscal second quarters were as follows:~~

Income Before Tax Segment Sales Percent of Segment Sales
(Dollars in Millions) June 30, 2019 July 1, 2018 June 30, 2019 July 1, 2018 June 30, 2019 July 1, 2018
Consumer $ 406
$ 829
$ 3,544
$ 3,504
11.5 % 23.7 %
Pharmaceutical 3,677
3,651
10,529
10,354
34.9
35.3
Medical Devices 3,189
796
6,489
6,972
49.1
11.4
Segment earnings before provision for taxes 7,272
5,276
20,562
20,830
35.4
25.3
Less: Expenses not allocated to segments ⁽¹⁾
231
303

Worldwide income before tax $ 7,041
$ 4,973
$ 20,562
$ 20,830
34.2 % 23.9 %

⁽¹⁾ ~~Amounts not allocated to segments include interest (income) expense and general corporate (income) expense.~~Consumer Health Segment

~~Consumer Segment~~

The Consumer Health segment income before tax as a percent of sales in the fiscal first ~~fiscal six months~~quarter of ~~2019~~2020 was ~~16.7%~~21.2% versus 20.0% for the same period a year ago. The first fiscal six months of 2019 included litigation expense of $0.2 billion and higher intangible asset amortization expense of $0.1 billion as compared to the prior year offset by a gain of $0.3 billion related to the Company's previously held equity investment in Ci:z Holdings (Dr Ci: Labo) and leveraging in selling, marketing and administrative expense. The first fiscal six months of 2018 included a gain of $0.3 billion related to the divestiture of NIZORAL^®22.3%. The Consumer segment income before tax as a percent of sales in the fiscal second quarter of 2019 was 11.5% versus 23.7% for the same period a year ago. The fiscal second quarter of 2019 included litigation expense of $0.2 billion and higher intangible asset amortization expense of $0.1 billion as compared to the prior year. This was partially offset by leveraging in selling, marketing and administrative expense as compared to the prior year. In addition, the fiscal second quarter of 2018 included a gain of $0.3 billion related to the divestiture of NIZORAL^®.

~~Pharmaceutical Segment~~

The Pharmaceutical segment income before tax as a percent of sales in the first fiscal six months of 2019 was 28.9% versus 36.2% for the same period a year ago. The Pharmaceutical segment income before tax as a percent of sales in the fiscal second quarter of 2019 was 34.9% versus 35.3% for the same period a year ago. The decrease in the income before tax as a percent of sales ~~for~~in the ~~first~~ fiscal ~~six months~~first quarter of ~~2019~~2020 as compared to the prior year was primarily ~~due to an in-process research and development charge of $0.9 billion, higher litigation expense of $0.3 billion, higher cost of products sold due to~~driven by the ~~negative impact of currency and increased spending in research and development primarily due to a $0.3 billion upfront payment to argenx. This was~~ following:


•	The fiscal first quarter of 2019 included a gain of $0.3 billion related to the Company's previously held equity investment in DR. CI:LABO

partially offset by $0.3 billion of higher unrealized gains on securities, lower Actelion acquisition related costs and leveraging in selling, marketing and administrative as compared to the prior year. In addition, the first fiscal six months of 2018 included a higher gain of $0.1 billion related to divestitures. by:


•	Planned prioritization and reduced brand marketing expense in the fiscal first quarter of 2020

Pharmaceutical Segment

The decrease in the income before tax as a percent of sales for the fiscal second quarter of 2019 as compared to the prior year was primarily due to unfavorable product mix and the negative impact of currency recorded in cost of products sold. In addition, the fiscal second quarter of 2018 included a higher gain of $0.1 billion related to divestitures. This was partially offset by $0.1 billion of higher unrealized gains on securities and leveraging in selling, marketing and administrative as compared to the prior year.

~~Medical Devices Segment~~

~~The Medical Devices~~Pharmaceutical segment income before tax as a percent of sales in the fiscal first ~~fiscal six months~~quarter of ~~2019~~2020 was ~~36.2%~~34.4% versus 17.3% for the same period a year ago. The increase in the income before tax as a percent of sales for the first fiscal six months was primarily attributable to a gain of $2.0 billion related to the divestiture of the ASP business, lower litigation expense of $0.4 billion, lower restructuring charges of $0.1 billion and lower intangible asset amortization expense of $0.1 billion. This was partially offset by increased investment spending. The Medical Devices segment income before tax as a percent of sales in the fiscal second quarter of 2019 was 49.1% versus 11.4%22.8% for the same period a year ago. The increase in the income before tax as a percent of sales for the fiscal ~~second~~first quarter of 2020 as compared to the prior year was primarily driven by the following:


•	Lower litigation expense of $0.2 billion ($0.1 billion in Q1 2020 vs. $0.3 billion in Q1 2019)


•	An in-process research and development charge of $0.9 billion in the fiscal first quarter of 2019


•	Lower research and development expense. The fiscal first quarter of 2019 included a $0.3 billion upfront payment to argenx

partially offset by:


•	Unrealized losses on securities of $0.3 billion in Q1 2020 vs. an unrealized gain of $0.1 billion in Q1 2019


•	Leveraging in selling, marketing and administrative expense

Medical Devices Segment

The Medical Devices segment income before tax as a percent of sales in the fiscal first quarter of 2019 was 34.1% versus 23.2% for the same period a year ago. The increase in the income before tax as a percent of sales for the fiscal first quarter was primarily ~~attributable to a gain of $2.0 billion related to~~driven by the ~~divestiture of the ASP business, lower litigation expense of $0.5 billion and lower restructuring charges of $0.1 billion. This was~~ following:


•	A contingent consideration reversal of approximately $1.0 billion related to the timing of certain developmental milestones associated with the Auris Health acquisition

partially offset ~~by increased investment spending.~~by:


•	Deleveraging in Selling, Marketing and Administrative Expenses resulting from the COVID-19 impact on sales


•	Establishment of incremental inventory reserves associated with the impact of COVID-19


•	Increased investments in robotics and digital solutions

Restructuring

~~Restructuring~~

In the second quarter of 2018, the Company announced plans to implement actions across its global supply chain that are intended to enable the Company to focus resources and increase investments in critical capabilities, technologies and solutions necessary to manufacture and supply its product portfolio of the future, enhance agility and drive growth. The Company expects these supply chain actions will include expanding its use of strategic collaborations, and bolstering its initiatives to

Table of Contents

reduce complexity, improving cost-competitiveness, enhancing capabilities and optimizing its network. Discussions regarding specific future actions are ongoing and are subject to all relevant consultation requirements before they are finalized. In total, the Company expects these actions to generate approximately $0.6 to $0.8 billion in annual pre-tax cost savings that will be substantially delivered by 2022. The Company expects to record pre-tax restructuring charges of approximately $1.9 to $2.3 billion. In the fiscal ~~second~~first quarter of 2020, the Company recorded a pre-tax charge of $118 million, which is included on the following lines of the Consolidated Statement of Earnings, $58 million in restructuring, $15 million in cost of products sold and $45 million in other (income) expense. In the fiscal first quarter of 2019, the Company recorded a pre-tax charge of ~~$142~~$90 million, of which ~~$38 million~~ is included on the following lines of the Consolidated Statement of Earnings, $36 million in restructuring, $23 million in cost of products sold and ~~$47~~$31 million ~~is included~~ in other (income) expense. Restructuring charges of ~~$0.5~~approximately $1.0 billion have been recorded since the restructuring was announced.

See Note 12 to the Consolidated Financial Statements for additional details related to the restructuring.

Provision for Taxes on Income

For discussion onrelated to the fiscal first quarter of 2020 provision for taxes refer to Note 5 to the Consolidated Financial Statements.

Swiss Tax Reform

~~On September 28, 2018 the Swiss Parliament approved the Federal Act on Tax Reform~~The Company is currently assessing and ~~AHV Financing (TRAF). On May 19, 2019 a public referendum was held~~awaiting approval for certain elective transition provisions related in Switzerland that approved the federal reform proposals and subsequently announced the TRAF will become effective on January 1, 2020. In the third fiscal quarter of 2019, the Swiss Federal Council enacted TRAF.

~~TRAF provides for parameters~~several cantons which ~~enable the Swiss cantons to establish localized tax rates and regulations for multinational companies. The new cantonal tax parameters~~ include favorable tax benefits for patents and an additional research and development tax deduction to encourage investment. The cantons are required to implement new local legislation by January 1, 2020 or the new federal law will be directly applied.

The significant cantons in which the Company operates have not yet enacted legislation in response to TRAF. The transitional provisions of TRAF are also expected to allow companies to elect tax basis adjustments to fair value which is used for tax depreciation and amortization purposes resulting in a deduction over the transitional period. The adjustment in the Company’s asset tax basis will likely require review and approval by thediscussions with federal and cantonal tax ~~agencies.~~authorities on the application of Swiss Tax reform. The Company has recorded the estimated impact of the transitional provisions based on the best available information for cantons where enactment has occurred, but the Company has not yet ~~applied for the adjustment~~received final tax rulings in all cantons. The result of these discussions with tax authorities may result in additional changes to the estimates that may be significant in the period in which they occur. Further, authoritative guidance from the relevant Swiss tax ~~basis.~~

~~As TRAF was not enacted as of June 30, 2019,~~authorities may be issued in the ~~Company has not reflected the financial impacts in its fiscal second quarter results. The Company estimates the impact of revaluing its deferred tax assets~~future and liabilities as a result of Swiss Federal enactment of TRAF, without consideration of future cantonal tax rate changes or the transitional provisions, to result in an incremental tax expense between $0.3 billion to $0.5 billionadditional revisions may be required in the fiscal third quarter of 2019. This amount does not include the impact of cantonal law changes expected to be enacted later in fiscal 2019. It also does not include the tax benefit derived from the transitional provisions previously described. Due to the uncertainty of the cantonal legislation and the approval of the transitional provisions, the Company is unable to reasonably estimate the combined financial impact of both the federal and cantonal component of Swiss Tax Reform for the remainder of 2019 or the impact to the consolidated effective tax rate beginning in 2020. The Company is continually assessing the impact of the proposed Swiss Tax Reform. When all aspectsperiod that they are ~~fully enacted, the federal and the cantonal tax law changes may have a material impact on the future results of operations.~~issued.

LIQUIDITY AND CAPITAL RESOURCES

Cash Flows

Cash and cash equivalents were ~~$14.4~~$15.5 billion at the end of the fiscal ~~second~~first quarter of ~~2019~~2020 as compared with ~~$18.1~~$17.3 billion at the end of fiscal year ~~2018.~~2019. The primary sources and uses of cash that contributed to the ~~$3.7~~$1.8 billion decrease ~~were approximately $9.5 billion~~were:



(Dollars In Billions)
$	17.3		Q4 2019 Cash and cash equivalents balance
3.4			cash generated from operating activities
(0.6		)	net cash used by investing activities
(4.3		)	net cash used by financing activities
(0.3		)	effect of exchange rate and rounding
$	15.5		Q1 2020 Cash and cash equivalents balance

Table of ~~cash generated from operating activities offset by $3.2 billion net cash used by investing activities and $10.1 billion net cash used by financing activities.~~ Contents

In addition, the Company had ~~$0.9~~$2.5 billion in marketable securities at the end of the fiscal ~~second~~first quarter of ~~2019~~2020 and ~~$1.6~~$2.0 billion at the end of ~~2018.~~2019.

Cash flow from operations of ~~$9.5~~$3.4 billion was the result of $9.4 billion of net earnings and $5.0 billion of non-cash expenses and other adjustments primarily for depreciation and amortization, stock-based compensation and asset write-downs (primarily related to the Alios IPR&D asset). This was reduced by $2.1 billion related to an increase in accounts receivable, an increase in inventories, a decrease in accounts payable and accrued liabilities, an increase in other current and non-current assets, a decrease in other liabilities and net gain on sale of assets/businesses of $2.1 billion (primarily related to the ASP divestiture) and $0.7 billion for the deferred tax provision.of:



(Dollars In Billions)
$	5.8		Net Earnings
2.1			non-cash expenses and other adjustments primarily for depreciation and amortization, stock-based compensation and the deferred tax provision.
0.3			decrease in other current and non-current assets
(3.8		)	an increase in accounts receivable and inventories coupled with a decrease in accounts payable and accrued liabilities and other current and non-current liabilities
(1.0		)	contingent consideration reversal (related to the timing of certain developmental milestones associated with the Auris Health acquisition)
$	3.4		Cash Flow from operations

Investing activities use of ~~$3.2~~$0.6 billion of cash was primarily used for acquisitions of $5.3 billion and additions to property, plant and equipment of $1.5 billion. Investing activities also included a source of $3.0 billion of proceeds from the disposal of assets/businesses, primarily ASP, and $0.6 billion from the net sales of investments.for:



(Dollars In Billions)
$	(0.9	)	primarily related to the acquisitions of bermekimab and related assets from XBiotech Inc. as well as the acquisition of all outstanding shares in Verb Surgical Inc.
(0.6		)	additions to property, plant and equipment
(0.5		)	net purchases of investments
1.7			proceeds from credit support agreements, net
(0.3		)	other
$	(0.6	)	Net cash used for investing activities

Financing activities use of ~~$10.1~~$4.3 billion of cash was primarily used for dividends to shareholders of $4.9 billion, the repurchase of common stock of $4.7 billion and the net retirement of short and long term debt of $1.0 billion. Financing activities also included a source of $0.5 billion from proceeds from stock options exercised/employee withholding tax on stock awards.for:

In the fiscal second quarter of 2019, the Company completed the divestiture of its ASP business and received $2.7 billion of cash proceeds. Additionally, the Company completed the acquisition of Auris Health, Inc. for approximately $3.4 billion, net of cash acquired.



(Dollars In Billions)
$	(2.5	)	dividends to shareholders
(1.7		)	repurchase of common stock
0.3			proceeds from stock options exercised/employee withholding tax on stock awards, net
(0.4		)	other
$	(4.3	)	Net cash used for financing activities

The Company has access to substantial sources of funds at numerous banks worldwide. In September ~~2018,~~2019, the Company secured a new 364-day Credit Facility. Total credit available to the Company ~~under the facility,~~approximates $10 billion, which expires on September ~~12, 2019, approximates $10.0 billion.~~10, 2020. Interest charged on borrowings under the credit line agreement is based on either bids provided by banks, the prime rate, or London Interbank Offered Rates (LIBOR), or other applicable market rates as allowed under the terms of the agreement, plus applicable margins. Commitment fees under the agreement are not material.

On December 17, 2018, the Company announced that its Board of Directors approved a share repurchase program, authorizing the Company to purchase up to $5.0 billion of the Company's shares of common stock. The repurchase program has no time limit and may be suspended for periods or discontinued at any time. Any shares acquired will be available for general corporate purposes. The Company intends to finance the share repurchase program through available cash. Through June 30, 2019, $3.8 billion has been repurchased under the program.

In the fiscal ~~second~~first quarter of ~~2019,~~2020, the Company's notes payable and long-term debt was in excess of cash, cash equivalents and marketable securities. As of ~~June 30, 2019,~~March 29, 2020, the net debt position was ~~$14.1~~$9.6 billion as compared to the prior year of $14.0 billion. Considering recent market conditions and the on-going COVID-19 crisis, the Company has re-evaluated its operating cash flows and liquidity profile and does not foresee any incremental significant risk. The Company anticipates that operating cash flows, the ability to raise funds from external sources, borrowing capacity from existing committed credit facilities and access to the commercial paper markets will continue to provide sufficient resources to fund operating ~~needs. Additionally, as a result of~~needs, including the ~~TCJA,~~agreement in principle to settle opioid litigation to be potentially paid over the ~~Company has access~~next two to ~~its cash outside~~three years. In addition, the ~~U.S. at a significantly reduced cost. The~~ Company monitors the global capital markets on an ongoing basis and from time to time may raise capital when market conditions are favorable. Additionally, as a result of the TCJA, the Company has access to its cash outside the U.S. at a significantly reduced cost.

~~Dividends~~

Table of Contents

Subsequent to March 29, 2020, the Company paid approximately $1.0 billion to the U.S. Treasury related to the normal estimated payment for the fiscal first quarter of 2020 and the current installment due on foreign undistributed earnings as part of the TCJA (see Note 8 to the Consolidated Financial Statements as contained in the Company’s Annual Report on Form 10-K for the fiscal year ended December 29, 2019).

Dividends

On ~~April 25, 2019,~~January 2, 2020, the Board of Directors declared a regular cash dividend of $0.95 per share, payable on ~~June 11, 2019~~March 10, 2020 to shareholders of record as of ~~May 28, 2019.~~February 25, 2020.

On ~~July 15, 2019,~~April 14, 2020, the Board of Directors declared a regular cash dividend of ~~$0.95~~$1.01 per share, payable on ~~September 10, 2019~~June 9, 2020 to shareholders of record as of ~~August 27, 2019.~~May 26, 2020. The Company expects to continue the practice of paying regular quarterly cash dividends.

OTHER INFORMATION

New Accounting Pronouncements

Refer to Note 1 to the Consolidated Financial Statements for new accounting pronouncements.

Economic and Market Factors

COVID-19 considerations and business continuity

The Company has considered various internal and external factors in assessing the potential impact of COVID-19 on its business and financial results based upon information available at this time, as follows:


•	Operating Model: The Company has a diversified business model across the healthcare industry with flexibility designed into its manufacturing, research and development clinical operations and commercial capabilities.


•	Supply Chain: The Company continues to leverage its global manufacturing footprint and dual-source capabilities while closely monitoring and maintaining critical inventory at major distribution centers away from high-risk areas to ensure adequate and effective distribution.


•	Business Continuity: The robust, active business continuity plans across the Company's network have been instrumental in preparing the Company for events like COVID-19 and the ability to meet the majority of patient and consumer needs remains uninterrupted.


•	Workforce: The Company has put procedures in place to protect its essential workforce in manufacturing, distribution, commercial and research operations while ensuring appropriate remote working protocols have been established for other employees


•	Liquidity: The Company's high-quality credit rating allows the Company superior access to the financial capital markets as needed.


•	Domestic and Foreign Legislation: The Company will continue to assess and evaluate the on-going global legislative efforts to combat the COVID-19 impact on economies and the sectors in which it participates. Currently, the recent legislative acts put in place are not expected to have a material impact on the Company’s operations.

The Company operates in certain countries where the economic conditions continue to present significant challenges. The Company continues to monitor these situations and take appropriate actions. Inflation rates and currency exchange rates continue to have an effect on worldwide economies and, consequently, on the way the Company operates. The Company has accounted for operations in Venezuela and Argentina as highly inflationary, as the prior three-year cumulative inflation rate surpassed 100%. This did not have a material impact to the Company's results in the period. In the face of increasing costs, the Company strives to maintain its profit margins through cost reduction programs, productivity improvements and periodic price increases.

In June 2016, the United Kingdom (U.K.) held a referendum in which voters approved an exit from the European Union (E.U.), commonly referred to as ~~“Brexit”~~“Brexit” and ~~in March 2017~~on January 31, 2020, the U.K. formally ~~started the process for the U.K. to leave~~exited the E.U. Given the lack of comparable precedent, it is unclear what the ultimate financial, trade, regulatory and legal implications the withdrawal of the U.K. from the E.U. will have. Brexit creates global political and economic uncertainty, which may cause, among other consequences, volatility in exchange rates and interest rates, additional cost containment by third-party payors and changes in regulations. However, the Company currently does not believe that these and other related effects will have a material impact on the ~~Company’s~~Company’s consolidated financial position or operating results. As of ~~June 30, 2019,~~March 29, 2020, the business of the ~~Company’s~~Company’s U.K. subsidiaries represented less than 3% of both the ~~Company’s~~Company’s consolidated assets and fiscal ~~six~~three months ~~revenue,~~revenues, respectively.

Table of Contents

Governments around the world consider various proposals to make changes to tax laws, which may include increasing or decreasing existing statutory tax rates. A change in statutory tax rate in any country would result in the revaluation of the ~~Company’s~~Company’s deferred tax assets and liabilities related to that particular jurisdiction in the period in which the new tax law is enacted. This change would result in an expense or benefit recorded to the ~~Company’s~~Company’s Consolidated Statement of Earnings. The Company closely monitors these proposals as they arise in the countries where it operates. Changes to the statutory tax rate may occur at any time, and any related expense or benefit recorded may be material to the fiscal quarter and year in which the law change is enacted. For discussion on Federal Act on Tax Reform and AHV Financing (Swiss Tax Reform) see Provision for Taxes on Income in Management's Discussion and Analysis of Financial Condition and Results of Operations.

The Company faces various worldwide health care changes that may continue to result in pricing pressures that include health care cost containment and government legislation relating to sales, promotions and reimbursement of health care products.

Changes in the behavior and spending patterns of purchasers of health care products and services, including delaying medical procedures, rationing prescription medications, reducing the frequency of physician visits and foregoing health care insurance coverage, may continue to impact the ~~Company’s~~Company’s businesses.

The Company also operates in an environment increasingly hostile to intellectual property rights. Firms have filed Abbreviated New Drug Applications or Biosimilar Biological Product Applications with the FDA, initiated Inter Partes Review proceedings in the United States Patent and Trademark Office, or otherwise challenged the coverage and/or validity of the Company's patents, seeking to market generic or biosimilar forms of many of the ~~Company’s~~Company’s key pharmaceutical products prior to expiration of the applicable patents covering those products. In the event the Company is not successful in defending the patent claims challenged in these actions, generic or biosimilar versions of the products at issue may be introduced to the market, resulting in the potential for substantial market share and revenue losses for those products, and which may result in a non-cash impairment charge in any associated intangible asset. There is also a risk that one or more competitors could launch a generic or biosimilar version of the product at issue following regulatory approval even though one or more valid patents are in place. For further information, see the discussion on ~~“REMICADE~~“REMICADE^®® Related ~~Cases”~~Cases” and ~~“Litigation~~“Litigation Against Filers of Abbreviated New Drug ~~Applications”~~Applications” in Note 11 to the Consolidated Financial Statements.

Item 3 —— QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

There has been no material change in the ~~Company’s~~Company’s assessment of its sensitivity to market risk since its presentation set forth in Item 7A, ~~“Quantitative~~“Quantitative and Qualitative Disclosures About Market Risk,”” in its Annual Report on Form 10-K for the fiscal year ended December ~~30, 2018~~29, 2019.

Item 4 —— CONTROLS AND PROCEDURES

Disclosure controls and procedures. At the end of the period covered by this report, the Company evaluated the effectiveness of the design and operation of its disclosure controls and procedures. The ~~Company’s~~Company’s disclosure controls and procedures are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the ~~SEC’s~~SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act is accumulated and communicated to the ~~Company’s~~Company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. Alex Gorsky, Chairman and Chief Executive Officer, and Joseph J. Wolk, Executive Vice President, Chief Financial Officer, reviewed and participated in this evaluation. Based on this evaluation, Messrs. Gorsky and Wolk concluded that, as of the end of the period covered by this report, the ~~Company’s~~Company’s disclosure controls and procedures were effective.

Internal control. During the period covered by this report, there were no changes in the ~~Company’s~~Company’s internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, the ~~Company’s~~Company’s internal control over financial reporting.

The Company is implementing a multi-year, enterprise-wide initiative to integrate, simplify and standardize processes and systems for the human resources, information technology, procurement, supply chain and finance functions. These are enhancements to support the growth of the ~~Company’s~~Company’s financial shared service capabilities and standardize financial systems. This initiative is not in response to any identified deficiency or weakness in the ~~Company’s~~Company’s internal control over financial

Table of Contents

reporting. In response to this initiative, the Company has and will continue to align and streamline the design and operation of its financial control environment.

~~Part II — OTHER INFORMATION~~

Part II — OTHER INFORMATION

Item 1 —— LEGAL PROCEEDINGS

The information called for by this item is incorporated herein by reference to Note 11 included in Part I, Item 1, Financial Statements (unaudited) —— Notes to Consolidated Financial Statements.

Item 2 —— UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

On December 17, 2018, the Company announced that its Board of Directors approved a share repurchase program, authorizing the Company to purchase up to $5.0 billion of the Company's Common Stock. Share repurchases take place from time to time on the open market or through privately negotiated transactions. The repurchase program has no time limit and may be suspended for periods or discontinued at any time.

The following table provides information with respect to Common Stock purchases by the Company during the fiscal ~~second~~first quarter of ~~2019.~~2020. The repurchases below also include the stock-for-stock option exercises that settled in the fiscal ~~second~~first quarter.

Fiscal Month Period
Total Number
of Shares Purchased⁽¹⁾

Avg. Price
Per Share

Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs⁽²⁾

Maximum Number of Shares that May Yet Be Purchased Under the Plans or Programs ⁽³⁾
April 1, 2019 through April 28, 2019 2,109,811
138.04
523,925
—
April 29, 2019 through May 26, 2019 2,258,105
140.29
—
—
May 27, 2019 through June 30, 2019 13,559,098
138.57
13,558,885
—
Total 17,927,014
14,082,810
8,827,270



Fiscal Month Period	Total Number of Shares Purchased⁽¹⁾	Avg. Price Per Share	Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs	Maximum Number of Shares that May Yet Be Purchased Under the Plans or Programs
December 30, 2019 through January 26, 2020	193,438	145.10		—
January 27, 2020 through February 23, 2020	6,424,714	150.13		—
February 24, 2020 through March 29, 2020	5,031,134	142.96		—
Total	11,649,286		—

⁽¹⁾

During the fiscal ~~second~~first quarter of ~~2019,~~2020, the Company repurchased an aggregate of ~~17,927,014~~11,649,286 shares of Johnson && Johnson Common Stock in open-market transactions, all of which ~~14,082,810 shares~~ were purchased ~~pursuant to the repurchase program that was publicly announced on December 17, 2018, and of which 3,844,204 shares were purchased in open-market transactions~~ as part of a systematic plan to meet the needs of the ~~Company’s~~Company’s compensation programs.


⁽²⁾	~~As of June 30, 2019, an aggregate of 27,739,317 shares were purchased for a total of $3.8 billion since the inception of the repurchase program announced on December 17, 2018.~~


⁽³⁾	As of June 30, 2019, the maximum number of shares that may yet be purchased under the plan is 8,827,270 based on the closing price of Johnson & Johnson Common Stock on the New York Stock Exchange on June 28, 2019 of $139.28 per share.

Table of Contents

Item 6 —— EXHIBITS

Exhibit 31.1 Certification of Chief Executive Officer under Rule 13a-14(a) of the Securities Exchange Act pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 —— Filed with this document.

Exhibit 31.2 Certification of Chief Financial Officer under Rule 13a-14(a) of the Securities Exchange Act pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 —— Filed with this document.

Exhibit 32.1 Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 —— Furnished with this document.

Exhibit 32.2 Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 —— Furnished with this document.

Exhibit 101:



EX-101.INS		Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
EX-101.SCH		Inline XBRL Taxonomy Extension Schema
EX-101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase
EX-101.LAB		Inline XBRL Taxonomy Extension Label Linkbase
EX-101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase
EX-101.DEF		Inline XBRL Taxonomy Extension Definition Document

Exhibit 104:		Cover Page Interactive Data File––the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

Table of Contents

SIGNATURES

~~SIGNATURES~~

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.



	JOHNSON && JOHNSON (Registrant)

Date: ~~July~~April 29, ~~2019~~2020	By /s/ J. J. WOLK
	J. J. WOLK
	Executive Vice President, Chief Financial Officer (Principal Financial Officer)

Date: ~~July~~April 29, ~~2019~~2020	By /s/ R. ~~A. KAPUSTA~~ J. DECKER Jr.
	R. ~~A. KAPUSTA~~ J. DECKER Jr.
	Controller (Principal Accounting Officer)

6257



(Dollars in Millions)	Operating Leases
2019 (for the remainder of fiscal 2019)	$	185
2020	245
2021	201
2022	156
2023	98
After 2023	214
Total lease payments	1,099
Less: Interest	88
Present Value of lease liabilities	$	1,011



(Dollars in Millions)
Non-current operating lease right-of-use assets	$	980
Current operating lease liabilities	262
Non-current Operating lease liabilities	749
Total operating lease liabilities	$	1,011



Line item in the Consolidated Balance Sheet in which the hedged item is included	Carrying Amount of the Hedged Liability			Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of the Hedged Liability
(Dollars in Millions)	June 30, 2019		December 30, 2018	June 30, 2019	December 30, 2018
Current Portion of Long-term Debt	$	498	494	1	5
Long-term Debt	—		—	—	—



Neuroscience
U.S.	664	639	3.8		1,387	1,263	9.8
International	875	889	(1.6	)	1,780	1,824	(2.4	)
Worldwide	1,538	1,528	0.6		3,167	3,087	2.6
CONCERTA^® / methylphenidate
U.S.	15	68	(78.6	)	112	134	(16.4	)
International	123	115	6.2		239	222	7.3
Worldwide	137	183	(25.2	)	351	356	(1.6	)
INVEGA SUSTENNA^® / XEPLION^® / INVEGA TRINZA^® / TREVICTA^®
U.S.	506	438	15.6		989	838	18.1
International	312	282	10.4		619	578	7.0
Worldwide	818	720	13.6		1,608	1,416	13.6
RISPERDAL CONSTA^®
U.S.	81	80	0.8		158	162	(3.0	)
International	101	108	(6.5	)	203	222	(8.4	)
Worldwide	182	188	(3.4	)	361	384	(6.2	)
OTHER NEUROSCIENCE
U.S.	62	53	16.1		128	129	(0.4	)
International	340	384	(11.5	)	719	802	(10.3	)
Worldwide	401	437	(8.1	)	847	931	(8.9	)

Oncology
U.S.	1,013	1,085	(6.6	)	1,975	2,018	(2.1	)
International	1,684	1,371	22.8		3,240	2,749	17.9
Worldwide	2,697	2,456	9.8		5,215	4,767	9.4
DARZALEX^®
U.S.	369	298	24.4		721	562	28.5
International	405	213	89.5		682	381	78.7
Worldwide	774	511	51.6		1,403	943	48.8
IMBRUVICA^®
U.S.	367	250	47.0		716	477	50.2
International	463	370	25.3		898	730	23.1
Worldwide	831	620	34.1		1,615	1,207	33.8
VELCADE^®
U.S.	—	—	—		—	—	—
International	224	280	(20.1	)	487	593	(17.9	)
Worldwide	224	280	(20.1	)	487	593	(17.9	)
ZYTIGA^® / abiraterone acetate
U.S.	198	486	(59.4	)	383	893	(57.1	)
International	500	423	18.0		994	861	15.4
Worldwide	698	909	(23.3	)	1,377	1,754	(21.5	)
OTHER ONCOLOGY
U.S.	78	51	50.5		154	86	77.7
International	92	85	8.8		179	184	(2.5	)
Worldwide	170	136	24.7		333	270	23.2



Pulmonary Hypertension
U.S.	439	429	2.2		869	790	10.0
International	251	236	6.7		477	460	3.7
Worldwide	690	665	3.8		1,346	1,250	7.7
OPSUMIT^®
U.S.	203	180	12.8		375	329	14.2
International	146	131	11.5		279	253	10.3
Worldwide	348	311	12.3		654	582	12.5
TRACLEER^®
U.S.	41	71	(41.8)		102	139	(26.3	)
International	62	72	(14.5)		118	144	(18.7	)
Worldwide	103	143	(28.0)		220	283	(22.4	)
UPTRAVI^®
U.S.	175	155	13.4		351	279	25.9
International	28	16	62.5		50	32	53.1
Worldwide	203	171	18.2		401	311	28.7
OTHER
U.S.	20	23	(18.2)		41	43	(8.4	)
International	16	17	3.7		31	31	4.1
Worldwide	37	40	(9.6)		72	74	(3.4	)

Cardiovascular / Metabolism / Other
U.S.	902	1,101	(18.1	)	1,849	2,204	(16.1	)
International	373	417	(10.5	)	771	831	(7.2	)
Worldwide	1,275	1,518	(16.0	)	2,620	3,035	(13.7	)
XARELTO^®
U.S.	549	679	(19.2	)	1,091	1,257	(13.2	)
International	—	—	—		—	—	—
Worldwide	549	679	(19.2	)	1,091	1,257	(13.2	)
INVOKANA^® / INVOKAMET^®
U.S.	132	169	(21.2	)	286	373	(23.2	)
International	43	46	(6.0	)	92	90	2.6
Worldwide	177	215	(17.9	)	379	463	(18.2	)
PROCRIT^® / EPREX^®
U.S.	113	156	(27.5	)	261	345	(24.3	)
International	70	80	(13.4	)	148	167	(11.7	)
Worldwide	183	236	(22.7	)	409	512	(20.2	)
OTHER
U.S.	107	97	9.3		211	229	(8.2	)
International	260	291	(10.5	)	531	574	(7.5	)
Worldwide	368	388	(5.5	)	742	803	(7.7	)

TOTAL PHARMACEUTICAL
U.S.	5,783	5,899	(2.0	)	11,365	11,253	1.0
International	4,746	4,455	6.5		9,408	8,945	5.2
Worldwide	10,529	10,354	1.7		20,773	20,198	2.8



MEDICAL DEVICES
Diabetes Care
U.S.	—	129	*		—	246	*
International	—	226	*		—	448	*
Worldwide	—	355	*		—	694	*
Interventional Solutions
U.S.	366	323	13.7		709	627	13.2
International	385	344	11.6		774	680	13.7
Worldwide	750	667	12.6		1,482	1,307	13.4
Orthopaedics
U.S.	1,331	1,332	(0.1	)	2,649	2,639	0.4
International	894	930	(3.8	)	1,779	1,873	(5.0	)
Worldwide	2,224	2,262	(1.6	)	4,428	4,512	(1.9	)
HIPS
U.S.	216	211	2.1		429	420	2.1
International	147	149	(0.7	)	295	303	(2.3	)
Worldwide	364	360	0.9		725	723	0.3
KNEES
U.S.	218	229	(4.8	)	441	457	(3.5	)
International	153	153	0.4		299	312	(4.0	)
Worldwide	372	382	(2.8	)	741	769	(3.7	)
TRAUMA
U.S.	407	394	3.3		824	801	2.9
International	265	281	(5.9	)	533	570	(6.5	)
Worldwide	672	675	(0.6	)	1,357	1,371	(1.0	)
SPINE & OTHER
U.S.	490	498	(1.5	)	955	961	(0.6	)
International	328	347	(5.3	)	651	688	(5.4	)
Worldwide	818	845	(3.1	)	1,606	1,649	(2.6	)
Surgery
U.S.	926	1,022	(9.5	)	1,927	2,015	(4.4	)
International	1,427	1,493	(4.4	)	2,821	2,923	(3.5	)
Worldwide	2,353	2,515	(6.5	)	4,748	4,938	(3.9	)
ADVANCED
U.S.	396	402	(1.7	)	800	795	0.6
International	633	603	5.0		1,209	1,176	2.8
Worldwide	1,029	1,005	2.3		2,009	1,971	1.9
GENERAL
U.S.	443	436	1.6		868	859	1.0
International	674	733	(7.9	)	1,339	1,437	(6.8	)
Worldwide	1,119	1,169	(4.3	)	2,208	2,296	(3.9	)
SPECIALTY
U.S.	87	184	(53.1	)	259	361	(28.3	)
International	120	157	(23.7	)	273	310	(12.1	)
Worldwide	206	341	(39.6	)	531	671	(20.8	)